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Polyamines are doing some important things, but we do not know what they are.
(Coffmo and Poznanski, J  Cell Biochem 1991;45, 54-58)
Polyamines, as plausible prebiotic DNA condensing agents, may have played a role in the 
evolution of life.
(Baeza et al, Orig Life Evol Biosph 1991-92;21,225-42)
The development of specific and sensitive (immuno)cytochemical methods for poly­
amines is hampered by the lack of immunogenicity of these compounds. They also share 
structural features and readily redistribute during processing of cells and tissues.
(Schipper et al 1999, In: Polyamines in Health and Nutrition, Bardocz and White,eds; p. 48)
De grote variatie in de distributie van ornithine decarboxylase in cellen en weefsels duidt 
op een dynamische rol van dit enzym in cellulaire processen.
(dit proefschrift)
Polyaminen spelen een belangrijke rol bij het biologisch gedrag (celgroei, celdifferentia­
tie, celdood) van zowel normale als kwaadaardige prostaatkliercellen.
(dit proefschrift)
In de prostaat kunnen verschillen in spermine concentraties met behulp van magnetische 
kernspin resonantie spectroscopie (MRS) worden opgespoord. Dit opent nieuwe 
perspectieven voor het voorspellen van het biologische gedrag van prostaatkankercellen 
wat behulpzaam kan zijn bij de diagnostiek van prostaatkanker.
(dit proefschrift)
Polyamine analogen zijn veelbelovende chemotherapeutische verbindingen bij de 
behandeling van prostaatkanker.
(dit proefschrift)
Het verstand, dat scherp is, maar niet breed, blijft steken bij ieder punt en komt niet 
verder.
(Rabindranath Tagore, Indisch dichter en wijsgeer, 1861-1941)
IX. Ontdekken is zien wat iedereen heeft gezien en denken wat niemand heeft gedacht.
(Albert Szent-Györgyi, H ongaars biochemicus, 1893-1986)
X. Geloven en weten zijn twee rails, die evenwijdig lopen en elkaar nooit ontmoeten, 
behalve bij het kind.
(Godfried Bomans)
XI. Doodgaan, dat is wel het laatste wat een kankercel zal doen.
XII. Het voorbeeld van de annexine-V methode ter detectie van celdood op orgaanniveau 
(Hofstra et al, Lancet 2000; 356: 209 -  212) bewijst eens te meer dat fundamenteel celbiologisch 
onderzoek kan leiden tot medische toepassingen.
XII. It is a paradox that many of us who claim to be “life scientist” actually spend the majority 
of our time studying dead organisms (Stoward, Histochem J2000;30,121).
Met de opmars van “live cell imaging” technieken wordt dan ook een droom van vele 
wetenschappers werkelijkheid: de cel als een “Big Brother huis” kunnen volgen op het 
scherm.
XIII. Een AIO verdient veel, maar krijgt weinig.
XIV. Het dient de aanbeveling om internet-sites te controleren op de houdbaarheidsdatum.
XV. Het wijdverspreid succes van het “I love you” virus bewijst eens te meer dat veel mensen 
op deze aarde hunkeren naar een liefdesverklaring.
XVI. De ideale opstelling van 2000: Van de Sar, Stam, de Boer, Bosvelt, Reiziger, Davids, 
Zenden, Overmars, Bergkamp, Kluivert en .... Rensenbrink.
XVII. Werelddierendag blijkt nog steeds gevierd te worden volgens het principe “Alle dieren 
zijn gelijk, alleen sommige dieren zijn meer gelijk dan andere” (George Orwell, Animal Farm, 
1945).
Raymond Schipper, 4 oktober 2000
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bovine serum albumin
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copper containing amine oxidase
dicycl ohexylcarbodiimide
decarboxylated S-adenosylmethionine
N 1,N11-di(ethyl)norspermine
a-difluoromethylornithine
dimethylformamide
dimethylsulfoxide
enzyme-linked immunosorbent assay 
foetal calf serum
n-9-fluorenylmethoxycarbonyl-succinimide 
granulocyte macrophage-colony stimulating factor 
human
hypoxanthine aminopterin thymidine 
high-performance liquid chromatography 
interleukin-1ß converting enzyme 
interleukin-1ß
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Chapter 1
General introduction
Raymond G. Schipper
Department o f  Pathology, University M edical Centre Nijmegen, 
Nijmegen, The Netherlands
Introdu ction
1.1 Polyam ine m etabolism  
Structure and metabolic pathways of polyamines
In mammals three types of polyamines have been described, i.e. putrescine (Put), spermidine 
(Spd) and spermine (Spm). These aliphatic amines have a low molecular weight, a simple 
chemical structure and are highly charged cations at physiological conditions (Figure 1). The 
metabolic pathways and homeostasis of polyamines are well established and have been 
summarized in several reviews (Persson et al 1996; Seiler et al. 1996; Seiler and Douaud 
1998).
Z V  / \  NH
H3 N  N / N /  3
Putrescine
Figure 1. The natural polyamines putrescine, spermidine and spermine at physiological pH.
Intracellularly, polyamine pool size and balance are maintained within very narrow limits 
since decrease in polyamine levels interferes with cell growth and excess of polyamines 
appears to be toxic. Therefore, cells have developed regulatory machinery, which controls 
polyamine pools in a fast, sensitive and accurate manner. With this, cells are able to newly 
synthesize or interconvert the polyamines into each other depending on the needs for a 
particular polyamine. The pathways of polyamine metabolism are summarized in Figure 2.
Putrescine, spermidine and spermine are derived from a common precursor, ornithine. 
Ornithine is decarboxylated by the first rate-limiting enzyme in the biosynthetic branch of the 
interconversion cycle, ornithine decarboxylase (ODC) to yield putrescine. S-adenosyl- 
methionine decarboxylase (SAMDC), the second rate-limiting enzyme in polyamine 
biosynthesis, converts s-adenosylmethionine (SAM) in decarboxylated S-adenosylmethionine 
(dc-SAM). DcSAM acts as an aminopropyldonor in the production of spermidine and 
spermine catalyzed by spermidine synthase and spermine synthase, respectively. In the 
catabolic branch of the interconversion cycle, spermine and spermidine are first acetylated by 
Spd/Spm N1-acetyltransferase (SSAT) to N 1-acetylspermine (N1-AcSpm) and N 1-acetyl- 
spermidine (N1-AcSpd), respectively. N 1-AcSpm and N 1-AcSpd can be excreted from the cell 
or finally oxidized by the FAD-dependent polyamine oxidase (PAO) to form spermidine and 
putrescine, respectively. The oxidation products are 3-acetamidopropanol and hydrogen
2
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peroxide. Polyamines can also be irreversibly degraded by oxidative deamination catalyzed by 
copper containing amine oxidases. The products of this terminal degradation of polyamines 
are unstable and toxic and are subsequently further degraded into urea, carbon dioxide and 
water.
In addition to the metabolic apparatus to synthesize and convert polyamines, cells can 
regulate intracellular polyamine pools by transport of polyamines across the membrane (Seiler 
et al. 1996). Cells are equipped with an efficient transport system for uptake of polyamines 
from extracellular sources. This energy-dependent carrier-mediated system can transport 
natural polyamines, some polyamine analogs (e.g. MGBG, BE-3-3-3) and other agents (e.g. 
paraquat). Extracellular polyamines can be derived from other cells that secrete polyamines or 
their acetylated conjugates. Polyamines can also be derived from dietary or microbial polya­
mines that are take up by the gastrointestinal tract (see Figure 3). These exogenous sources and 
their importance in the maintenance of body pools will be discussed more in detail in the next 
paragraph.
SAM
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Figure 2. Pathway o f  the polyamine interconversion cycle in mammalian cells. Putrescine, spermidine and spermine are 
derived from a common precursor, ornithine. Decarboxylated S-adenosylmethionine (dcSAM) acts as an aminopropyldonor 
in the biosynthetic branch o f  the interconversion cycle. DcSAM is produced from S-adenosyl to form methylthioadenosine 
(MTA). In the catabolic branch o f  the interconversion cycle spermine and spermidine are first acetylated to form N1- 
acetylspermine and N 1-acetylspermidine, respectively, and finally oxidized to form spermidine and putrescine respectively. 
The oxidation products are 3-acetamidopropanol and hydrogen peroxide. The enzymes involved are (1) ornithine 
decarboxylase (ODC), (2) S-adenosylmethionine decarboxylase (SAMDC), (3) spermidine synthase, (4) spermine synthase, 
(5) spermidine/spermine N 1-acetyltransferase (SSAT), (6) polyamine oxidase (PAO).
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The polyamine system responds to a variety of hormones, growth factors or toxic agents, 
however, adjustment of polyamine pools seems to be essentially mediated by the polyamines 
themselves. Studies by Porter and co-workers showed that when polyamine pools increase the 
biosynthetic activity of the ODC and SAMDC rapidly decrease and vice versa.
The molecular mechanism by which this very sensitive up- and down-regulation is exerted 
is not known but it probably occurs at the translational and post-translational levels of enzyme 
synthesis and enzyme turnover (Porter et al. 1992). Polyamines and polyamine analogs also 
regulate their transport. Evidently, in vivo, the concentrations of free polyamines in the 
circulation as well as within the cell are assumed to be important (Seiler et al. 1996). 
Interestingly, up-regulation of transport by polyamine depletion occurs rather slowly whereas 
down-regulation of transport by exogenous polyamines or relatively minor changes in intracel­
lular pools is a very sensitive and rapid process (Kramer 1996). Presumably, to avoid 
cytotoxic levels of polyamines is more critical to a cell than to adjust reduced growth due to 
inadequate polyamine supply.
Polyamine homeostasis
As discussed before, intracellular polyamine pool sizes and balance are maintained by the 
contribution of de novo synthesis, interconversion, terminal degradation, secretion and uptake 
of exogenous polyamines. In the same way, body polyamine pools are maintained since all 
organs require polyamines for their growth, renewal and metabolism. Although the organism 
is able to synthesize polyamines itself, it has been shown that the body relies on additional 
polyamines derived from exogenous sources, e.g. diet or microbial flora.
En d o g e n o u s  s o u r c e s  
De novo synthesis
As described earlier, de novo synthesis of polyamines occurs by the activity of ODC and 
SAMDC, which are dramatically increased during growth, development and regeneration. 
Activity of these biosynthetic enzymes can be rapidly induced by growth promoting stimuli, 
including hormones, growth factors, carcinogens and drugs (Tabor and Tabor 1984). In 
mammalian cells, ornithine, the substrate of ODC is synthesized from arginine in the liver and 
the kidney. The precursor of the aminopropyl moiety in the synthesis of spermidine and 
spermine is methionine. It is suggested, that 20-30% of the methionine pool is used for polya­
mine biosynthesis
Interorgan transport
Polyamines or their acetylated forms can also be secreted by (e.g. dying) cells. These circula­
ting polyamines and their acetylated intermediates can be take up and reused by polyamine 
demanding cells. Transport of polyamines from one cell to another via biological fluids is 
believed to be carrier-mediated. These circulating polyamine transporters can be proteins (e.g. 
anti-polyamine antibodies, lipoproteins) or cells (peripheral blood cells). Moulinoux et al. 
showed that more than 95% of circulating spermidine and spermine is transported by red 
blood cells (RBC's) and that the RBC polyamine levels correlate with tumor progression in 
tumor-grafted animals. Results from these studies and investigations in other animal models 
suggest that RBC polyamine levels reflect the proliferation status of normal or cancerous 
tissues (Cipolla et al. 1996; Moulinoux et al. 1996).
4
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Figure 3. Homeostasis o f body polyamine pools. Poyamines are derived from endogenous (de novo bio­
synthesis, interconversion, interorgan transport) as well as exogenous sources (diet, microbial flora).
As demonstrated by these studies, interorgan polyamine transport is realized by means of 
circulating polyamines, which participate in supporting normal and malignant proliferation. 
These extracellular polyamines play therefore an important role in homeostatic control of 
growth, not only at the level of the cell but also at the level of the whole organism.
Ex o g e n o u s  s o u r c e s  
Dietary polyamines
Systemic analyses of different foods revealed that a normal diet contains substantial amounts 
of polyamines (Bardocz et al. 1995; Ralph et al. 1999) All types of food, either of plant 
(vegetables and fruit) or animal origin (milk, eggs, meat) contained polyamines in varying 
amounts. Interestingly, the major types of food differ in their polyamine composition; red 
meat contained more spermine that putrescine or spermidine while fish had putrescine as the 
major polyamine component. Fruits or vegetables were rich in putrescine and spermidine. In 
milk, spermidine was the dominant polyamine while cheese was rich in putrescine and 
spermidine. Based on these data, the daily intake of polyamines for Dutch adults was 
estimated at 350-500 ^mol/per person per day (Ralph et al. 1999). Interestingly, analyses of 
polyamine contents in breast and formula milk showed that babies on breast milk are exposed 
to much higher polyamines than babies on artificial feed (Romain et al. 1992).
It is suggested that, as in the case of essential amino acids, the diet contains sufficient 
polyamines to support cell renewal and growth. However, only a part of the polyamines
5
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supplied by the diet is available for use by the body. Studies using radiolabeled polyamines 
demonstrated that polyamines are readily taken up by the gut probably by passive diffusion. 
Putrescine was predominantly metabolized by diamine oxidases to non-polyamine metabolites 
while 70-80% of spermidine and spermine remained in its original form. As measured by the 
accumulation of ingested 14C labeled spermidine in different rat tissues, it was found that the 
distribution of the labeled polyamine correlated with metabolic activity and growth of 
particular organs (Hughes et al. 1998; Bardocz et al. 1993, 1996, 1999).
In conclusion, the diet contains large amounts of polyamines, which can be absorbed and 
passed into the systemic circulation. By this, they can reach every tissue of the body and 
contribute to polyamine homeostasis. The importance of dietary polyamines in growth and 
health probably changes with the physiological or pathological state of the person. Polyamine 
requirements are higher in newborn and young during intensive growth and development. In 
adults, dietary polyamines play an important role during periods where intensive growth is 
required, e.g. wound healing, post-operative recovery and compensatory growth of the liver, 
lung and gut.
Since neoplastic growth also requires high concentration of polyamines, dietary polyamines 
could be used as target for the control of tumor growth. Studies in various tumor animal 
models have shown that a polyamine-free diet contributes to a more profound depletion of 
polyamines and subsequent arrest in tumor growth in animals treated with polyamine metabo­
lic inhibitors (Quemener et al. 1994). Furthermore, Pryme et al. demonstrated that the growth 
of grafted Krebs II cells tumors could be reduced by inducing intensive intestinal growth by 
inclusion of lectins in the diet. It was hypothesized that an interorgan competition for 
polyamines exists between vital organs and the tumor (Pryme et al. 1996, 1999).
Microbial flora
Bacteria present in the GI tract synthesize polyamines, predominantly putrescine and 
spermidine. Putrescine formation takes place by ornithine decarboxylation or by the combined 
action of arginine decarboxylase and agmatinase. In the latter reaction putrescine is produced 
(via arginine) from agmatine by release of urea. Spermidine is formed in the same way as in 
mammalian cells. Spermine is found in low levels only in particular species e.g. Acetobacteria 
Spp (Paulin et al. 1983). Putrescine can also be formed from ornithine by a so-called 
biodegradative ODC. In contrast to the biosynthetic enzyme, it is located extracellularly and 
induced in under semi-anaerobic and acid conditions (Gale, 1946).
The contribution of polyamines, produced by microbial flora in the GI tract, to body 
polyamine pools is still a matter of debate. Osborne and Seidel (1990) showed that putrescine 
and cadaverine synthesized by colonic bacteria are absorbed and transported to the proximal 
gut via enterohepatic circulation.
Function of polyamines
The exact molecular mechanisms by which polyamines perform their cellular functions are 
not yet well understood. With the exception of the incorporation of spermidine in hypusine 
(Park et al. 1997) polyamines are not incorporated into macromolecules but act as 
metabolically independent entities. Because of their basic character at physiological pH, in 
vitro, polyamines are able to bind to a variety of organic compounds, such as nucleic acids, 
proteins and phospholipids. Therefore, it has been suggested that in vivo polyamines are 
involved in the stabilization of these molecules and/or possibly facilitate their conformational 
shifts.
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The modes of interactions of the polyamines with DNA have been studied extensively in 
vitro using physical-chemical studies and computer-assisted molecular modeling. Spermidine 
and spermine cause condensation and aggregation of DNA and induce B-Z- and B-A 
transitions in certain DNA sequences (Thomas et al. 1991). These polyamine-DNA 
interactions and the resultant structural changes in DNA may provide the molecular basis by 
which the polyamines regulate cell proliferation. It has been suggested that a major biological 
function of the cationic polyamines related to cell division may be the stabilization of 
replication complexes between DNA and the nuclear matrix and the condensation and 
packaging of newly synthesized DNA into nucleosomes and chromatin (Matthews 1993; 
Raspaud et al. 1999). Baeza et al. (1991) hypothesized based on the plausible role of 
spermidine in condensation, protection, encapsulation, and biological properties of DNA that 
polyamines have played an important role in prebiotic evolution. In DNA replication, 
polyamines have been shown to be involved in the linking of Okazaki-like fragments, 
probably by interfering with DNA phosphorylation (Pohjanpelto and Holtta 1996). 
Polyamines also seem to be associated with the stabilization of RNA (Bolton and Kearns 
1977; Heerschap et al. 1985; Knapp 1989). NMR studies of interactions of polyamines with 
tRNAphe showed specific binding of spermidine and spermine with the double-stranded 
section of RNA. Furthermore, polyamines are involved in protein synthesis since spermidine 
is incorporated in hypusine, an essential factor in the translation initiation factor eIF-5A (Park 
et al. 1997). Recently, it has been recognized that polyamines can act as endogenous modifiers 
of ion-channel gating, properties that were previously assumed to be entirely intrinsic to the 
channel proteins. Several reports have now established that polyamines modulate the NMDA 
receptor ion channel and the voltage-dependent Ca2+ and K+ channels (Williams 1997).
Role of polyamines in cell proliferation and cell differentiation
Evidence from in vitro as well as in vivo experiments indicate that polyamines are intimately 
involved in cell proliferation. Thus, e.g. (a) cell mutants deficient in polyamine biosynthesis 
do not grow unless polyamines are added to the culture medium; (b) resting cells contain low 
levels of polyamines, but if  these cells are stimulated to divide by trophic factors levels of 
polyamines rise; (c) cell proliferation can be blocked by specific inhibitors of polyamines 
biosynthesis. Polyamine depletion causes an aberrated cell cycle progression and accumu­
lation of cells in either one of the phases in the cell cycle (Heby et al. 1978). Inhibition of 
polyamine biosynthesis has shown to have several effects on cell cycle -related features such 
as DNA sensitivity to DNAses (Baeza et al. 1991), topoisomerase-II directed chemotoxicity 
(Alm et al. 1999) and cyclin expression (Ray et al. 1999).
Polyamines also appear to influence cell differentiation. It is suggested that the decrease of 
the spermidine/spermine ratio reflects a transition from a proliferation into a differentiation 
state (Jänne et al. 1978). Further evidence for this supposition is based on ontogenetic studies 
showing the coincidence of increased polyamine levels and certain developmental events. In 
addition, normal development can be disturbed by exposure of the animals to substances 
known to inhibit polyamine biosynthesis (Heby 1981). Recent studies show that spermine, 
orally given in unweaned rat induces maturation of the liver, characterized by entering 
hepatocytes in a non-proliferative phase (G0) with the simultaneously appearance of specific 
functions of differentiated liver (Wery et al. 1996). Spermine also induces haemoglobulin 
synthesis in the differentiation of erythroleukemia cells (Delcros et al. 1995).
7
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Role of polyamines in cell death
13The number of cells (10 ) in an average adult human is kept remarkably constant due a fine 
balance between cell proliferation and cell turnover in a variety of organs. This means that for 
every new cell generated, one old cell must die to maintain the status quo in any multicellular 
organism. This controlled cell death occurs by a process referred as "programmed cell death" 
or apoptosis. Likewise cell proliferation, apoptosis is initiated by specific physiological 
signals, which activate a gene-directed cascade of biochemical and morphological events (see 
for review Fadeel et al. 1999). In apoptosis these events include oligonucleosomal DNA 
degradation, cytoplasmic and nuclear condensation and subsequent formation of membrane- 
bound apoptotic bodies. Apoptosis occurs extensively in a variety of normal tissues, in 
particular those with a high cell turnover such as gastrointestinal tract, liver and assorted 
lymphoid organs. In the embryo, apoptosis occurs at precise developmental stages of 
organogenesis. Cell death via apoptosis can also be a major determinant of the rate at which 
tumors grow. In addition, abnormal apoptosis can promote cancer development. Dysfunction 
of this controlled cell death can lead to serious pathological consequences, including 
oncogenesis, autoimmunity and degenerative disease.
The essential role of polyamines in cell growth and differentiation has been well 
established but evidence is merging that they also are important mediators of cell death. 
Changes in polyamine homeostasis have been reported during neuronal necrotic cell death, in 
programmed cell death of embryonic cells and in various in vitro systems of apoptosis. 
Exposure of cells to too high levels of polyamines or their analogs can lead to necrotic as well 
as apoptotic cell death. In addition, manipulating polyamine homeostasis by either inhibitors, 
analogs or exogeneously added polyamines, has profound effects on the rate of cell death. 
Induction of the rate-limiting biosynthetic enzyme ODC seems to be an early event in the 
induction of neuronal necrosis and apoptosis. However, it has yet to be unraveled if polyamine 
production has real physiological significance in cell death or is merely a secondary response 
or an attempt towards cell survival.
Aside an over-accumulation of polyamines, decreases of polyamine levels seems to be a 
more common feature in cell death especially in apoptotic pathways. Since polyamines are 
important in the stabilization of important cellular components such as cell membranes and 
chromatin structures, too low levels of polyamines could lead to loss of cell integrity and 
finally cell death. The observation made by several studies that exogeneously added 
polyamines can protect against cell death favors the idea of polyamines being important in 
processes needed for cell viability and cell survival.
Several mechanisms by which polyamines mediate cell death have been suggested, such as 
the stimulation of calcium fluxes, the formation of oxygen radicals, the modulation of 
transglutaminase activity, the regulation of cation channels, the protection against oxidative 
stress, and their ability to modulate DNA structure.
Studies on the involvement of polyamines in apoptosis are reviewed more in detail in chapter
9 of this thesis. From the studies reviewed, it can be concluded that polyamines are not only 
essential for cell growth and viability but also are intimately involved in cell injury and cell 
death. The variety of factors which can induce polyamine production and the many different 
effects that polyamines display in cellular physiology make them obvious candidates as 
important cellular regulators of cell proliferation as well as cell death. It is becoming more and 
more evident that the polyamine system takes part of well-regulated control machinery, which 
at any time takes final decisions in the choice between growth, survival or death of a cell.
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The growing awareness of the fundamentally important role of polyamines in cell kinetic 
behavior has enlarged the attraction towards the polyamine system as biomarkers for 
malignant behavior and as a target for chemotherapeutic intervention in the treatment of 
cancer and other diseases.
Role of polyamines in tumor cell growth and carcinogenesis
Polyamines are required for cell proliferation and, in tumor cell growth, increase of the 
polyamine pools and of the regulating enzymes in polyamine biosynthesis was demonstrated. 
Transfection as well as inhibition studies showed that ODC activity and polyamines are 
essential for transformation (Auvinen et al. 1992; O’Brien et al. 1997; Shantz and Pegg 1998; 
Tabib and Bachrach 1998). In some cases polyamines and their metabolic enzymes appear to 
be useful tumor markers. For example, erythrocyte polyamines are claimed to be of diagnostic 
value in prostatic adenocarcinoma and acute lymphoblastic leukemia (Cipolla et al, 1993), and 
ODC activity seems to be a marker of neoplastic growth in brain (Ernestus et al., 1993). SSAT 
proved to be a reliable biochemical marker for reversible and irreversible proliferation of 
bladder epithelium (Matsui Yuasa et al. 1992). More recently, polyamines have been 
described as potential biomarkers for cervical malignancies (Nishioka et al. 1995).
Inhibition of polyamine metabolism as target for antineoplastic therapy
Since polyamines are important for tumor cell growth, interference with polyamine 
metabolism could provide a promising target for chemotherapy of cancer. Several compounds 
are able to inhibit the action of the enzymes involved in the polyamine biosynthesis. Their 
potential as antineoplastic has been investigated and extensively reviewed (Porter et al. 1992; 
Marton and Pegg 1995; Kramer 1996). Although they can suppress tumor cell growth in vitro, 
so far, they fail to be successful as anti-cancer agents in vivo. Besides a lack of specificity and 
potency, also other factors related to the polyamine homeostasis might be responsible for this 
clinical failure, such as: (a) rapid turnover of the enzymes involved in the polyamine 
biosynthesis, (b) compensatory increase of the non-inhibited polyamine enzymes, (c) 
compensatory increase of polyamine uptake from extracellular sources, (d) compensatory 
retroconversion of the intracellular polyamine pools, since a single inhibitor can not deplete 
all three polyamine pools.
Antitumor activity of polyamine analogs
Recently, it has become clear that structural analogs of polyamines can act as antineoplastic 
agents. Polyamine analogs were initially developed to investigate the regulatory mechanisms 
that control polyamine homeostasis. Subsequently, research was done for polyamine analogs 
that down-regulate the biosynthetic enzymes, deplete intracellular polyamine pools and inhibit 
cell growth by failing to substitute for the depleted natural polyamines in functions required 
for proliferation. From all the compound synthesized so far, the most potent in cell growth 
inhibition are bis(ethyl)-analogs of spermine, and to a lesser extent, bis(ethyl)analogs of 
spermidine (Casero et al. 1989; Basu et al. 1994). Growth inhibitory effects of these 
compounds have been reported in L1210 cells, CHO cells oncogene transfected Rat-1 cells, 
large and small cell lung carcinoma, mouse and human melanoma cell lines, human pancreatic 
carcinoma, human colon carcinoma, human brain tumor cell lines, breast carcinoma and
1.2 O ncological aspects  of polyamines
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bladder cell lines. (Marton and Pegg 1995, and references herein). The cellular responses to 
these compounds were (a) inhibition of ODC and SAMDC activity, (b) depletion of the 
natural polyamine pools and (c) increase of SSAT activity.
Until now, the exact mode of action remains unclear, but depletion of mitochondrial DNA, 
inhibition of cell respiration and interactions with chromatin, probably resulting in dysfunctio­
nal changes, have been suggested as possible mechanisms. Also the huge induction of SSAT, 
which is directly or indirectly related to the sensitivity of the cells for the drugs, can have 
potential chemotherapeutic benefits. However, the relationship between induction of SSAT 
and the inhibition of cell growth is not yet fully understood. Several working mechanisms 
have been suggested, e.g. increased excretion and/or metabolism could rapidly deplete the 
intracellular polyamine pools, and acetylation of the polyamines could reduce their positive 
charges, and therefore reduce their ability to interact with macromolecules.
In conclusion, interference with polyamine homeostasis as a tool to inhibit tumor growth has 
been studied with various polyamine biosynthesis inhibitors and polyamine analogs. Inhibition 
of polyamine biosynthesis proved to be mostly cytostatic, since growth inhibition could be 
reversed by inhibitor withdrawal or polyamine repletion. These reversible cytostatic effects 
explain the limited success of these compounds in tumor growth inhibition in vivo attributed 
to the presence of exogenous polyamines allowing tumor cells to proliferate at a normal rate 
even if endogenous de novo production of polyamines is blocked. Most likely, specific 
inhibitors that will block the entry of exogenous polyamines into cells may provide better 
possibilities for therapeutic intervention in the polyamine metabolism. Manipulation of 
polyamine body pools, for instance by dietary means, may have additional value in the 
chemotherapy and chemoprevention of cancer.
Compared to polyamine biosynthesis inhibitors, polyamine analogs may have even more 
clinical value, since these compounds can be cytotoxic. It is evident that polyamine analogs 
are effective inhibitors of the growth of different types of cancer. Currently, some of the 
analogs are under phase I or II clinical investigation with promising results.
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Despite extensive biochemical and molecular biological research the precise role of the 
polyamine system in cellular physiology remains to be clarified. It is assumed that most 
functions of the polyamines are based on the electrostatically binding to ribosomes, DNA, 
RNA and membranes. Knowledge of the exact cellular and subcellular localization of 
polyamine metabolic enzymes might greatly contribute to the elucidation of the specific 
physiological functions of polyamines.
P art I  describes our efforts to establish the cellular sites of the polyamine biosynthetic 
metabolic enzyme ornithine decarboxylase (ODC) and the polyamine catabolic enzyme 
polyamine oxidase (PAO).
In the past several attempts have been made to localize ODC in cells and tissues with the 
use of biochemical, enzyme cytochemical, immunocytochemical and hybridocytochemical 
techniques. A literature study was performed to summarize and compare the various methods 
used for the in situ detection of ODC and the results obtained with these methods with respect 
to the distribution patterns of ODC in various cells and tissues (chapter 2).
A widely applied approach to localize ODC is immunocytochemistry is based on the use of 
antibodies that specifically bind to the enzyme protein. However, these studies showed 
different localization patterns depending on the cell system studied and the antibody used. An 
explanation for these discrepancies may be the lack of specificity of the ODC antibodies that 
were used. Furthermore, effects of cell and tissue preparation on the preservation and/or 
accessibility of the ODC protein for the antibodies were hardly defined.
To circumvent the problems with the heterogeneity of polyclonal antisera and the use of 
purified fractions of ODC as antigens, we produced monoclonal antibodies (MP16-2 and 
MP16-3) against an artificial immunogen, a hexadecapeptide representing a computer- 
calculated epitope (amino acid residues 345-360) of ODC (chapter 3). In this way, we were 
able to use a well-defined antigen both for immunization and for selection of monoclonal 
antibodies. Chapter 4 describes the conditions required for an optimal detection of ODC with 
the MP16-2 monoclonal antibody in homogenates, intact cells and tissue sections. Using 
optimized techniques we demonstrated high ODC immunoreactivity in cells and tissues that 
are engaged in growth or differentiation processes.
Although studies of polyamine homeostasis are focused on polyamine biosynthesis, recently 
the importance of the highly regulated process of polyamine catabolism has become apparent. 
Specific degradation of spermine and spermidine occurs via an interconversion pathway in 
which the polyamines are N 1-acetylated first before they are oxidized by PAO into spermidine 
and putrescine. With respect to the localization of the polyamine catabolic enzyme PAO, 
discrepancy exists about the substrate specificity and exact subcellular localization of this 
enzyme.
In chapter 5 we describe the development of a cytochemical technique for the localization 
of the activity for PAO in unfixed rat tissues. With this technique, insight was obtained in the 
substrate specificity of the enzyme and the heterogeneous distribution of its activity in various 
tissues, cells and intracellular peroxisome populations.
1.3 A im  and  o u tlin e  of  t h e s is
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The involvement of polyamines in cellular growth and differentiation has prompted many 
studies of their possible role in cellular neoplasia, including prostatic carcinoma and benign 
hyperplasia, which represent increasingly important pathologies in men.
The second objective of this thesis, as outlined in Part II, was to establish the use of 
polyamines as determinants of malignant cellular behavior and as potential targets for 
chemotherapy in prostate cancer.
As reviewed in chapter 6, polyamines are important for growth and function of the 
prostate. Preliminary results (chapter 7) and data from others (chapter 6) show that spermine 
levels are high in normal and benign prostatic hyperplasia in contrast to malignant tissues. We 
explored the possibilities of using magnetic resonance spectroscopy (MRS) for the detection 
of polyamines, especially spermine, to gain insight in the cell differentiation state of prostatic 
tissue in a non-destructive way. The preliminary results as described in chapter 7 suggest that 
non-invasive determination of spermine by in vivo proton MRS may be feasible in the future, 
providing a valuable new tool in the early diagnosis and in predicting the biological behavior 
of prostatic cancer.
Recent studies indicate that di(ethyl) analogs of polyamines have significant antitumor 
activity in several human solid tumor models. Chapter 8 describes the in vitro and in vivo 
studies of the antitumor effect of the polyamine analog bis(ethyl)norspermine (BE-3-3-3) on 
human prostatic cancer cells. The in vitro studies showed that all tested human prostatic 
cancer cells lines were sensitive to BE-3-3-3 in micromolar concentrations. An in vivo study 
in athymic nude mice showed that BE-3-3-3 was able to inhibit tumor growth of xenografts of 
a human prostatic cancer cell line.
Recent studies suggest that polyamines are not only essential for cell growth and viability but 
also are intimately involved in cell injury and cell death
Part I I I of this thesis deals with the putative functions of polyamines in controlled cell death 
also referred as programmed cell death or apoptosis. Chapter 9 gives a survey of the literature 
on the involvement of polyamines in apoptosis. Using in vitro cell systems, we investigated 
whether polyamine metabolism and intracellular levels of polyamines were changed during 
TNF-induced apoptosis in different human and murine cell lines (chapter 10), and calcium- 
ionophore induced apoptosis of prostatic cancer cells (chapter 11). In these studies, we also 
investigated the effects of compounds known to interfere with polyamine metabolism on 
apoptosis in these cells.
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ABSTRACT
Ornithine decarboxylase (ODC) is a key enzyme in poly amine biosynthesis. Increased 
polyamine levels are required for growth, differentiation and transformation o f cells. The 
exact cellular and subcellular localization o f ODC is still not known and hampers 
understanding o f the biological role o f the ODC/polyamine system. ODC has been localized 
in cells and tissues with the use o f biochemical, enzyme cytochemical, immunocytochemical, 
and in situ hybridization techniques. This review summarizes and compares the various 
methods that have been used for in situ detection o f ODC. Distribution patterns o f ODC that 
were obtained with these methods in various mammalian cells and tissues are interpreted. 
Differential localization patterns at the cellular level have been described, depending on type 
o f cells or tissues that were studied. These patterns varied from exclusively cytoplasmic to 
both cytoplasmic and nuclear. In general, localization patterns o f ODC are compatible with 
the hypothesis that ODC is intimately involved in rapid growth, tissue remodeling, 
differentiation and malignant transformation.
Key WORDS: ornithine decarboxylase / polyamines / localization, / enzyme cytochemistry / immuno- 
cytochemistry / in situ hybridization /
INTRODUCTION
O r n i t h i n e  d e c a r b o x y l a s e  (ODC, EC 4.1.1.17) is the first and regulatory enzyme in the 
polyamine synthesis pathway. It converts the amino acid ornithine to the diamine putrescine 
that is the obligatory precursor in biosynthesis of the polyamines spermidine and spermine 
(Figure 1). Polyamines are multifunctional organic bases which play an essential role in cell 
growth, differentiation and malignant development (Pegg 1986). For a comprehensive 
overview of the biochemistry and physiology of polyamines, the reader is referred to the 
books recently published by Cohen (1998) and Bardocz and White (1999). Biochemical and 
physiological features of ODC have aroused considerable interest in various fields of 
scientific research (see reviews by Russell 1985; Pegg 1986; Heby and Persson 1990; McCann 
and Pegg 1992; Hayashi and Murakami 1995; Hayashi et al. 1996).
The enzyme exhibits rapid and diverse changes in biological activity as an early response to 
virtually all growth promoting stimuli to cells including that of hormones, drugs, growth 
factors, mitogens and tumor promoters. Recent studies showed that overexpression of ODC 
can cause cellular transformation suggesting that the enzyme can be considered as a proto­
oncogen product (Auvinen et al. 1992, 1997; O’Brien et al. 1997; Shantz and Pegg 1998; 
Tabib and Bachrach 1998). The native enzyme is active as a homodimer and uses pyridoxal L- 
phosphate as cofactor. ODC can exist in multiple forms but it is not yet clear whether these 
different forms are isoenzymes, chemically modified enzyme protein or mutated ODC 
proteins (Cohen 1998).
ODC activity is controlled at the transcriptional, translational as well as posttranslational 
level and is under strict negative feedback control by its polyamine products (Heby and 
Persson 1990). Rapid and dramatic regulation of ODC expression is possible because of its 
extremely short half-life of several minutes to one hour (the shortest half-live of any known 
enzyme). Its degradation is regulated by a unique regulatory protein named antizyme, which is 
induced by polyamine-mediated translational frame-shifting (see for review Hayashi et al. 
1996). Antizyme binds reversibly to monomers of ODC and promotes its proteolytic 
degradation by the 26S proteosome. Additionally, antizyme also downregulates polyamine 
uptake by cells. Activity of antizyme is regulated by another unique protein. This antizyme
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inhibitor is highly homologous to ODC but lacks its activity completely and is believed to 
prevent ODC degradation by trapping the antizyme (Murakami et al. 1996). The enzymatic 
features of ODC are schematically summarized in Figure 1.
Despite extensive research the precise role of the ODC/polyamine system in cellular 
physiology remains to be clarified. Insight in the exact cellular and subcellular localization of 
ODC might provide valuable information on the role of this system in cellular physiology. 
Several approaches have been applied to localize ODC expression or activity in cells using 
biochemical, enzyme cytochemical, immunocytochemical and hybridocytochemical methods. 
This review summarizes and compares the various detection methods with respect to 
sensitivity and specificity. Furthermore, the results obtained with the various methods with 
respect to distribution patterns of ODC in tissues and cells in various organ systems are 
presented and interpreted.
Growth factors Tumor promoters
Mitogens Hormones
Drugs
Figure 1. Schematic overview o f the enzymatic features o f ornithine decarboxylase (ODC). See text for details.
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Methods for in  s it u  detection  of o r n it h in e  decarboxylase
Several approaches are available to localize enzyme protein and activity in cells and tissues. 
One of the methods is based on biochemical analysis of enzyme activity in fractionated cells. 
It allows detection of enzyme activity in subcellular fractions provided that redistribution or 
loss of activity of the enzyme does not occur during preparation of the subcellular fractions. 
However, the use of fractionated cells does not provide information on heterogeneity of ODC 
activity in a tissue or cell population.
A second approach, the enzyme cytochemical method, is based on precipitation and 
visualization of product(s) of a reaction catalyzed by the enzyme. In this case, the information 
on heterogeneity of activity can be acquired although several problems may occur. First, 
conditions of tissue preparation and incubation have to be chosen carefully to retain the 
enzyme at the original site in cells or tissues and to preserve activity. Furthermore, the final 
product has to be specific for the enzyme reaction and the precipitate should not diffuse or 
inhibit the enzyme (Stoward and Pearse 1991; Van Noorden and Frederiks 1992).
A relatively new and less elaborated strategy is the use of labeled specific irreversible 
inhibitors. Depending on the label that is used (fluorescence or radioactivity) the site of active 
enzyme can be demonstrated by fluorescence microscopy or autoradiography. Immunohisto- 
chemistry is a fourth more widely used approach, and based on the use of antibodies that 
specifically bind to the enzyme protein. These antibodies have to be applied to properly fixed 
and pre-treated cells or tissues and their site has to be revealed by a suitable detection system 
(Polak and Van Noorden 1997). Validity of the immunocytochemical method depends 
strongly on monospecificity of the antibody as well as preservation and accessibility of the 
antigenic site of the enzyme protein during processing of cells or tissue specimens. However, 
information on activity of the enzyme cannot be obtained.
An additional approach to gain information on cellular distribution patterns of an enzyme is 
to determine its gene expression at the mRNA level using in situ hybridization techniques. In 
situ hybridization is a powerful technique to study the spatial and temporal levels of specific 
gene activity. In conduction with activity localization and immunolocalization studies, 
information on tissue-specific gene regulation, enzyme degradation and posttranslational 
processing can be obtained.
As summarized in Table 1, all these approaches have been applied to localize ODC in 
mammalian cells and tissues as will be discussed in detail in the next sections.
Biochemical studies
Activity of ODC is routinely determined by measuring production of 14CO2 from [1- 
14C]ornithine (Pegg and Williams-Ashman 1968). This biochemical method is highly 
sensitive, but care has to be taken that improper homogenization procedures or storage of 
frozen supernatants cause artefacts due to the metabolism of ornithine via the mitochondrial 
pathway (Gaines et al. 1988).
This CO2-trapping technique has been used to determine ODC activity in subcellular 
fractions of rat prostate (Pegg and Williams-Ashman 1968), rat liver (Ono et al. 1972; Murphy 
and Brosnan 1976; Bitonti and Couri 1981; Grillo and Fossa 1983; Bartholeyns 1983) and 
mouse fibroblasts (McCormick 1977). Most studies showed that ODC activity is mainly or 
exclusively found in the cytosolic fraction (Pegg and Williams-Ashman 1968; McCormick 
1977; Grillo and Fossa 1983) with or without induction by growth stimuli (Ono et al. 1972; 
Murphy and Brosnan 1976). However, some studies demonstrated the presence of ODC in the 
nucleus (Snyder and Russell 1970; Bitonti and Couri 1981). On the basis of an improved
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fractionation procedure, Bartholeyns (1983) could establish that ODC activity is equally 
distributed over nuclear and cytoplasmic fractions in nonstimulated liver. Nuclear ODC, 
which was mainly found in the nucleoli, was not induced by growth stimuli in contrast to 
cytoplasmic ODC. A study using barley seeds suggested that ODC is predominantly present in 
the nucleus, tightly bound to chromatin (Panagiotidis 1982).
Table 1. Methods for in situ detection o f ornithine decarboxylase
Method Marker Specificity Sensitivity Application Reference
Biochemistry
Activity
Measurement
o
C4 High High Fractionated
cells
Pegg and Williams- 
Ashman 1968 
Snyder and Russell 1970 
Ono et al. 1972 
Raina and Jänne 1968 
Murphy and Brosnan 1976 
McCormick 1977 
Bitonti and Couri 1981 
Panagiotidis 1982 
Bartholeyns 1983 
Grillo and Fossa 1983
Enzyme cytochemistry
Cytochemical trapping CO2 Not clear High Tissues Dodds et al. 1990
Labeling with irreversible 
enzyme inhibitor
14C-DFMO High Low Tissues Pegg et al. 1982 
Zagon et al. 1984
3h -d f m o
Rhodamine-
DFMO,
Biotine-
DFMO
High 
Not clear
Moderate
Moderate
Cells/Tissues
Tissues
Emanuelsson and Heby 1982 
Anehus et al. 1984 
Zagon et al. 1984 
Morris et al. 1986 
Schweitzer et al. 1988 
Gritli-Linde and Linde 1994
Gilad and Gilad 1981
Immunocytochemistry
Labeling with anti-ODC 
Antibodies
Polyclonal
antiserum
Variable High Cells/Tissues Persson 1982 
Isomaa et al. 1983 
Seely and Pegg 1983 
Greenfield et al. 1986 
Kahana and Nathans 1984 
Pomidor et al. 1995
Monoclonal
antibody
High High Cells/Tissues Matsufuji et al. 1984 
Nishiyama et al. 1989 
Schipper et al. 1993, 
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In situ hybridization
Labeling with cDNA or 
CRNA probe
3H-UTP,35S- 
UTP, DiG- 
UTP
High High Tissues Blackshear et al. 1989 
Kaipia et al. 1990 
Jänne et al. 1991 
Bertuzzi et al. 1992, 1995 
Gan et al. 1992, 1993 
Crozat et al. 1992 
Koibuchi et al. 1993a, 1995 
Wright et al. 1995 
Keinanen et al. 1997 
Takada et al. 1998 
Ohtsuka et al. 1998
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The results of biochemical fractionation studies on the localization of ODC activity are 
rather conflicting. Possible contamination of the nuclear fraction with cytosolic ODC may 
have lead to false conclusions about the presence of ODC in the nucleus. On the other hand, 
rigorous homogenization can damage nuclei causing leakage of nuclear ODC to the 
cytoplasm. However, our interpretation of the data is that ODC activity is present in both 
cytoplasm and nucleoplasm or nucleoli. Nuclear ODC might be differently regulated since 
ODC activity induced by growth promoting stimuli, is only increased in the cytoplasm.
Enzyme cytochemical demonstration of ODC activity
ODC decarboxylates ornithine to produce putrescine and CO2. A method to localize CO2 in 
cells or tissue has been described by Dodds et al. (1990). In this method, lead 
hydroxyisobutyrate is used to precipitate CO2. The colorless reaction product, apparently lead 
carbonate, is subsequently converted in a second step with ammonium sulfide to black lead 
sulfide. This colored precipitate can be measured cytophotometrically with the use of image 
analysis. The major criticism of this method is that CO2 from other sources such as carbonic 
anhydrase (Wright and McMillan 1990) might cause inaccurate localization of ODC activity. 
Although difluoromethylornithine (DFMO), a specific irreversible inhibitor of ODC (Metcalf 
et al. 1978), decreased the amount of final reaction product (Dodds et al. 1990), specificity of 
the method needs further validation
Another enzyme cytochemical method is based on the use of labeled DFMO to localize the 
site of active ODC. Since DFMO is highly specific for ODC and does not react with the 
inactive ODC-antizyme complex (Kitani and Fujisawa 1986a) a reliable labeling of 
catalytically active ODC can be obtained. However, the use of DFMO to localize ODC in vivo 
has some drawbacks. Accuracy and sensitivity of ODC localization strongly depend on in vivo 
binding of the labeled inhibitor to ODC. Low levels of ODC are not detected and it is not 
clear whether DFMO is taken up in similar way by the different cell types or subcellular 
compartments that have been investigated (Seely et al. 1982; Kitani and Fujisawa 1986b).
Gilad and Gilad (1981) have used DFMO that was conjugated to rhodamine or biotin, 
which can then, be visualized directly or indirectly. However, specificity of these DFMO 
conjugates for ODC is questionable since conjugation of the amino groups of DFMO may 
markedly decrease affinity for ODC as has been shown for other analogues of ornithine (Bey 
et al. 1978). The problem of decreased specificity and/or affinity of the inhibitor for ODC 
after conjugation can be overcome by the use of a radioactive derivative of DFMO. studies 
clearly show that ODC is labeled stoichiometrically with radioactive DFMO (Pritchard et al. 
1981; Pegg et al. 1982; Zagon et al. 1984; Gritli-Linde and Linde 1994). Binding of the 
labeled inhibitor to ODC was rapidly lost or reduced in vivo after inhibition of protein 
synthesis by cycloheximide which is consistent with the rapid turnover of ODC (Pegg et al. 
1982; Zagon et al. 1984; Gritli-Linde and Linde 1994).
Autoradiographic localization studies of ODC with 14C-labeled (Pegg et al. 1982; Zagon et 
al. 1984) or 3H-labeled DFMO (Emanuelsson and Heby 1982, 1983; Anehus et al. 1984; 
Zagon et al. 1984; Morris et al. 1986; Schweitzer et al. 1988; Gritli-Linde and Linde 1994) 
have been performed on cultured cells as well as on tissues (Tables 2 and 3).
Enzyme cytochemical detection of ODC is of utmost importance since its links ODC 
activity topologically to cell and tissue structures. Interestingly, these studies suggest that 
ODC is localized in both cytoplasm and nucleoplasm or nucleoli. These data corroborate with 
our interpretation of the biochemical data of ODC activity.
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Im m unocytochem ical localiza tion  o f  ODC
Purification of ODC and its application as an antigen to produce specific antibodies is a 
laborious and specialized task due to the extremely low cellular concentrations and high 
instability of the enzyme. In early attempts to produce anti-ODC antiserum, purified enzyme 
preparations from rat liver were used as antigen for immunization (Höltta 1975; Theoharides 
and Canellakis 1976; Obenrader and Prouty 1977; Kallio et al. 1979). However, specificity of 
the antisera was difficult to establish. The introduction of improved purification methods 
enabled development of antisera with higher specificity against ODC isolated from yeast 
(Tyagi et al. 1981), rat liver (Kameji et al. 1982), mouse kidney (Persson 1982; Seely and 
Pegg 1983; Isomaa et al. 1983; Nishiyama et al. 1989) and murine RAW 264 cells (Greenfield 
et al. 1986). Partially purified preparations of ODC of rat liver and mouse kidney have also 
been used as antigen for the production of anti-ODC monoclonal antibodies (Matsufuji 1984; 
Pegg et al. 1984; Donato et al. 1986; Kopitz et al. 1990a). In these studies, ODC labeled with 
radioactive DFMO was applied to select antibodies that were specifically directed to ODC.
To circumvent some of the methodological problems with ODC immunocytochemistry, we 
produced monoclonal antibodies (MP16-2 and MP16-3) against an artificial immunogen, a 
hexadecapeptide representing a computer-calculated epitope (amino acid residues 345-360) of 
ODC (Schipper et al. 1993, chapter 3). In this way, we were able to use a well-defined antigen 
for both immunization and selection of monoclonal antibodies. Another advantage of this 
approach is that the specificity of the ODC epitope can be confirmed by comparing the 
selected sequence with primary sequences of other proteins. Immunoblotting studies revealed 
that the MP16 antibodies recognized native ODC protein but not ODC complexed with 
DFMO indicating that the antibodies were directed to the active site of ODC (Schipper et al. 
1993,1999, chapter 3,4). Poulin et al. (1992) reported that a cysteine at position 360 is very 
important for catalytic activity of ODC and this amino acid is present in the hexadecapeptide 
that we used as antigen. Since DFMO-labeled ODC is not recognized by our antibodies, 
additional information on the catalytically active fraction of immunostained ODC becomes 
feasible by comparing staining patterns that are obtained in DFMO-treated and untreated cells 
and tissues. However, the use of DFMO in vivo has some disadvantages as discussed earlier. 
We are currently investigating whether ODC immunoreactivity towards the MP16 antibodies 
can be blocked by other irreversible ODC inhibitors that are more suitable to label ODC in 
vivo than DFMO.
The antisera and monoclonal antibodies described above (Table 1) have been used to 
localize ODC in cultured cells (Table 2) and tissues (Table 3). The ODC localization patterns 
in these studies varied from a cytoplasmic or (peri)nuclear pattern to a both cytoplasmic and 
nuclear localization depending on the cell system studied and the antibody used. An 
explanation for these discrepancies may be the lack of specificity of some of the ODC 
antibodies that were used. Furthermore, effects of cell and tissue preparation (e.g. fixation 
procedures, permeabilization, dehydration and embedding in paraffin) on preservation and/or 
accessibility of ODC protein for the antibodies were hardly defined in most studies. Antigens 
in cells, although well preserved after fixation, might be masked or linked to other 
components (for instance by means of hydrogen or disulfide bonds) and therefore hardly 
accessible to antibodies. Another problem in ODC immunocytochemistry is that formation on 
the nature or activity of the detected ODC protein cannot be obtained. ODC antibodies may 
also react with catalytically inactive forms of ODC, e.g. monomeric subunits of ODC or 
monomers bound to the ODC-inhibitory antizyme protein. Furthermore, ODC antibodies may 
possibly cross-react with the antizyme inhibitor, which shows a high homology with ODC
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protein but lacks its catalytic activity (Murakami et al. 1996). The existence of multiple or 
modified forms of ODC may further complicate the immunocytochemical localization of 
ODC. In preparations of mouse kidney, two species of active ODC protein were found which 
might represent true isoenzymes (Kitani and Fujisawa 1988). ODC has been shown to be 
posttranslationally modified by arginylation or phosphorylation producing heterogeneous 
ODC molecules, which are differently charged and/or have different enzymatic properties 
(Kopitz et al. 1990b; Reddy et al. 1996; Brown et al. 1994). Phosphorylation has been shown 
to mask an epitope of mouse ODC that is recognized by a monoclonal antibody (Donato et al. 
1986).
In most of the immunocytochemical studies, ODC localization was found to be 
predominantly cytoplasmic. The presence of ODC in the cytoplasm may be justified by the 
fact that polyamines play essential roles in the machinery of protein biosynthesis. This 
hypothesis is further supported by immunoelectron microscopical studies of ODC and 
polyamines in which the label was closely associated with rough endoplasmic reticulum and 
polyribosomal structures, respectively (Morisett et al. 1986; Fujiwara et al. 1998).
Anehus et al. (1984) compared an immunocytochemical and an enzyme cytochemical 
method using radiolabeled DFMO to determine the intracellular localization of ODC in ODC- 
overproducing CHO cells. The immunocytchemical method using polyclonal antibodies of 
Persson (1982) showed considerably more ODC in the cytoplasm than in the nucleus. In 
contrast, ODC that was demonstrated by autoradiography using radiolabeled DFMO was 
evenly distributed over the cell. This difference in distribution patterns suggests the existence 
of a cytoplasmic pool of catalytically inactive ODC protein, which might represent 
posttranslationally modified ODC. Another explanation is that ODC largely exist as inactive 
complex with antizyme protein in the cytoplasm as was reported to exist in adult mouse brain 
(Laitinen 1985).
Interestingly, in some immunocytochemical studies ODC protein was also detected at the 
nuclear envelope and plasma membranes or associated with cytoskeletal components, an 
observation not made in studies using biochemical and enzyme cytochemical methods. 
Overall, data obtained by immunocytochemistry can be interpreted that most of the 
cytoplasmic ODC fraction is inactive and that a fraction of this inactive ODC is associated 
with structural elements of the cell, e.g. membrane-associated structures or cytokeletal 
components.
In situ hybridization histochemistry of ODC mRNA
The promotor of the ODC gene contains multiple regulatory elements and increased 
transcription of the ODC has been observed in response to growth factors, hormones, 
oncogene products and tumor promotors. For example, ODC mRNA is increased 10-20 fold 
after 4 days of testosterone treatment in mouse kidney (Kontula et al. 1984). Two mRNA 
species (2.1 Kb and 2.6 Kb) have been identified in mouse cells whereas rat tissues contain a 
third mRNA species (1.6 Kb) (Hirvonen 1988).
In situ hybridization studies using a labeled cRNA or cDNA probe specifically hybridizing 
with ODC mRNA have been performed on mouse, rat and human tissues. The localization 
patterns of ODC mRNA was, at least partially, consistent with ODC localization patterns 
obtained in biochemical and immunocytochemical studies. However, many other experiments 
have provided evidence for translational and posttranslational control of ODC (Heby and 
Persson 1990). Therefore, localization and concentration of mRNA may not actually reflect 
ODC expression at the level of ODC protein and/or enzyme activity.
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D i s t r i b u t i o n  p a t t e r n s  o f  ODC i n  c e l l s  a n d  t i s s u e s  
Cultured cells
Intracellular localization of ODC in cultured cells was studied for the first time in stimulated 
murine macrophage-like RAW 264 cells using a polyclonal antiserum against ODC that had 
been purified from this cell line (Greenfield et al. 1986). ODC immunoreactivity was found 
exclusively in the cytoplasm whereas in a cell line of epidermal origin (JB6), ODC protein 
was found in both cytoplasm and nucleoplasm but not in nucleoli.
Shayovits and Bachrach (1994) detected immunocytochemically ODC in human epithelial 
carcinoma cells and transformed mouse fibroblasts. ODC immunoreactivity was decreased 
after treatment with cell growth-inhibiting drugs. ODC showed a perinuclear/nuclear distri­
bution pattern in the growing cell fraction of human keratinocytes but it became more 
diffusely localized in the cytoplasm when cell growth was arrested (Pomidor et al. 1995). 
Recently, a combined biochemical and immunocytochemical study demonstrated translocation 
of a fraction of cytosolic ODC to the plasma membrane during cell activation and 
transformation of rat fibroblasts (Heiskala et al. 1999).
Table 2. Localization o f ornithine decarboxylase in cells
Cell type species Method subcellular
localization
Reference
Fractionated cells
Prostate cells Rat B Cyt Pegg and
Williams-Ashman 1968
Liver cells Rat B Cyt/Nuc Snyder and Russell 1970
Cyt Ono et al. 1972
Cyt Raina and Jänne 1968
Cyt Murphy and Brosnan 1976
Cyt/Nuc Bitonti and Couri 1981
Cyt Grillo and Fossa 1983
Cyt/Nuc Bartholeyns 1983
Fibroblasts Mouse B Cyt/Nuc McCormick, 1977
Seeds Barley B Nuc/Cyt Panagiotidis 1982
Cultured cells
Mutant ovary cells Chinese - ICa - Cyt/Pnuc
Hamster - EC - Cyt/Nuc Anehus et al. 1984
RAW 264-macrophage-like Mouse ICc - Cyt
JB6-epidermal - Cyt/Nuc Greenfield et al. 1986
- KB1- epithelial carcinoma, Human ICe Cyt
- Transformed NIH 3T3 fibroblasts Mouse Shayovits and Bachrach 1994
NHEK-keratinocytes Human ICb,h Pnuc/Nuc Pomidor et al. 1995
Ts RSV-infected fibroblasts Rat B;ICd,f Cyt/Pmem Heiskala et al. 1999
- WISH-amnion cells Human ICg Cyt/Pnuc
- HCT 116 colon cancer cells Human Schipper et al. 1999,
- Transformed NIH 3T3 fibroblasts Mouse chapter 4
B, Biochemistry; EC, Enzyme cytochemistry; ICa-h, Immunocytochemistry using a) polyclonal antiserum from Persson 1982; 
b) polyclonal antiserum from Isomaa et al. 1983; c) polyclonal antiserum from Greenfield et al. 1986; d) monoclonal antibody 
from Matsufuji et al., 1984; e) polyclonal antiserum o f Kahana and Nathans 1984; f) monoclonal antibody from Nishiyama et 
al. 1989; g) monoclonal antibody o f Schipper et al. 1993, chapter 3; h) polyclonal antiserum o f Pomidor et al. 1995; Cyt, 
cytoplasmatic; Nuc, nuclear; PMem, plasma membrane; Pnuc, perinuclear.
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Table 3. Localization o f ornithine decarboxylase in tissues
Tissues Species Inducing
event
Method subcellular
localization
Reference
Brain
Cerebral cortex (7 day old) Rat Maturation EC Cyt/Nuc Gilad and Gilad 1981
Whole brain (9 day old) Rat Maturation EC Cyt/Nuc Morris et al. 1986
- Whole brain (2-6 days old) Rat Maturation ICb - Cyt/Nuc
- Hippocampal neurons and Purkinje - Cyt/Nuc
dendrites (7-14 days old) Dorn et al. 1987
- Dendrites, axons, putative terminals Rat ICa - Cyt
- All neurons - Nuc Cintra et al. 1987
Neurons Gerbil Ischemia IC PNuc Dempsey et al. 1988
External granular zone, Purkinje layer Rat Ischemia EC Cyt/Nuc Schweitzer et al. 1988
Hippocampal glial cells Rat Subconvulsi- IC Cyt/Nuc Orzi et al. 1990
ve stimuli
Pituitary gland Xenopus ICb Cyt/Nucl Müller et al. 1991a
laevis D.
Lateral striatum, hippocampus Gerbil Ischemia ICb Pnuc Müller et al. 1991b
Spinal motoneurons, motoric nerves, Rat IC Cyt/Pnuc
myoneural junctions Juntilla et al. 1993
Neurons/neuroblasts Human Maturation ICb Müller et al. 1993
- Neocortical neurons (scarcely) Human - Normal EC - Pnuc
- Neocortical neurons (ubiquitously) - Alzheimer - Nuc Bernstein
disease and Müller 1995
Glial cells in hippocampus, hilus, Rat Subconvulsi- ICb Cyt
subculum, fornix and corpus ve stimuli Bernstein et al. 1995
callosum
Ipsilateral dentate gyrus and cortex Rat Ischemia ISH Keinanen et al. 1997
Cerebral cortex Rat Maturation IC Cyt Ichikawa et al. 1997
Cochlea
Ganglion spirale Guinea pig ICb Cyt Müller et al. 1988
- Organ of Corti Rat ICd Cyt
- Lateral wall/coclear nerve Henly et al. 1995
Kidney
Highest in proximal tubuli Mouse Testosterone EC Cyt/Nuc Pegg et al. 1982
Highest in proximal tubuli Mouse Testosterone EC Cyt/Nuc Zagon et al. 1984
Proximal tubuli Mouse Testosterone ICa Cyt Persson et al. 1982a,
1983
Tubuli Rat Maturation ICb Cyt Dorn et al. 1983,
Müller et al. 1986
S3 cells in proximal tubuli Rat Testosterone ISH Blackshear et al. 1989
Highest in poximal tubuli (granular-like) Mouse Testosterone EC Cyt Dodds et al. 1990
- Inner proximal tubuli (heterogenous) Mouse Testosterone ICg, ISH Cyt
- Outer proximal tubuli (granular-like) Koibuchi et al. 1990,
1993a,b, 1995
Liver
- Normal Human ICd, ISH - Cyt
- Cirrhosis, hepatocellular carcinoma - Cyt Gan et al. 1993
Liver parenchyma Rat EC Cyt Gilad and Gilad 1981
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Ovary
Thecal layer round follicles in interstitial Rat, 
gland tissue, internal thecal layer
Human
chorionic
gonadotropin
ICa
Interstitial gland 
Granulosa cells
pancreas
Exocrine cells
A-cells of islets of Langerhans 
Exocrine cells 
Islets of Langerhans
Prostate/ Testis/ Epididymus
Prostatic acinar cells
Acromosomal regions of spermatids 
and epididymal spermatozoa
Seminiferous epithelium
Rat,
Hamster
Rat
Rat
Rat
Rat
Rat
Rat
Rat
Rat
Rat, Mouse
Pro-oestrus ICa
Pregnant Ice 
mare serum 
gonadotropin
ICa*
ICb
ICh
Maturation ICh
ICb
Testosterone ICh 
ICd
ISH
Cyt
Cyt
Cyt
Nuc/R.E.R
Cyt
Cyt/Nuc
Cyt
Cyt
Cyt
Cyt
Persson et al. 1982b
Persson et al. 1986 
Lee and Dias 1988
Morisset et al. 1986 
Dorn et al. 1986 
Romain et al. 1998 
Schipper et al. 1999, 
chapter 4
Dorn et al. 1985 
Muller et al. 1986 
Schipper et al. 1999, 
chapter 4
Qian et al. 1985
Kaipa et al. 1990
Skin
Suprabasal keratinocytes hair follicles 
Basal and corneal layer 
Squamous cell carcinoma 
Keratinocytes
- Perifollicular cells
- Interfollicular and perifollicular areas
- Interfollicular epidermis
- Hair follicles (normal)
- Suprabasal layer (after TPA)
- Suprabasal layer (papillomas)
Keratinocytes in dermal follicular cysts
- Few basal cells (normal pappilloma)
- Suprabasal cells (transgenic papilloma)
Epidermis
stomach/ small intestine/ Colon
Oxyntic gland mucosa
- Villus cells
- Villus and crypt cells
- Crypt cells
Mouse TPA ICc
Human IC
Human ICc
Mouse TPA FCc
Mouse - TPA ICc; FCc
- mezerein
- EPP
Mouse TPA ICc
Mouse ODC- ICc 
transgenic
Mouse ODC- ICc 
transgenic
Human systemic ISH 
clerosis
Rat Gastrin ICd
Rat - Fasting ICd
- Refeeding
- Gastrin
Cyt Gilmour et al. 1986
Cyt Verrando et al. 1987
Cyt Hietala et al. 1988
Cyt Robertson et al. 1990
Cyt
Gilmour et al. 1992
Cyt
Sundberg et al. 1994 
Cyt Megosh et al. 1995
Cyt
O’Brien et al. 1997 
Ohtsuka et al. 1998
Cyt Johnson et al. 1988
- Enuc,
- Enuc/Cyt Johnson et al. 1989,
- Cyt Haddox et al. 1992
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Miscellaneous
Germ cells Polychaete Oogenesis EC Nuc/Nucl Emanuelsson and 
Heby 1982
Heart atrial granules Rat Isoproterenol ICd* Cyt Tipnis et al. 1989
Palate Mouse Maturation ICa Cyt/Pnuc Gawel and 
Greene 1992
Dental tissues Mouse Maturation EC Cyt/Nuc Gritli-Linde and 
Linde 1994
Bladder Rat Papillo­
matosis
ISH Takada et al. 1998
B, Biochemistry; EC, Enzyme cytochemistry; FC, Flow cytometry, ICa-i, Immunocytochemistry using a) polyclonal 
antiserum from Persson 1982; b) polyclonal antiserum from Isomaa et al. 1983; c) polyclonal antiserum from Seely and 
Pegg 1983; d) polyclonal antiserum from Greenfield et al. 1984; e) polyclonal antisera from Kahana and Nathans 1984; f) 
monoclonal antibody from Matsufuji et al. 1984; g) polyclonal antiserum from Nishiyama et al. 1989; h) monoclonal 
antibody from Schipper et al. 1993,chapter 3; i) polyclonal antiserum o f Pomidor et al. 1995; ISH, in situ hybridization; 
Cyt, cytoplasmic; Nuc, nuclear; Nucl, nucleoli; Enuc, epinuclear; Pnuc, perinuclear. * by electron microscopy
With our monoclonal antibody MP16-2, we examined localization of ODC in various 
human and murine cell lines (Schipper et al. 1999, chapter 4). Strong immunoreactivity of 
ODC was detected in the proliferating fraction of cultured cells, especially in those cells 
showing mitotic figures. In confluent cells, ODC staining was faint and diffusely distributed 
throughout the cell, predominantly in the cytoplasm with the highest density in the perinuclear 
region, as revealed by confocal laser scanning microscopy.
It is not yet clear whether the distinct changes in ODC expression or localization patterns 
actually reflect progression through the cell cycle. The ODC gene has been described as a cell 
cycle-dependent gene that is only weakly expressed in quiescent cells. Its expression is 
strongly increased in proliferating cells (Kaczmarek 1986). ODC is an "early gene", its 
transcription is increased early in the cell cycle (Kaczmarek et al. 1987; Pena et al. 1995). 
ODC mRNA increases at the beginning of the G1 phase both in cycling and stimulated 
quiescent smooth muscle cells (Campan et al. 1992). ODC activity increases in late G1 and 
peaks in G2 before the onset of mitosis suggesting that ODC expression is biphasic during cell 
cycle (Heby et al. 1976; Fredlund et al. 1995). Interestingly, recent data indicate that changes 
in ODC activity and translocation is associated with rearrangements of the cytoskeleton 
(Pomidor et al. 1995, Heiskala et al. 1999) suggesting attachment of ODC to structural 
elements and/or a role of ODC in cytokinesis. In order to draw firm conclusions about ODC 
levels in relation with the cell cycle, detailed studies using synchronized cell cultures are 
necessary. For instance, flow cytometric detection of ODC expression in relation with DNA 
content would provide new information. Furthermore, dynamic studies of ODC within living 
cells would greatly improve our understanding of the role of ODC in cell kinetic processes. 
For this purpose, we are currently investigating the applicability of green fluorescent protein, a 
recently developed powerful tool to study dynamic molecular events within living cells 
(reviewed by Tsien 1998), as a marker of ODC gene expression and ODC protein targeting in 
intact cells and organisms.
In general, in most studies higher levels of ODC were detected in smaller, more rapidly 
growing cells. ODC expression seems to be correlated with cell proliferation and cell 
transformation. Translocation of ODC might be an important regulatory event in these cellular 
processes. In situ detection of ODC may therefore be useful as biomarker for (malignant) 
cell proliferation or, conversely, as an indicator for sensitivity to anti-proliferative drugs as 
suggested by Shayovits and Bachrach (1994).
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Nervous system
Considerable evidence exists for a role of ODC and polyamines in neurobiological systems 
(for a review, see Bernstein and Müller 1999). In brain, temporal relationships between ODC 
activity and developmental or behavioral patterns have been found (Slotkin 1979; Slotkin and 
Bartholome 1986). Besides, a function of brain-associated ODC in response to mechanical, 
chemical and ischemic injuries has been documented (Paschen, 1991).
In rat and mouse brain, ODC activity is highest during birth and declines after the first 
week to a low adult level (Slotkin and Bartholome 1986). Localization studies of ODC during 
brain development in rat (Gilad and Gilad 1981; Morris et al. 1986; Dorn et al. 1987) and 
human (Müller et al. 1993) correlate with these biochemical findings. ODC expression was 
highest and ubiquitously distributed in rat cerebellum during the first week of development 
(Gilad and Gilad 1981; Dorn et al. 1987; Ichikawa et al. 1997) and remained present in 
discrete neural structures, e.g. the molecular layer of the cerebellum (Morris et al. 1986; Dorn 
et al. 1987) or spinal motoneurons (Cintra et al. 1987; Juntilla et al. 1993). Similarly, during 
human brain development, high ODC immunoreactivity was found in the first stages that are 
characterized by neuroblast proliferation and migration. In adult human brain, immuno­
reactivity was restricted to motoric and hippocampal neurons (Müller et al. 1993).
A sharp rise in brain ODC activity has also been found in various pathological conditions 
of the brain (Paschen 1992, and references herein). During cerebral ischemia, ODC gene 
expression and ODC protein synthesis are markedly increased after reflow, which is followed 
by a vast and prolonged increase in putrescine levels. The post-ischemic rise of ODC was 
found only in neurons in all brain structures but its expression was most pronounced in 
vulnerable brain areas (Schweitzer et al. 1988; Dempsey et al. 1988; Müller et al. 1991b). The 
close relation between ODC activity and the density of neuronal necrosis argues for a role of 
ODC in cell injury after ischemia. Polyamine levels may play an important role in the 
breakdown of the blood-brain barrier and formation of vasogenic edema processes, which 
occur after ischemic and traumatic brain injury (Baskaya et al. 1996). In addition, polyamines 
have deleterious effects on nerve cells by interactions with the N-methyl-D-aspartate (NMDA) 
receptor, which contains specific recognition sites for polyamines (Williams et al. 1991). 
However, recent studies support the idea that ODC activation and polyamine accumulation are 
attempts to protect or repair neurons during brain ischemia (Reeben et al. 1996; Keinanen et 
al. 1997; Lukkarinen et al. 1997, 1998). Increased ODC immunoreactivity in glial cells has 
also been found after subconvulsive electric and chemical stimuli of the brain (Orzi et al. 
1990; Bernstein and Müller, 1999). ODC expression is often increased in neocortical neurons 
including dendrites and axons due to Alzheimer's disease (Bernstein and Müller, 1995). These 
studies suggest that induction of ODC occurs in stress-induced pathological disturbances of 
the brain.
In conclusion, ODC expression may be closely associated with normal and pathological 
processes in the brain. However, whether induction of ODC has real pathological 
consequences or is merely a trophic response to stress or an epiphenomenon remains to be 
established. During brain maturation, ODC localization is restricted to neurons, which is in 
agreement with the proposed role of ODC in neuronal migration, axogenesis and 
synaptogenesis (Slotkin and Bartolome 1986). In pathological conditions, ODC is generally 
localized in neurons except after subconvulsive stimuli resulting in the appearance of ODC in 
glial cells.
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Urogenitical system
ODC is particularly active in epithelial cells of rodent kidneys and accessory sex organs and is 
regulated by sex hormones inducing hyperplastic and hypertrophic responses (Pegg et al. 
1970; Blackshear et al. 1989; Jänne et al. 1991; Crozat et al. 1992; Fjosne et al. 1992; 
Calandra et al. 1996). Studies of the murine ODC gene revealed that the ODC promoter 
contains an androgen-responsive element-like sequence that can bind to the androgen receptor 
in vitro (Crozat et al. 1992. Increased levels of ODC mRNA and activity induced by 
androgens have been reported in kidney, testis, prostate and seminal vesicles (Crozat et al. 
1992; Calandra et al. 1996). In addition, ODC has been found in human prostatic fluid, 
seminal plasma and sperm (Jänne et al. 1973; Mohan et al. 1999).
Localization of ODC expression in mouse or rat kidney following testosterone treatment 
has been studied with use of enzyme cytochemical (Pegg et al. 1982; Zagon et al. 1984; Dodds 
et al. 1990) and immunocytochemical tools (Persson et al. 1982a, 1983; Müller et al. 1986; 
Koibuchi et al. 1990; Schipper et al. 1999, chapter 4). Consistently, ODC expression was 
heterogeneously localized in epithelial cells of tubules, and predominantly in the epithelial 
cells of the proximal tubule. This observation is in agreement with biochemical and 
hybridocytochemical studies in androgen-treated mice and rats showing that ODC is mainly 
expressed in proximal tubules (Levillain and Hus-Citharel 1998; Jänne et al. 1991; Crozat et 
al. 1992; Koibuchi et al. 1993a,b). ODC was found immunocytochemically in the cytoplasm 
only, but cytochemical detection of ODC activity with radiolabeled DFMO also revealed 
ODC activity in the nucleus (Pegg et al. 1982; Zagon et al. 1984).
Elevated activity of ODC has been associated with androgen-dependent proliferation of 
Sertoli cells and germ cells in testis, and principal cells in the epididymal epithelium 
(Calandra et al. 1996). Qian et al. (1985) found ODC-immunoreactivity in the cytoplasm of 
isolated testicular cells, epididymal spermatozoa, and cultured Sertoli cells. The highest 
concentration was found in acrosomal vesicles of round spermatids and in the acrosome 
region of epididymal spermatozoa. Studies in transgenic mice that overexpress ODC 
suggested that putrescine production has selective local stimulatory and inhibitory effects on 
DNA synthesis during spermatogenesis (Hakovirta et al. 1993). Spermine has been localized 
in the middle and top parts of the acrosome and possibly modulates sperm fertilization 
competence and the acrosome reaction (Rubinstein and Breitbart 1994).
Prostate cells of human and rat origin produce polyamines at high levels. Its apparent 
functions are related to cellular proliferation and secretory activities. ODC has been localized 
immunocytochemically in rat prostate gland revealing a heterogeneous cytoplasmic staining of 
acinar cells (Dorn et al. 1985; Müller et al. 1986; Schipper et al. 1999, chapter 4). Three types 
of ODC-immunoreactive cells were observed, i.e. strongly positive, weakly positive and 
negative cells, which may represent different cell types in the prostate epithelium.
ODC activity is strongly induced in the ovary of rat, hamster and chicken during the 
ovalutory cycle (Persson et al. 1982b, 1986; Armstrong 1987). Immunocytochemical studies 
in prepubertal rats showed that ODC was localized in the thecal layer as well as interstitial 
gland tissue in human chorionic gonadotropin-stimulated rats (Persson et al. 1982b) and in rat 
and hamster during pro-estrus (Persson et al. 1986). The rapid and strong induction of ODC 
by gonadotropin was due to an increase in the amount or stability of ODC mRNA (Sertich et 
al. 1987). In ovaries of immature rats that had been treated with pregnant mare serum 
gonadotropin, ODC immunostaining was confined to the cytoplasm of granulosa cells. The
15-fold increase in ODC activity after treatment with pregnant mare serum gonadotropin 
could not be fully explained by the 2-fold increase of ODC mRNA suggesting an additional
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regulation of ODC at the translational and/or posttranslational level (Weiner and Dias 1993). 
These studies imply that ODC expression in ovary is mediated by different physiological 
stimuli acting on different target cell types in the ovarian tissue than in other tissues.
Gastrointestinal tract
Cell growth in the gastrointestinal tract, induced by food, hormones, refeeding after starvation 
and intestinal adaptation is paralleled by increases in ODC activity (Luk 1992, and references 
herein). Furthermore, inhibition of ODC with DFMO has a rather universal inhibitory effect 
on cell proliferation in liver, stomach, pancreas, small intestine and colon during postnatal 
maturation and adaptive growth suggesting that ODC plays an essential role in regulating 
mucosal growth of the gastrointestinal tract.
The liver has been an important organ in the initial studies of regulation of ODC activity. 
ODC expression was rapidly and strongly elevated during liver regeneration before the onset 
of nucleic acid and protein synthesis (Raina and Jänne 1968; Russell and Snyder 1969; Höltta 
1975). Localization studies of ODC have been performed in human liver specimens showing 
a heterogeneous pattern of immunoreactive ODC protein in the cytoplasm of hepatocytes, 
which paralleled with ODC mRNA levels (Gan et al. 1992, 1993).
The role of ODC in proliferation of the gastric oxyntic cell is still a matter of debate. An 
increase in mucosal ODC activity could not be detected biochemically in response to 
refeeding or gastrin stimulation. Furthermore, treatment with DFMO had no effect on normal 
gastric epithelial growth, only partially prevented the trophic response to refeeding but did 
inhibit the trophic action of gastrin. However, immunocytochemical analysis of stomach 
epithelium of fasted animals showed that ODC protein was present only in a narrow band of 
cells at the base of gastric pits and at the top of oxynthic glands, which increased after feeding 
or gastrin stimulation (Johnson et al. 1988). A localization study at the ultrastructural level 
showed that ODC was present in the mucous neck cells, which are the progenitor cells of the 
epithelium (Haddox et al. 1992). Thus, growth processes in epithelium of the stomach are 
promoted by induction of ODC in the proliferative fraction of gastric cells, which may well be 
too small a fraction to be detected by biochemical analysis of the heterogeneous mucosa of the 
stomach. In this case biochemical analysis is hampered by the fact that stroma is also included 
in the tissue. Furthermore, the presence of high levels of nonspecific decarboxylases in the 
stomach may well mask the increase in ODC levels in the activity assay (Johnson et al. 1988).
ODC and polyamine levels are increased during rapid growth phases in maturation and 
recovery of intestinal epithelium during adaptive hyperplasia, during lactation, after intestinal 
obstruction, during post-starvation-refeeding and after feeding with lectins (Luk 1992, and 
references herein). In all studies, DFMO treatment suppressed epithelial growth suggesting a 
specific role for ODC in intestinal epithelial growth processes. However, the exact cellular 
physiology of ODC and polyamines in the intestinal mucosa is still not well understood. 
Several biochemical studies using the fasting-refeeding model have shown that ODC activity 
is induced after refeeding and is higher in villus epithelial cells than in crypt epithelial cells. 
Immunocytochemical studies showed that in fasted animals, ODC was localized in the 
epinuclear and basal side of the nucleus of enterocytes along the entire villus (Haddox et al. 
1992). Refeeding caused an increase in immunoreactive protein in villus cells but also 
induced ODC expression in proliferative crypt cells. Exposure of isolated jejunal segments to 
glycine induced an increase in immunoreactive ODC protein, which was confined to cells 
along the villus. Gastrin, however, only increased ODC in crypt cells near the crypt villus 
border (Haddox et al. 1992). In isolated enterocytes of the colon of fasting patients, levels of
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ODC activity, immunoreactive ODC protein and polyamine concentrations were not different 
in lower and upper crypt regions (Elitsur et al. 1993).
These studies and studies using cultured enterocyte cell lines (Iwami et al. 1990) suggest 
that ODC regulation is different in epithelial cells of crypt and villus which might actually be 
due to expression of a different ODC (iso)enzyme in maturating villous cells as compared 
with proliferative crypt cells. Induction of ODC and increased levels of polyamines in 
enterocytes migrating from crypt to villus may be involved in maintenance of mitochondrial 
function and integrity necessary for nutrient absorption (Madsen et al. 1996).
ODC activity is increased in the early stages of cell growth in intestine and pancreas during 
the neonatal period (Morisset and Grondin 1987). With the use of an optimized 
immunocytochemical method to detect ODC in tissues we performed ODC localization 
studies in developing rat intestine and pancreas (Schipper et al. 1999, chapter 4). In small 
intestine of 7, 14 and 21 day-old rats, immunoreactivity was present in both crypts and villi 
whereas in 28 and 100 days old rats, strong positivity of ODC was found in crypts only. In the 
pancreas of neonatal rats, islets of Langerhans showed a strong cytoplasmic staining. In the 
pancreas of 14 day-old rats, heterogeneous staining of exocrine cells was observed (Romain et 
al. 1998). The observed age-related localization patterns in developing rat small intestine and 
pancreas may reflect changes in ODC expression during growth and maturation of these 
organs (Romain et al. in preparation). An immunocytochemical study at the ultrastructural 
level showed that ODC was localized in the nucleus and rough endoplasmic reticulum of 
pancreatic rat acinar cells (Morisset et al. 1986).
Malignancies
ODC expression is upregulated in cancer cells resulting in high basal levels of ODC and 
polyamines in many tumor types. Recent studies show that ODC overexpression coincides 
with expression of oncogenes during cellular transformation (Auvinen et al. 1992, 1997; 
O’Brien et al. 1997; Shantz and Pegg 1998; Tabib and Bachrach 1998).
The role of ODC in cancer progression has been extensively studied in a murine multi-step 
model of carcinogenesis in the skin (reviewed by Digiovanni 1992). Treatment of mouse 
epidermis with the potent carcinogenic phorbolester 12-O-tetradecanoylphorbol-13-acetate 
(TP A) resulted in a rapid and transient induction of ODC and subsequent accumulation of 
polyamines. Furthermore, epidermal tumors contain constitutively high levels of ODC 
activity, with carcinomas expressing higher ODC levels than papillomas. Immuno- 
cytochemical examination of ODC in TPA-treated epidermis of mice showed that ODC 
expression is most intense in the suprabasal keratinocytes located around hair follicles. In 
papillomas and squamous cell carcinomas, heterogeneous ODC staining was observed 
(Gilmour et al. 1986, Hietala et al. 1988). However, ODC expression was found to be 
different in skin of mice after TPA treatment when using a different immunocytochemical 
method (Sundberg et al. 1994). Intense diffuse staining of suprabasal cells was found in 
interfollecular epidermis with occasionally more intense staining around follicles. In addition, 
ODC staining in papillomas was diffuse throughout the suprabasal layer in contrast to the 
staining patterns in scattered areas as was found by Gilmour et al. (1986). 
Immunocytochemical and flow cytometric studies further supported the hypothesis that 
specific subpopulations of epidermal keratinocytes may be more sensitive to ODC modulation 
and neoplastic transformation (Robertson et al. 1990; Gilmour et al. 1992). Differential 
regulation of ODC may be due to the presence of a structurally and functionally altered ODC 
in epidermal tumors (O’Brien et al. 1988; Hietala et al. 1988). Studies in transgenic mice in
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which ODC was targeted to epidermal keratinocytes of the hair follicle further support the 
hypothesis that hair follicles are the possible origin of skin tumors and that ODC 
overexpression is sufficient for tumor promotion in mouse skin (Megosh et al. 1995; O’Brien 
et al. 1997). Immunolocalization studies of human skin showed that ODC is present in both 
basal and corneal layers of normal skin (Verrando et al. 1987) and is constitutively increased 
in squamous cell carcinomas (Hietala et al. 1988). Subcellular localization studies of ODC in 
normal human keratinocytes revealed that ODC is present in the perinuclear/nuclear region. 
Intracellular localization becomes more diffuse over the cytoplasm after treatment with TPA. 
Interestingly, changes in ODC localization were associated with rearrangements of the 
cytoskeleton suggesting attachment of ODC to structural elements and/or a role of ODC in 
cytokinetic processes.
ODC localization studies have also been performed in some other types of malignancies, 
i.e. hepatocellular carcinoma (Gan et al. 1993) and papillomatosis of bladder epithelium 
(Takada et al. 1998). ODC expression was increased in these lesions indicating an important 
role of ODC in diseases characterized by cell proliferation. Gan et al. (1993) quantitated ODC 
expression in liver specimens by in situ hybridization and immunocytochemistry. A hetero­
geneous pattern after immunostaining of ODC protein was found in the cytoplasm of 
hepatocytes. The amount of immunoreactive ODC protein progressively increased from 
normal, to normal liver adjacent to carcinoma, to cirrhosis and to hepatocellular carcinoma. 
ODC mRNA levels were generally in agreement with protein levels. Recent biochemical 
studies of ODC activity and polyamine levels in hepatocellular carcinomas further provided 
evidence that polyamine metabolism may be a parameter of degree of malignancy in 
hepatocellular carcinomas (Kubo et al. 1998).
Concluding remarks
In the past thirty years, many approaches have been published to localize ODC in situ in cells 
and tissues. Early studies focussed on biochemical measurement of ODC activity in 
fractionated cell preparations. Activity of the enzyme was found in cytoplasmic as well as 
nuclear fractions and particularly in nucleoli. However, redistribution of ODC during isolation 
and fractionation procedures may have affected accurate localization. Development of the 
highly specific and irreversibly binding ODC-inhibitor DFMO enabled cytochemical 
localization of ODC activity using fluorescent or radioactive labeled derivatives of DFMO. 
Most of these studies report that ODC is localized in both cytoplasm and nuclear 
compartments.
Immunocytochemical detection of ODC revealed different localization patterns depending 
on the cell system studied and the antibody used. These patterns varied from cytoplasmic or 
(peri)nuclear localization to localization both in cytoplasm and nucleus. Besides differences in 
specificity of antibodies against ODC, effects of cell and tissue preparation procedures such as 
fixation, permeabilization, dehydration, embedding can greatly affect preservation and/or 
accessibility of the ODC protein for the antibodies. We recently attempted to systematically 
develop a reliable method for the immunocytochemical detection of ODC (Schipper et al. 
1999, chapter 4). In these studies, we observed that fixation and antigen retrieval methods have 
substantial effects on the intensity and specificity of ODC immunostaining. In contrast to the 
findings obtained with biochemical and enzyme cytochemical studies, immunocytochemical 
studies of ODC showed that ODC is mainly present in the cytoplasm. This discrepancy may 
mean that catalytically active nuclear ODC exist in a complexed or cryptic form or is less
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accessible for antibodies to bind. On the other hand, cytosolic ODC may exist in an immuno­
logically active but enzymatically inactive form. As observed in adult mouse brain, complex 
formation of ODC with antizyme may contribute to the differences between 
immunocytochemical and enzyme cytochemical subcellular localization patterns of ODC 
(Laitinen 1985).
In general, ODC expression has been found in the cytoplasm as well as in nucleus. The 
physiological significance of ODC in the nucleus remains unclear. It has been suggested that 
posttranslationally modified ODC is translocated to the nucleolus where it may regulate RNA 
polymerase I activity (Manen and Russell 1977; Russell 1985). However, more purified 
fractions of ODC did not affect the latter enzyme activity (Urata et al. 1987; Eichler and Con-
1992) and DFMO was not able to inhibit rRNA transcription (Iapalucci et al. 1984). 
Polyamines are implicated to have an essential role in modulation of DNA structure and 
stability. Subcellular localization studies of polyamines using autoradiographic, cytochemical 
and immunocytochemical techniques have confirmed the presence of polyamines in the 
nucleus (Roch et al. 1997 and references herein). Therefore, nuclear ODC may be an 
important source of nuclear polyamines.
As for nuclear ODC, the precise functional role of ODC in the cytoplasm still needs to be 
elucidated but numerous studies suggest that ODC and polyamines play essential roles in the 
machinery of protein biosynthesis. This hypothesis is further supported by immunoelectron 
microscopical studies of ODC and polyamines in which the label was closely associated with 
rough endoplasmic reticulum and polyribosomal structures, respectively (Morisset et al. 1986, 
Fujiwara et al. 1998). Recent immunocytochemical localization of ODC in cultured cells 
using confocal laser scanning microscopy (Pomidor et al. 1995; Heiskala et al. 1999; Schipper 
et al. 1999, chapter 4) have demonstrated that ODC is associated with the plasma membranes 
or nuclear envelope. Because translocation of ODC occurred during cell activation, ODC may 
play a role in cellular signaling pathways as well.
Despite the fact that many attempts have been made to localize ODC, the exact subcellular 
localization of ODC is still subject to controversy. The different results in the studies 
reviewed here may actually reflect the variety of mechanisms by which ODC can be regulated 
and/or modified. Overall, cytochemical results clearly showed that ODC expression and 
regulation can greatly vary within cell populations, individual cells or cell compartments. 
Furthermore, these cytochemical data have greatly contributed to the growing awareness that 
ODC and polyamines have important multifunctional roles in cell kinetic behavior.
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Monoclonal antibodies against Ornithine decarboxylase
Abstract
In order to develop a method for the immunocytochemical detection o f ornithine decarboxylase 
(ODC), EC 4.I.I.I7, we have prepared and characterized monoclonal antibodies against ODC. 
The primary structure o f rat ODC (Rat Norvegicus) was used for the selection o f an epitope by 
computer calculations. The epitope (PI6), a hexadecapeptide representing ODC-(345-360), 
was synthesized by means o f Solid Phase Peptide Synthesis and coupled to a carrier protein. A 
bovine serum albumin conjugate o f the PI 6 peptide was used as the immunogen for the 
production o f MAbs in mice. Hybridoma clones were screened and the specificity o f the 
monoclonal antibodies was tested in an ELISA utilizing a thyroglobulin conjugate o f the 
hexadecapeptide. Two hybridoma cell lines were developed, i.e. M PI6-2 and M PI6-3. The 
epitope specificity o f the MAbs produced by these cell lines was characterized in an ELISA 
using a set o f small peptides representing parts o f the P I6  hexadecapeptide chain. M PI6-2 
recognized the ODC-(355-360) portion whereas MPI6-3 reacted with the ODC-(345-350) part 
o f the hexadecapeptide. Further studies showed that both MAbs also recognized native ODC 
but not the inhibited (i.e. ODC labeled with H-DFMO) enzyme indicating that the selected 
epitope was associated with the active site o f ODC or a locus in its direct vicinity.
Key WORDS: ornithine decarboxylase / Computer Assisted Epitope Analysis / Solid Phase Peptide 
Synthesis / monoclonal antibodies / active centre
I ntroduction
O r n i t h i n e  d e c a r b o x y l a s e  (ODC), EC 4.1.1.17, the initial and rate-limiting enzyme in the 
biosynthetic pathway of polyamines, is involved in the conversion of ornithine to putrescine. 
Polyamines are polycationic cellular components, which play an essential role in cell growth 
and differentiation (Pegg 1986). During recent years the biochemical, physiological and 
molecular biological aspects of ODC have aroused considerable interest and much of the 
available information is summarized in several reviews (Pegg 1986; Russell 1985; Heby and 
Persson 1990). The biological activity of ODC is rapidly induced in response to virtually all 
agents known to promote cell proliferation including hormones, drugs, growth factors, 
mitogens and tumor promoters. In vivo, ODC has a half-life of 8-30 minutes, the shortest half­
life time yet reported in eukaryotic cells. Its activity is regulated at the transcriptional and 
translational as well as post-translational levels. Lack of knowledge of the exact cellular and 
subcellular localization of ODC and/or polyamines is one of the main obstacles to a more 
precise interpretation of the biological role of the ODC/polyamine system.
In the past several cytochemical procedures to localize ODC have been reported (see for 
review chapter 2). One approach is based on the conversion of ornithine into putrescine (Dodds 
et al. 1990). However, these enzyme cytochemical techniques were apparently not 
advantageous because the reaction products formed, i.e. putrescine and carbon dioxide, were 
poorly precipitable. Other techniques, based on the binding of irreversible inhibitors of ODC, 
e.g. radioactive labeled alpha-difluoromethylornithine ( H-DFMO) (Pegg et al. 1982, Zagon et 
al. 1984) or DFMO labeled with rhodamine or biotin (Gilad and Gilad 1981), have been used 
only in a limited number of experiments and need further validation. Finally, efforts were made 
to localize ODC using antibodies to ODC. Antibodies to ODC have been prepared by several 
research groups (see Table I, chapter 2). At first, ODC was isolated from rat liver. Since the 
isolated enzyme possessed a low specific activity the specificity of the antisera obtained was 
difficult to establish. With the advent of improved purification methods ODC antisera with a
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higher degree of specificity were obtained with preparations from yeast, rat liver, mouse kidney, 
and murine RAW 264 cells.
Having developed monoclonal antibodies to polyamines (Schipper et al. 1991) we next 
wished to produce highly specific and potent MAbs for the immunocytochemical detection of 
the ODC. It has proved difficult to purify ODC due to its low cellular concentration and its 
extreme instability during purification procedures (Kopitz et al. 1990). Therefore, we decided to 
raise MAbs against a defined epitope of ODC. This epitope was selected by prediction of the 
secondary structure of ODC using the computer programme Peptide Structure, a CAMMSA 
program from the Genetic Computer Group, University of Winconsin. We now report the 
selection and synthesis of an ODC epitope and the preparation and characterization of MAbs 
directed against this epitope.
Materials and m ethods
Materials
TLC plates (Silicagel 60 F254 TLC) and the ion exchanger column (Merck, acetate cycle, 
column dimension 10 x 1.5 cm), were obtained from Merck (Darmstadt, Germany). The protein 
carriers bovine serum albumin (BSA) and thyroglobulin were purchased from Sigma Chemical 
Co. (St. Louis, MO, U.S.A.), resp. cat no. A-7638 and cat no. T-1001. The bifunctional reagent 
6-(1-maleinimido) hexanoic acid N-succinimidyl ester (MHS) was obtained from Fluka AG 
(Buchs, Switzerland), cat no. 63177. DMF was from Merck (Darmstadt, Germany), cat no. 
3034. Freund's adjuvants were obtained from Difco Laboratories (Detroit, MI, U.S.A.). Fetal 
calf serum was purchased from Gibco Laboratories (Grand Island, NY, U.S.A.), cat no. 011­
0629004, batch no. 10F0277D. RPMI 1640 medium (lot. 9030642) and HAT solution (cat. no.
16-808-49) were obtained from Flow Laboratories (Zwanenburg, The Netherlands). Poly­
ethylene glycol-4000 was from Merck (Darmstadt, Germany), cat no. 9727. Peroxidase- 
conjugated rat anti-mouse immunoglobulins (P161, lot 068) were from Dakopatts (Glostrup, 
Denmark), 5-aminosalicylic acid (cat no. A-3021) was obtained from Sigma (St. Louis, MO, 
U.S.A.) and Tween-20 from Merck (Darmstadt, Germany). Rabbit anti-mouse subclass-specific 
immunoglobulins (IgG1, IgG2a, IgG2b, IgG(7s), IgA and IgM) were from Meloy (Springfield, 
U.S.A.). Polystyrene 96-well microtiter plates were supplied by Costar (Cambridge, MA), cat 
no 3595 and cat no. 3424. Plates were read with a Multiscan, VT1000 (Digital, Utrecht, The 
Netherlands). All other chemicals were of analytical reagent grade quality.
Selection o f the ODC epitope
From the primary sequence of rat ODC as published and submitted to the NBRF Protein 
Database by Van Kranen et al. (1987) a pattern of the antigenic index was calculated with the 
algorithm of Jameson and W olf (1988). This algorithm is based on three characteristics of the 
protein chain, i.e. the hydrophilicity as predicted by Hopp and Woods (1981), the surface 
probability as calculated by Emini et al. (1985) and Janin et al. (1978), and the chain flexibility 
as calculated by Karplus and Schulz (1985). The selected sequences were checked for 
homology in the compilation of the NBRF Database (George et al. 1986) and the SWISSPROT 
Database.
The accession number of the ODC used for computer calculations is PIR1:A27361.
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Peptide Synthesis
Synthetic peptides were obtained with the solid phase methodology using an (acid-labile) p- 
alkoxybenzyl alcohol linker in the resin support (Wang, 1973). Synthesis was carried out with a 
semi-automatic apparatus (Labortec SP 640 Peptide Synthesizer, Bubendorf, Switzerland). The 
base-labile Fmoc function was exploited for temporary amino protection whereas semi­
permanent protection of the side chains was effected using acid-labile functions (Boc, OButt or 
But). Dicyclohexylcarbodiimide and 1-hydroxybenzotriazole (DCC/HOBt) were used as the 
coupling agents. In each cycle, three equivalents of an amino acid derivative and the 
condensation agent were used with respect to the pertinent amino acid content of the pre-loaded 
support (Advanced Chemtech, Louisville, Kentucky, USA). The synthesis was started by 
deprotection of the anchored amino acid derivative (20 % piperidine in DMF, 3 reaction periods 
of 6 min). The presence of free amino groups was checked using a ninhydrin test (Kaiser et al. 
1970). With this test the completeness of condensation was checked in each cycle following a 
reaction period of 30 min. As an additional security each acylation was followed by acetylation 
to block residual free amino functions escaping the Kaiser test. After the introduction of the last 
amino acid of the selected epitope, L-norleucine (Nle) was introduced and its amino function 
was acylated subsequently with SATA, (Duncan et al. 1983). Nle served to facilitate amino acid 
analysis as an internal standard once the epitope had been conjugated. Smaller peptides were 
conjugated without insertion of Nle.
After completion of the synthesis the resin was suspended in a mixture of trifluoroacetic 
acid, ethanedithiol and water (38:1:1 v/v, 10 ml) and left for 4 h. Subsequently, the suspension 
was filtered and the residue was washed with a small amount of dichloromethane and 
discarded. The filtrate was then diluted with ether (50 ml) to give a slightly yellow solid, which 
was washed again with ether to remove most of the TFA and the thiol. The crude peptide from 
which the acid-labile protective functions had been removed, as checked by NMR, was 
dissolved in 0.1 M acetic acid and converted into the acetate form by filtration through a weakly 
basic ion exchanger column (dimension 10 x 1.5 cm). Finally, the eluate was lyophilized.
Purification and analysis
The acetate form of the peptide was purified with counter current distribution in n- 
butanol/acetic acid/water (4:1:5) using an instrument from Labortec (Bubendorf, Switzerland). 
The purified peptide, dissolved in buffer A (0.1 % TFA in water), was subjected to HPLC using 
a RP18 column (HPLC Technology, England), Techsil 5 C18 stationary phase, 25 cm x 4.6 
mm; a gradient was applied from buffer A to buffer B: 90 % acetonitrile and 10 % water 
(containing 0.08 % TFA) within 35 min. An HPLC apparatus from ACS (Macclesfield, UK) 
was used. NMR spectra of deutero-methanolic solutions of the peptide were recorded using a 
Bruker 100 MHz NMR (Rheinstetten, Germany) apparatus. TLC chromatography was 
performed using 20 |ig samples as methanolic solutions of the peptide. The silicagel plates were 
developed with n-butanol/acetic acid/water (4:1:1).
For amino acid analysis 1 mg of the peptide was dissolved in 2 ml of 5.7 M HCl-solution and 
hydrolyzed at 100 °C for 24 h. Subsequently, the solution was evaporated three times with 
water and analyzed with a Varian Amino Acid Analyzer (Walnutcreek, USA) using pre-column 
derivatization with the Fmoc method.
Conjugation Method
In order to obtain well-defined immunogens, hetero-bifunctional cross-linkers were used to 
couple the peptide to the protein carrier in a predictable fashion. Advantage was taken of the
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fast nucleophilic addition of a thiol function to the double bond of a maleimide group (Marrian 
1949). To this end, a number of alpha-amino groups of the lysyl residues of the carrier were 
acylated with MHS (Keller and Rudinger 1975), a substance which is essentially non- 
immunogenic (Peeters et al. 1989).
25 mg BSA were activated with 2.2 mg of MHS and subjected to gel filtration over a PD-10 
column to separate unreacted MHS. The -SH function from the SATA in the peptide was 
deprotected with the mixture DMF/MeOH/4 N NaOH (14:5:1), which is 0.2 M in base, for 30 
sec. After neutralization with acetic acid to give a pH of about 6 the peptide was mixed with the 
activated carrier. Subsequently, the solution was dialyzed against phosphate buffer, pH 6.9, and 
lyophilized. The generally accepted structure of the conjugates is shown in Figure 1.
Figure 1. Structure o f the P16 peptide (ODC-(345-360)-conjugate. Bovine serum albumin or thyroglobulin were used as 
protein carriers.
Production o f MAbs
Four Female BALB/c mice were injected intraperitoneally with 50 ^g of the immunogen 
suspended in 1 ml Freund's complete adjuvant. On days 40, 41, 42 and 43 post-immunization 
30 ^g of the immunogen were given intravenously as a booster. At day 44 one mouse was 
sacrificed and spleen cells were harvested. Spleen cells (1.43 X 10 ) were fused with non­
producing myeloma cells (7.0 X 107 ), SP 2/0 strain, in the presence of 45 % PEG 4000 and 5 
% DMSO in RPMI 1640, essentially as described by Köhler and Milstein (1975). The cell 
suspension was diluted over 10 microtitre plates of 96 wells. Media of growing cells were 
screened for antibody production. Cell lines producing the desired antibodies were cloned, 
recloned and frozen in liquid nitrogen in the presence of 10 % DMSO, 10 % FCS and 69 % 
RPMI 1640. Hybridomas were selected using an enzyme-linked immunosorbent assay (ELISA) 
as previously described before (Schipper et al. 1991). In brief, 96-well microtitre plates were 
pre-coated with 1 % poly-L-lysine. Subsequently, the plates were coated with the peptide 
immobilized to thyroglobulin (Tg), as the first antigen (conjugated as described above) and 
blocked with 1 % gelatine. Immunoreactive mouse immunoglobulins were visualized with 
horseradish peroxidase (HRP)-labeled rabbit-anti-mouse immunoglobulins using 5-amino- 
salicylic acid and H2O2 as a substrate mixture.
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Characterization o f MAbs
(1) Antibody specificity. The antibodies were further characterized using an ELISA procedure. 
Plates were now coated with one of the following antigens: BSA, BSA-P16, Tg or Tg-P16 (the 
coating in which the epitope was used exclusively proved ineffective). Antibody was added and 
the antibody-antigen complex visualized as described above.
(2) Determination of antibody isotype. Immunodiffusion tests with cell culture medium from 
hybridoma cell lines using rabbit anti-mouse subclass-specific immunoglobulins (IgG1, IgG2a, 
IgG2b, IgG(7s), IgA and IgM) were performed according to Ouchterlony and Nilsson (1978).
(3) Epitope mapping. To define the actual epitope recognized by the P 16-antibodies, a set of 
small peptides were synthesized (Table 1) and processed as the hexadecapeptide but now 
immobilized to casein. ELISA plates, coated with these antigens were used to determine the 
reactivity of the P16-antibodies. All experiments were performed twice and all sampled assayed 
in duplicate. (Schipper et al. 1991).
(4) Binding of MAbs to native ODC. ODC was isolated from 200 kidneys of testosterone- 
treated NMRI mice as described by Kopitz et al. (1990). Subsequently, SDS-polyacrylamide- 
gel electrophoresis and immunoblotting were performed with the following ODC preparations: 
a) cytosolic ODC, b) purified ODC and c) ODC labeled with 2-(difluoro-methyl)-3,4-di-3H- 
DL-ornithine. (Schipper et al. 1999, chapter 4).
R e s u l t s  
ODC structure
The ODC sequence with the highest calculated antigenic index occurred between amino acid 
residues 340 - 360. From this part of the enzyme the sequence 345-360 was selected for peptide 
synthesis. The amino acid sequence of this hexadecapeptide (P16) is shown in Figure 2a.
The selected P16 sequence derived from the amino acid sequence of rat ODC was also 
present in other known eukaryotic ODC sequences, i.e. Chinese hamster, mouse, human. The 
most homologous sequence, not found in ornithine decarboxylase, occurred in the Hypothetical 
UL25 Protein from cytomegalovirus (strain AD 169), residue 95 to 110. This sequence showed 
8 mismatches [see below: Discussion].
A) 345................................350..............................355..............................360
Lys-Pro-Asp-Glu-Lys-Tyr-Tyr-Ser-Ser-Ser-Ile-Trp-Gly-Pro-Thr-Cys
B) 345................................350..............................355..............................360
Ata-Nle-Lys-Pro-Asp-Glu-Lys-Tyr-Tyr-Ser-Ser-Ser-Ile-Trp-Gly-Pro-Thr-Cys(Acm)-OH
F ig u re  2 . Representation o f A) the selected epitope and B) the synthesized derivate, prepared for N-terminal conjugation
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Synthesis o f P16 peptide
According to the "Kaiser"-test all acylations ran with complete acylation. Following acidolysis 
(TFA and scavangers, 4 h), as indicated in the Materials and Methods, and drying in vacuum, 
917 mg of a slightly yellow crude peptide were harvested for use (Figure 2b).
Analysis o f the P16 peptide
(1) Thin Layer Chromatography. When 2 ^l of the peptide solution were subjected to thin layer 
chromatography, 3 spots appeared; R f = 0.07, 0.3 and 0.4. The lowest spot only was positive 
with sodium nitroprusside after spraying with ammonia solution (Stahl 1962) indicating the 
presence of the complete peptide with the SATA group, comprising a protected thiol 
function at the N-terminus.
(2) NMR. NMR measurement of the crude hexadecapeptide indicated the presence of one or 
more But-functions. Therefore, it was necessary to resume the acidolysis (TFA for 1.5 hour). 
Following this treatment NMR measurement indicated a fully deprotected peptide. 
Deprotection of the smaller peptides exhibited the same behavior, i.e. if three seryl residues 
were present, the deprotection was incomplete whereas peptides with two or one seryl 
residue were fully deprotected.
(3) Counter Current Distribution. After purification the residue was dissolved in water and 
lyophilized to yield 551.3 mg of a white solid. The Nernst partition coefficient K, 
determined as described by Hecker (1955), amounted 1.50 (r = 72, n = 120).
(4) Amino acid analysis. A mixture of peptides was obtained containing the acetyl-thio- 
acetylated hexadecapeptide. Since each synthesis cycle was followed by a capping reaction 
(acetylation) no acetylthioacetyl functions were expected to be present in the truncated 
sequences.
Conjugation
The selectivity and the rate of the nucleophilic addition of a sulfhydryl group to the 
maleinimido group of the protein carrier ensured that in this mixture following removal of the 
s-acetyl group only the hexadecapeptide would react with the activated protein carrier. 
Therefore, this mixture was used as such for conjugation since undesirable peptides present in 
the mixture would not take part in the conjugation reaction.
After removal of the acetyl group from the SATA residue of the P16 peptide the solution was 
mixed with BSA which was activated with MHS. Amino acid analysis indicated the presence of 
8 mol Nle per mol BSA.
Fusion and selection
10 days after the fusion, cell growth was observed in 257 of the 960 seeded wells. The media in 
these wells were tested with an ELISA and 7 wells appeared to be positive. The cells in these 
wells were then cloned and recloned. Two clones ceased producing antibody after five days and 
were discarded. Of the remaining five two the clones MP16-2 and MP16-3 were studied in 
detail.
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Table 1. Tabular representation o f the hexadecapeptide p16 and the set o f  diagnostic small peptides
P16
Peptide amino acid sequence
Lys-Pro-Asp-Glu-Lys-Tyr-Tyr-Ser-Ser-Ser-Ile-Trp-Gly-Pro-Thr-Cys(Acm)
1 Lys-Pro-Asp-Glu-Lys-Tyr
2 Pro-Asp-Glu-Lys-Tyr-Tyr
3 Asp-Glu-Lys-Tyr-Tyr-Ser
4 Glu-Lys-Tyr-Tyr-Ser-Ser
5 Lys-Tyr-Tyr-Ser-Ser-Ser
6 Tyr-Tyr-Ser-Ser-Ser-Ile
7 Tyr-Ser-Ser-Ser-Ile-Trp
8 Ser-Ser-Ser-Ile-Trp-Gly
9 Ser-Ser-Ile-Trp-Gly-Pro-Thr-Cys(Acm)*
10 Ser-Ile-Trp-Gly-Pro-Thr-Cys(Acm)*
11 Ile-Trp-Gly-Pro-Thr-Cys(Acm)*
* Cysteinyl residue that is susceptible to oxidation o f its thiol function, was protected with the hydrophilic Acm group
Characterization o f MAbs MP16-2 and MP16-3
(1) Antibody specificity. Standard titration curves of MAbs MP16-2 and MP16-3 are shown in 
Figure 3. Both MAbs recognized the P 16-conjugates but did not react with the protein 
carriers indicating that MP16-2 and MP16-3 were specific for the P16 peptide.
(2) Determination of antibody isotype. Both MP16-2 and MP16-3 were identified as IgG1 
immunoglobulins.
(3) Epitope mapping. Results of the ELISA experiments on MAbs MP16-2 and MP16-3 using 
the set of smaller peptides are shown in Figure 4. It was found that the C-terminal part of the 
selected epitope was recognized by MP16-2 whilst MP16-3 recognized the N-terminal 
fragment of the hexadecapeptide. Neither MP16-2 nor MP16-3 recognized the three peptide 
fragments comprising the connecting sequence ODC-(349-356).
(4) Binding of MAbs to native ODC. Purification of 200 testosterone-treated mouse kidneys 
yielded 180 ^g of enzyme protein with a specific activity of 28.3 U/mg of protein which 
represented a relative purification of 4760-fold and a recovery of 41% of the cytosol activity. 
Immunoblotting tests revealed that MP16-2 and MP16-3 were able to recognize native ODC 
but not ODC labeled with 2- (difluoro-methyl)-3,4-di-3H-ornithine. (Schipper et al. 1999; 
see for MP16-2 Figure 1, chapter 4).
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MP16-2 MP16-3
ùilution(1/x) ùilution(1/x)
»B SA *P 16+ B SA *- Tg*P16G- Tg+B /ancc -B S A * P 1 6 + B S A * - Tg*P16& Tg +  Blanco
Figure 3. ELISA titration curves o f the MAbs MP16-2 and MP16-3. Wells were coated with 0,1 :g protein (bovine serum 
albumin (BSA), thyroglobulin (Tg) or conjugates o f these proteins with the P16 peptide. Both MAbs recognized the P 16- 
conjugates but did not react with the protein carriers indicating that MP16-2 and MP16-3 were specific for the P16 peptide
E450 E450
n
£
12 
11 
10 
9 -  
8
7  -  
6 
5
4 -  
3 
2 -  
1
Epitope mapping MP16-2 MP16-3
0
Lys Pro Asp Glu Lys Tyr Tyr Ser Ser Ser He Trp Gly Pro Thr Cys
P16 Amino acid
Figure 3. Epitope mapping o f antibodies to the P16 peptide. A set o f 11 smaller peptides along the P16 hexa-decapeptide 
chain was synthesized (left part o f Figure) and applied as antigen in an ELISA using MP16-2 or MP16-3 as antibody (right 
part o f Figure). Results show that MP16-2 recognizes the peptides representing the C-terminal part whereas MP16-3 reacts 
only with the peptides representing the N-terminus part o f the hexadecapeptide chain
53
Monoclonal antibodies against Ornithine decarboxylase
Dis c u s s io n
Production of polyclonal antibodies against ODC isolated from different sources has been 
described by several authors. Specificity tests of these antisera have been performed but it 
should be noted that complete homogeneity of the ODC antigen used for immunization and 
specificity tests was not guaranteed. Moreover, by definition, polyclonal antisera consist of 
different antibodies with heterogeneous immunoreactivity. Production of monoclonal 
antibodies against ODC has been described by Pegg et al. (1984) and Kopitz et al. (1990). 
Antibodies were selected using a radioactive antigen, i.e. ODC labeled with 3H-DFMO. DFMO 
is an irreversible inhibitor of ODC since it forms a covalent bond with the active site of the 
enzyme. In this way the functional homogeneity of the labeled antigen could be ensured since 
the interaction of DFMO with ODC is highly specific. However, a major disadvantage of this 
approach is that one cannot identify and select antibodies that are directed against the active site 
of the enzyme (Pegg et al. 1984).
For these reasons we decided to raise a monoclonal antibody to a defined epitope 
representing ODC as a whole. Such an approach has several advantages. Firstly, purified 
enzyme preparations are not needed for the production of the antibodies. The isolation of the 
complete enzyme and its application as an immunogen is a laborious and specialized task due 
to the extremely low cellular concentration and the highly unstable character of the endogenous 
enzyme. On the contrary, the production of an artificial immunogen is relatively faster and 
cheaper and no experimental animals are needed. Secondly, the selected epitope can be 
synthesized to give the desired amounts and can be prepared in a chemically pure form. 
Therefore, the specificity of the antibodies can be established using a homogeneous chemically 
defined antigen instead of a heterogeneous biochemically purified antigen. Furthermore, 
epitope mapping is feasible using overlapping peptides along the epitope chain and the cross­
reactivity of the antibody can easily be checked by comparing the selected sequence with the 
primary sequences of other proteins to establish the authenticity of the selected epitope.
Computer calculations of protein structure to predict the spatial structure of an epitope are 
mainly based on the assumed conformity of the underlying Röntgen structures and the shape of 
the actual molecule in water. The predictions based on existing structures are by Chou and 
Fasman (1978)) and by Garnier, Osguthorpe and Robson (1978). Predictions based on 
hydrophilicity/hydrophobicity, surface probability and chain flexibility are expressed in the 
algorithm of Jameson and W olf who also derived an Antigenic Index. Application of these 
computer calculations makes the selection of an epitope a reasonable basis for antigen design.
Using computer calculations, the sequence 0DC-(345-360) was identified as a serious 
candidate epitope in the construction of an immunogen for raising MAbs selective for ODC. 
Therefore, a hexadecapeptide (P16) representing this ODC sequence was synthesized and used 
for the immunization of mice. As expected, the production and characterization of monoclonal 
antibodies was achieved in a relatively short time due to the homogeneity of the immunogen 
which was the result of the highly selective conjugation through the N-terminally located thiol 
function.
To characterize our monoclonal antibodies, we performed epitope mapping with a small set 
of overlapping peptides as shown in Table 1. From immunochemical investigations it is well 
known that antigenic epitopes involve about six aminoacyl residues (Geysen et al. 1985; Lam et 
al. 1991). Therefore, the investigated compounds listed in Table 1 were selected as 
hexapeptides. In those cases where the carboxyl terminus should contain a prolyl group in the 
ultimate or penultimate position, 2,5-dioxo-piperazine derivatives would rapidly form during 
solid phase synthesis and would be released from the support (Barany and Merrifield 1980) on
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Table 2. Homology o f the P16 sequence found in the NBRF database and the SWISSPROT database.
ODC protein sequences for human (Van Steeg et al., 1989), rat (Van Kranen et al., 1987), mouse (Coffino and Chen, 1988) 
and Chinese hamster (Grens et al., 1989) are deduced from cDNA sequence. The protein sequence for yeast (Fonzi and 
Sypherd, 1987) and T. b. brucei (Phillips et al., 1987) are deduced from intron-less genomic sequence. Mismatches are 
underlined.
deprotection of the alpha-amino function. It was therefore decided to omit the sequences H-Ser- 
Ser-Ile-Trp-Gly-Pro-OH and H-Ser-Ile-Trp-Gly-Pro-Thr-OH from the set of overlapping 
fragments and to use instead the octapeptide H-Ser-Ser-Ile-Trp-Gly-Pro-Thr-Cys-OH and the 
heptapeptide H-Ser-Ile-Trp-Gly-Pro-Thr-Cys-OH and to complete the series with the regular C- 
terminal hexapeptide. The cysteinyl residue -which is susceptible to dimerization by oxidation 
of the thiol function- was protected with the hydrophilic Acm group.Using these peptides it was 
found that MP16-3 recognizes the N-terminal part (345-350) of the epitope and MP16-2 
recognizes the C-terminal part (355-360) of the epitope, which contains the cysteinyl residue. 
An investigation (by comparative homology) of the sequences recognized by MP16-2 (- 
IWGPTC-) and MP16-3 (-KPDEKY-) showed that neither of the sequences were present in any 
proteins other than ODC. Furthermore the hexapeptide -IWGPTC- is present in all known 
eukaryotic ODC sequences. The authenticity of the hexadecapeptide sequence is also supported 
by an search for allowable mismatches: the nearest sequence occurred in a "hypothetical 
protein" from cytomegalovirus and showed 8 mismatches (Table 2). From this it can be 
concluded that both MAbs are directed exclusively to ODC determinants.
Immunoblotting with ODC isolated from mouse kidney showed that the antibodies MP16-2 
and MP16-3 also recognized native ODC (Schipper et al. 1999; see for MP16-2 Figure 1, 
chapter 4). Native ODC was recognized despite the fact that the protecting Acm-function at the 
thiol group in the cysteine of the immunogen was not present in Cys360 of the native enzyme 
protein. In contrast, neither MAb recognized the enzyme if it was labeled with 3H-DFM0. 
Inhibition of ODC with DFMO is understood to imply alkylation of some nucleophile in the 
active site (Bey et al. 1987), most probably, at the thiol function (Poulin et al. 1992). From 
these data it may be inferred that: (1) the shape of the epitope is not apparently affected by the 
presence of (hydrophilic) sulphur protection; (2) the epitope is associated with the active site of 
the enzyme.
The concept of "pars pro toto" which was applied in the production of MAbs to ODC has 
proved itself, i.e. the native enzyme can be replaced by nearly unlimited amounts of a 
chemically defined antigen. Consequently model studies become feasible, e.g. investigation of 
the influence of fixation procedures on the immunoreactivity of ODC. Furthermore, studies of 
the enzymatic activity of ODC will also become possible since our MAbs are directed against 
(at least in part) the active site of the enzyme. These studies will be the subject of a forthcoming 
publication (Schipper et al. to be published).
ODC-(345-360) Rat, mouse, human 
ODC-(339-354) Chinese hamster 
ODC-(396-411) Yeast 
ODC-(365-380) T  b. brucei
K P D E K Y Y S S S I W G P T C 
K P D E K Y Y S S S I W G P T C 
T R S E Y P Y K V S I W G P T C 
I P N E K L Y P S S V W G P T C
UL25-(95-110) Cytomegalovirus K P S E K K R  S S S R R Q P Q I
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Abstract
Ornithine decarboxylase (ODC), a regulatory enzyme o f polyamine biosynthesis, is involved 
in cell growth and differentiation. Lack o f information on the exact cellular and subcellular 
localization o f ODC is one o f the main obstacles for the precise interpretation o f biological 
roles o f the ODC/polyamine system. In the present report we describe the development and 
optimization o f an immunocytochemical method to detect ODC in cells and tissues. For this 
purpose a monoclonal antibody (MP16-2) directed against a defined epitope o f ODC protein 
was developed. Specificity o f the antibody for ODC was substantiated by Western blotting and 
ELISA analysis using cell and tissue homogenates. In cultured cells optimum staining results 
were obtained after fixation with cross-linking fixatives followed by permeabilization with 
methanol. In rat tissues ODC immunoreactivity was best preserved in paraffin sections fixed  
with Bouin ’s fixative. Antigen retrieval using SDS and citrate buffer substantially increased 
ODC immunostaining and lowered background staining. Localization studies o f ODC in 
different cell lines showed that strongest staining for ODC was found in the nucleoplasm of  
mitotic cells whereas confluent cells showed moderate perinuclear staining. Immunocyto­
chemical studies o f various rat tissues showed high cytoplasmic immunostaining o f ODC in 
epithelial cells o f kidney, prostate and adrenal medulla o f testosterone-treated rats, in 
glandular epithelium o f small intestine and in pancreas o f neonatal and adult rats.
Key WORDS : ornithine decarboxylase / monoclonal antibody / immunocytochemistry / tissue fixation / 
cell lines / rat
in t r o d u c t io n
O r n i t h i n e  d e c a r b o x y l a s e  (ODC, EC 4.1.1.17) is the initial and regulatory enzyme of 
polyamine synthesis converting the amino acid ornithine into the polyamine precursor put- 
rescine. Polyamines are organic bases that play an essential role in cell growth and 
differentiation (Pegg 1986). The enzymatic characteristics of ODC have gained considerable 
interest in various biomedical fields and have been summarized in several reviews (Russell 
1985; Persson et al. 1988; Hayashi et al. 1996). The enzyme exhibits rapid and diverse 
changes in biological activity as an early response to the effect of virtually all growth 
promoting stimuli including hormones, drugs, growth factors, mitogens and tumor promoters 
on cells. Recent studies have shown that overexpression of ODC can cause cellular 
transformation suggesting that the enzyme can be considered as a proto-oncogen product 
(Auvinen et al. 1992, 1997; Tamori et al. 1995; O'Brien et al. 1997; Shantz and Pegg 1998; 
Tabib and Bachrach 1998).
Despite extensive biochemical and molecular biological research the precise role of the 
ODC/polyamine system in cellular physiology remains to be clarified. Insight in the exact 
cellular and subcellular localization of ODC might provide valuable information on the role of 
this metabolically important enzyme. Efforts to assess the (sub)cellular localization of ODC 
by immunocytochemical means have been made in the past (for review see chapter 2). 
However, different localization patterns were found depending on the cell system studied and 
the antibody used. These patterns varied from a cytoplasmic or (peri)nuclear pattern to a both 
cytoplasmic and nuclear localization. An explanation for these discrepancies may be the lack 
of specificity of the ODC antibodies that were used. Furthermore, effects of cell and tissue 
preparation (e.g. fixation procedures, permeabilization, dehydration and embedding in
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paraffin, etc.) on the preservation and/or accessibility of the ODC protein for the antibodies 
were hardly defined.
In order to develop a reliable method for the immunocytochemical detection of ODC we 
have raised a specific and potent mouse monoclonal antibody (MP16-2) to a synthetic 
hexadecapeptide (P16) corresponding to a computer-calculated epitope of ODC (amino acid 
residues 345-360) (Schipper et al. 1993, chapter 3). The purpose of the present study was to 
investigate systematically the applicability of the MP16-2 antibody to detect immunocyto- 
chemically ODC in cells and tissues. For this purpose, we further characterized the specificity of 
the antibody for ODC by Western blotting and ELISA analysis using cell and tissue 
homogenates. In order to determine how the ODC epitope was preserved during the consecutive 
steps of the immunocytochemical procedure model studies were performed using artificial 
preparations of P16-coupled Sepharose beads as well as intact cells (human amnion WISH 
cells). Subsequently, localization studies were performed on cultured cells (WISH cells, HCT 
116 human colon cancer cells, ODC-overexpressing NIH 3T3 mouse fibroblasts) as well as on 
rat tissues using optimized preparation procedures as established in the model studies.
M a te r ia l s  a n d  M e th o d s  
Antibody
A mouse monoclonal antibody against a defined epitope of ODC was produced and 
characterized as described previously (Schipper et al. 1993, chapter 3). In short, a computer 
calculated hexadecapeptide (P16), representing the amino acid sequence 345-360 of ODC, was 
coupled to bovine serum albumin and used for the production of monoclonal antibodies. 
Antibodies were screened in an ELISA using thyroglobulin (Tg) as a protein carrier for P16. 
One hybridoma cell line, MP16-2, was positive for the P16-Tg conjugate whereas it did not react 
with the protein carrier indicating that MP16-2 was specific for the P16 peptide. The MP16-2 
antibody was identified as an Ig1 immunoglobulin recognizing the C-terminal part (correspon­
ding to amino acids IWGPTC of the ODC sequence) of the P16 peptide as determined by 
epitope mapping. Purified antibody fractions were prepared from hybridoma cell cultures by 
affinity chromatography (HiTrap Protein G; Pharmacia, Uppsala, Sweden) and stored in stock 
solutions of 1 mg/ml. P16-peptide was used as an antigen in the artificial model preparations. 
P16-Tg was also used as an antigen-protein carrier conjugate in the ELISA assays and for pre­
absorption of MAb MP16-2 for control immunocytochemical studies.
Cell and tissue preparations
Human amnion WISH cells (American Type Culture Collection, Rockville, MD, USA), HCT 
116 human colon cancer cells (American Type Culture Collection) and NIH 3T3 mouse 
fibroblast cells (American Type Culture Collection) were cultivated in Dulbecco's modified 
Eagle's medium (DMEM, Flow Laboratories; Zwanenburg, The Netherlands) supplemented 
with 10% fetal calf serum (FCS, Integro BV; Zaandam, The Netherlands), 100 IU/ml penicillin 
and 100 ^g/ml streptomycin (ICN Biomedicals Ltd.; Irvine, UK). A solution of 0.5 mg/ml 
trypsin (Difco Laboratories; Detroit, MI, USA) and 0.2 mg/ml ethylene di-amino tetra-acetic 
acid (EDTA) in phosphate buffered saline (PBS) was used to detach cells for passage.
To investigate ODC immunoreactivity in ODC-overexpressing cells, NIH 3T3 cells were 
transiently transfected with an expression construct (12.3 kb) carrying the full-length gene 
encoding human ODC driven by gut-specific promoter sequences. Transfected cells showed
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elevated levels of ODC mRNA (2 to 20 times) and enzyme activity (3.5 to 40 times) compared 
with non-transfected cells (Tan et al. in preparation).
Cell homogenates were prepared for immunochemical analysis (Western blotting, ELISA) by 
homogenization of 1 x 105 cells in lysis buffer (50 mM Tris, 1 mM EDTA, 0,3% SDS, pH 7.2). 
After clarification of the lysates by centrifugation at 12,000 g at 4 0C for 10 minutes, the 
supernatant was used for further analyses.
We purified ODC from kidneys of testosterone-treated NMRI mice as described by Kopitz et 
al. (1990) to examine whether the anti-P16 antibody recognized native ODC protein. Two 
hundred kidneys yielded 180 Mg of enzyme protein with a specific activity of 28.3 mU  /mg of 
protein (U = mol/min). A relative purification of 4760-fold and a recovery of 41% of cytosolic 
ODC activity were obtained. A fraction of the purified ODC was labeled with the selective
3 3inhibitor 2-(difluoromethyl)-3,4-di- H-DL-ornithine ( H-DFMO) as described earlier (Kopitz et 
al. 1990). This preparation contained no detectable ODC activity after labeling with DFMO.
The crude fraction of cytosolic ODC, highly purified ODC and purified ODC fraction labeled 
with H-DFMO were subsequently applied as antigen for immunochemical studies using 
Western blotting and/or ELISA.
Western blotting
Homogenates were boiled with sample buffer (62 mM Tris-HCl, pH 6.8, 10 % glycerol, 2 % 
sodium dodecyl sulphate (SDS), 650 mM ß-mercaptoethanol, 0.025% bromophenol blue) for 5 
min at 100 0C. The samples and molecular weight markers (Pharmacia) were loaded on 10 % 
SDS-polyacrylamide gels (acryl/bisacryl 29.2/0.8) and subsequently electrotransferred onto 
nitrocellulose sheets (Millipore; Bredford, MA, USA) in blotting buffer (25 mM Tris-HCl, pH 
8.6, 192 mM glycin, 20% methanol, 0.02% SDS).
Blots were washed with PBS containing 0.05% Tween 20 (Merck; Darmstadt, Germany) 
(PBST) and incubated for 3 hrs at room temperature (RT) in PBST containing 5% low fat milk 
powder to block nonspecific binding sites. The blots were rinsed in PBST and incubated 
overnight at RT with MP16-2 antibody (1 Mg/ml) in PBST. After washing three times for 10 min 
in PBST, blots were incubated with secondary antibody, i.e. peroxidase-coupled goat anti-mouse 
IgG (Dako, Glostrup, Denmark) diluted 1:2000 in PBST. Finally, bound antibodies were 
visualized using a chemiluminescent detection system (Boehringer Mannheim, Almere, The 
Netherlands) followed by exposure to radiographic film (Kodak X-OMAT-R, Kodax Industries; 
France) for 10-30 sec.
ELISA
ELISA analysis was performed as described previously (Schipper et al. 1993) with some 
modifications. Briefly, polystyrene 96-well microtiter plates (Costar; Cambridge, MA) were 
precoated with 1 % poly-L-lysine in PBS for 3 hrs at 37 0C. Plates were subsequently coated 
with the antigen solution, e.g. dilutions of P16-coupled Tg (5 Mg/ml), HCT 116 cell supernatant 
(2.5 mg/ml) or purified ODC (0.5 Mg/ml), and incubated overnight at 4 0C. Antigen solution was 
removed and the plates were incubated with PBS containing 1 % gelatin for 3 hours at 37 0C to 
prevent aspecific binding of the antibody. After washing with PBST the MP16-2 antibody (1 Mg 
per well) diluted in PBS containing 2% bovine serum albumin (BSA) (Sigma) and 0.1% Triton 
X-100 (Sigma) was added to each well and incubated for 1 hr at 37 0C. After rinsing with PBST, 
incubation with peroxidase-labeled conjugate (RaM-PO, Dako) diluted 1/1000 in PBST was 
performed for 1 hr at 37 0C. After rinsing, wells were filled with a solution of the chromogen 5- 
aminosalicylic acid (1 mg/ml) (Sigma) and H20 2 (0.25%) in 50 mM phosphate buffer (pH 6.0)
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and incubated for 30 min at RT. Production of final reaction product was measured by reading 
the absorbance at 450 nm in an ELISA plate reader (Titertek, Flow Laboratories, Zwanenburg, 
The Netherlands).
Artificial model preparations
To investigate the effects of the immunocytochemical procedure on P16 antigenicity the so- 
called defined antigen substrate spheres (DASS) system was used (Streefkerk et al. 1975; Capel 
1975). For this purpose, P16 peptide was coupled to EAH Sepharose 4B beads (Pharmacia).
First, the free amino groups of the Sepharose beads were activated with a stoichiometric 
amount of 6-(1-maleinimido)hexanoic acid 1-succinimidyl ester (MHS, Fluka; Switzerland) in 1 
ml N,N-dimethylformamide (DMF, Merck, Darmstadt, Germany) for 30 min. Beads were then 
rinsed with DMF, treated with acetic-acid N-hydroxysuccinimidic ester (AcONSu, Merck) in 
DMF for 10 min to block non-activated amino groups and again rinsed with DMF. For the 
coupling of 1 ml activated beads 5 mg decapped P16 was used. P16 was dissolved in 100 |il 
DMF/methanol, 14:5 (v/v), and added to the activated beads. After 1 hr beads were rinsed with 
PBS and stored at 4 0C. Intact bead preparations were used for immunocytochemical model 
experiments. Alternatively, beads were embedded in paraffin and 4 Mm thick sections from the 
paraffin blocks were mounted on object slides.
Fixation methods
Cross-linking as well as coagulant fixatives were tested with the use of artificial model 
preparations and intact cells. Cross-linking fixatives were phosphate buffered solutions of 2 and 
4 % paraformaldehyde (pH 7.3), 4 % paraformaldehyde with 0.1 % glutaraldehyde, Zamboni’s 
fixative and Bouin’s fixative. Fixation was performed for 1 hr at 4 0C. The coagulating fixatives 
were methanol, ethanol and acetone with an incubation time of 30 min at -20 0C.
Immunocytochemistry
a. Artificial models and cultured cells
Artificial model preparations were made of P16-coupled Sepharose beads that were air-dried on 
object slides. For intact cell preparations cells were grown on 8-well chamber slides until 80 % 
confluency. After washing with PBS slides were incubated with the appropriate fixative. After 
washing cells were permeabilized with methanol, ethanol or acetone series (100, 50, 25 %) each 
step 15 min at -20 0 C. In order to decrease aspecific binding of antibodies slides were acetylated 
using a tri-ethanolamine solution (0.1 M tri-ethanolamine, pH 8.8, acetic acid-anhydride 0.25 %) 
(Hayashi et al. 1978).
Immunoreactivity of the MP16-2 antibody was visualized using indirect immunoperoxidase 
or immunofluorescence methods. Secondary antibodies were rat anti-mouse immunoglobulins 
conjugated with horseradish peroxidase (RaM-PO; Dako) or rat anti-mouse immunoglobulins 
conjugated with fluorescein di-isothiocyanate (RaM-FITC; Dako). Primary as well as secondary 
antibodies were diluted in PBS containing 2% BSA and 0.1% Triton X-100. Specificity was 
investigated by pre-absorbing MP16-2 antibody solution with various concentrations (0, 0.1, 0.5, 
1, 10 Mg/ml) of P16-coupled thyroglobulin for 30 min at RT. Immunoglobulin type-matched 
mouse monoclonals against S-100 (Ma-S100; IgG2a) and follicle stimulating hormone (Ma- 
FSH;IgG1) (Biogenex Laboratories; San Ramon, CA, USA) or dilution buffer were used as 
negative controls. Slides were incubated with primary (diluted 1/100) or secondary antibodies 
(diluted 1/300) for 90 min at RT and subsequently washed with PBS. Peroxidase was visualized 
using 0.06% diaminobenzidine and 0.015 % H20 2 in PBS. Object slides incubated with RaM -
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FITC were mounted in glycerol (Merck) 90%/Tris-HCl (Merck) 10%/ NaN3 (Merck) 0.1%. All 
other slides were mounted in Permount (Fisher; Fair Lawn, NJ, USA). Slides mounted in 
Permount were stored at RT. Slides used for immunofluorescence were stored in the dark at 4 
0C.
Staining results were examined using a Zeiss Axiophot microscope (Carl Zeiss, Oberkochen, 
Germany). Confocal laser scanning microscopy was carried out using a Nikon Diaphot (Nikon, 
Tokyo, Japan) and a Bio-Rad MRC 1000 (Hemel Hampstead, UK) equipped with a krypton­
argon laser as described previously (Scheenen et al. 1996).
b. Tissues
Adult male rats (Wistar) were treated with testosterone by subcutaneous implantation of a 
time release pellet containing 50 mg of testosterone (Innovative Research of America; Sarasota, 
FL, USA). After 72 hrs the rats were killed by cervical dislocation, and adrenals, colon, kidney, 
liver, pancreas, prostate, small intestine, and spleen were removed. In a separate experiment 
pancreas and intestinal tissues of 1, 7, 14, 21, 28 and 100 days old rats were obtained. Specimens 
of the tissues were fixed overnight at 4 0C in 4 % paraformaldehyde or Bouin’s fixative and 
paraffin-embedded. Sections, 4 Mm in thickness, were mounted on object slides, dewaxed, 
rehydrated through a series of ethanol solutions and treated with 3 % H20 2 in methanol for 3 
min to block endogenous peroxidase activity. For heat-induced antigen retrieval (Cattoretti et al.
1993), the slides were boiled in 0.01 M sodium citrate, pH 6.0, for 15 min, in a microwave oven 
at 800 Watts. Slides were incubated with MP16-2 antibody (1 mg/ml) diluted 1/100 in antibody 
buffer (PBS containing 1% BSA, 0.1% Tween 20 and 0.01% SDS) for 18-24 hrs at 4 0C. 
Specificity of the staining method was investigated by pre-absorbing MP16-2 antibodies with 
various concentrations (0, 0.1, 0.5, 1, 10 Mg/ml) of P16-coupled thyroglobulin for 30 min at RT. 
Bound antibodies were visualized with ABC Elite Vectastain reagents (Vector Laboratories; 
Burlingame, CA, USA) using H20 2 and diaminobenzidine as chromogen. Sections were placed 
in a developing medium containing 0.006 % H20 2 and 1 mg/ml diaminobenzidine, and incuba­
ted for 10 min at RT.
Results
Characterization of the antibody
Western blotting analysis was used to evaluate the immunoreactivity of MAb MP16-2 towards 
ODC in different cell and tissue preparations. The antibody reacted with a 53 kDa protein of the 
same molecular weight (Mr) as ODC (Figure 1, lanes 1-3). ODC- transfected NIH 3T3 cells 
expressed high levels of ODC protein (Figure 1, lane 1) as compared to non-transfected cells that 
showed only a very weak band (data not shown). In mouse kidney cytosol, other more weak 
bands with higher Mr are present which may represent complexed forms of ODC (Figure 1, lane 
2). The antibody did not react with purified ODC complexed with H-DFMO (Figure 1, lane 4) 
indicating that binding of DFMO masks or changes the epitope recognized by MP16-2.
ELISA studies showed that the MAb MP16-2 detected ODC in cell and tissue homogenates 
adhered to plastic surfaces (Figure 2B,C). One microgram of antibody was able to detect 60 Mg of 
cell homogenate and 6,5 ng of ODC purified from stimulated mouse kidney, which 
corresponded to 3,5 pU and 330 pU of ODC activity, respectively. For comparison, Figure 2A 
shows the ELISA standard titration curve for P16- peptide conjugate of thyroglobulin.
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F ig u re  1 . Western blotting o f different ODC preparations o f a cell homogenate (Lane 1) and testosterone-stimulated mouse 
kidneys (Lane 2-4) using the MP16-2 antibody. Lane 1, ODC-overexpressing NIH 3T3 cells; lane 2, kidney cytosol; lane 3, 
purified ODC; lane 4, purified ODC labeled with 3H-DFMO.
Figure 2. Typical ELISA curves of MAb MP16-2. Wells were coated with dilutions of (A) P16 peptide- 
conjugated thyroglobulin, (B) cell homogenate of HCT 116 cells or (C) ODC purified from kidney cytosol. 
Results are means of two measurements performed in two separate experiments.
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Methodological studies
The effects of different fixatives on MP16-2 immunostaining in artificial model preparations 
(DASS system) and the WISH cells are shown in Table 1. All cross-linking fixatives used were 
capable of retaining antigenicity of P16 in the DASS system (Figure 3), whereas the use of 
coagulating fixatives did not result in any immunostaining with MP16-2. Comparable results 
were obtained in experiments with cultured WISH cells. Fixation with 4% paraformaldehyde or 
Bouin’s fixative provided the best results in intact cells.
The effects of fixation time, permeabilization procedures and addition of glutaraldehyde in 
various concentrations to the 4 % paraformaldehyde-containing fixative on immunostaining of 
P16-coupled Sepharose beads or WISH cells are shown in Table 2. The effects on intact beads or 
paraffin sections of beads were similar. In cultured cells optimal staining results was achieved 
after 1 hr of fixation. After prolonged fixation times staining intensity decreased. Treatment with 
a methanol series proved to be the best procedure to permeabilize cells, whereas all 
permeabilization methods tested did not affect immunostaining of the artificial model 
preparations. Glutaraldehyde concentrations higher than 0.1 % decreased staining intensity in 
artificial model preparations as well as cultured cells (results not shown).
Beads were not stained after incubation with control antibodies instead of the MP16-2 antibody 
(Figure 3, inset) whereas cultured cells showed a non-specific background staining. However, 
treatment of the cells with an acetylating solution as described by Hayashi et al. (1978) 
prevented this background staining.
Since fixation with 4 % paraformaldehyde or Bouin’s fixative provided the best results in the 
model studies these fixatives were applied to tissue sections. ODC immunoreactivity was best 
preserved in rat tissues with fixation according to Bouin. Addition of 0.01 % SDS to the 
antibody buffer solution increased the staining intensity considerably. Further increase in 
staining intensity and reduction of background staining were achieved with the antigen retrieval 
procedure using citrate buffer
Table 1. Effect o f fixation methods on MP16-2 immunostaining a
DASS system b Cultured WISH cells c
Cross-linking fixatives d 
None + +
2% paraformaldehyde + + +
4% paraformaldehyde + + + + +
4% paraformaldehyde + 0.1 + +
% glutaraldehyde 
Zamboni’s fixative + + + +
Bouin’s fixative + + + + +
Coagulating fixatives e
Methanol - -/+
Ethanol - -
Acetone - -
a Immunoreactivity was visualized using the indirect immunoperoxidase technique. Level o f staining was scored from - 
(negative) to + + + (strongly positive). b P 16-peptide coupled to EAH Sepharose beads 4B was used as antigen. c After 
fixation with cross-linking fixatives, cells were permeabilized with methanol 100%, 50% and 25%, each step 15 min at -20 0 
C. d Material fixed for 1 hr at 4 0 C. e Material fixed for 30 min at -20 0 C.
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Figure 3. Photomicrograph of P16 peptide-coupled Sepharose beads after paraformaldehyde fixation and staining with 
MAb MP16-2 using the indirect immunofluorescence technique. Inset: control staining with irrelevant MAb Ma-FSH. 
Staining was absent after using MAb MP16-2 when the beads were fixed with coagulating fixatives. Bars = 50 nm.
Table 2. Effect of fixation time, permeabilization procedures and glutaraldehyde on MP16-2 
immunostaining a
DASS system
Intact beads Paraffin sections
Cultured WISH cells
Confluent cells Mitotic cells
Fixation time?
0 min + + + + - -
30 min + + + + + + +
1 hr + + + + + + + + +
4 hr + + + + + + +
24 hr + + + + +
Permeab ilizationc
None + + nd -/+ -
Methanol + + nd + + + + + +
Ethanol + + nd -/+ +
Acetone + + nd - -/+
Gl utaraldehyde 
concentration (%)c 
0.01 + + + + + + + +
0.05 + + + + + + + +
0.1 + + + +
0.5 + + + +
a All preparations were fixed with 4% paraformaldehyde. Immunoreactivity was visualized using the indirect 
immunoperoxidase technique. Level of staining was scored from - (negative) to + + + (strongly positive). nd, not 
done. b After fixation, cells were permeabilized with methanol 100%, 50% and 25%, each step 15 min at -20 0 C. 
c Material fixed for 1 hr at 4 0 C.
67
Immunocytochemical localization of Ornithine Decarboxylase
Localization patterns
Typical immunocytochemical staining patterns are shown in Figure 3 and Figure 4. P16-coupled 
beads were positively stained after incubation with MP16-2 antibodies (Figure 3). Control 
incubations were negative (Figure 3, inset). Staining was restricted to the periphery of the beads 
and the intensity was heterogeneous among beads. MP16-2 immunostaining studies of different 
cell lines showed that all cells showed positivity for ODC. Immunostaining was substantially 
increased in ODC-transfected cells (Figure 4A) as compared with non-transfected cells (Figure 
4B). Mitotic cells were more intensely stained than confluent cells (Figure 4C-4F).
Figure 4 . Cultured cells stained with MAb MP16-2 using indirect immunoperoxidase (A-E) or indirect immunofluores­
cence (F) techniques. Staining of ODC-overexpressing (A) and normal (B) NIH 3T3 cells. Staining o f HCT 116 cells after 
pre-absorption with 0.1 (C), 0.5 (D) or 1 (D, inset) jug/ml o f P16 peptide-conjugated thyroglobulin. Staining of human 
amnion WISH cells using light (E) or confocal laser scanning (F) microscopy. Note the strong nucleoplasmic and moderate, 
predominantly perinuclear staining o f cultured mitotic and confluent cells respectively. Bars = 50 jam.
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In confluent cells, ODC staining was predominantly cytoplasmic, particularly in the 
perinuclear region as revealed by confocal scanning microscopy (Figure 4F).
Distribution patterns of ODC immunoreactivity in rat tissues are summarized in Table 3 and 
Figure 5. In testosterone-treated rats strong cytoplasmic staining was found in proximal tubules 
of kidney (Figure 5C), acinar cells of prostate and adrenal medullary cells. In the small intestine 
of 7, 14 and 21 days-old rats immunoreactivity was present in both crypts and villi whereas in 28 
days old and adult (100 days old) rats (Figure 5A) strong positivity for ODC was found in crypts 
only. In the pancreas of neonatal (1 day old) rats, islets of Langerhans showed a strong 
cytoplasmic staining (Figure 5B). In the pancreas of 14 days-old rats, a heterogeneous staining of 
exocrine cells was observed (Romain et al. 1998).
Pre-absorption with 1 ag/ml of P16 peptide or more completely eliminated staining of 
cultured cells and all tissues investigated (Figure 4C,D, inset of D). No distinct differences were 
observed between results obtained with immunoperoxidase and immunofluorescence 
visualization methods.
Figure 5. Indirect immunoperoxidase staining of rat tissues with MAb MP16-2. (A) small intestine o f adult rat. (B) 
pancreas of neonatal rat. (C) kidney of testosterone-treated rat. Note the immunoreactivity in the intestinal crypts, 
pancreatic islets and renal proximal tubules respectively. Bars = 50 jam.
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Discussion
The purpose of the present study was to systematically develop and optimize a reliable 
method for the in situ detection of ODC utilizing a monoclonal antibody (MP16-2) directed 
against an artificial antigen representing an ODC epitope (P16; amino acid residues 345-360). 
Authenticity of the P16 ODC epitope was proven by comparing the selected sequence with the 
primary sequences of other proteins. The sequence -WGPTC-, recognized by MP16-2, is 
present in all known eukaryote ODC's (Schipper et al. 1993). Immunoblotting results of the 
present report further confirm that the MP16-2 antibody also reacts with the epitope in the3
native ODC. Interestingly, the antibody did not bind to ODC complexed with H-DFMO, 
which is in agreement with studies of Poulin et al. (1992) and Tobias and Kahana (1993). 
These authors reported that the amino acid Cys360, present in our selected epitope, is essential 
for ODC activity. Since DFMO-labeled ODC was not recognized by MP16-2, DFMO-treated 
cells and tissues could have been used for additional negative controls in the ODC 
cytochemical staining. However, the use of DFMO in vivo has significant drawbacks. Since 
ODC has a very short half-life, large and frequent doses of DFMO would be needed. 
Furthermore, the inhibitor is not taken up well by cells and it has to compete with ornithine to 
bind to the active site of ODC, which further complicates inhibition. Finally, it is also not 
certain whether different cell types or subcellular compartments take up DFMO in a similar 
way. Therefore, we did not perform these control studies.
Our ELISA experiments showed that the MP16-2 antibody could also be used to detect 
ODC in homogenates of cells or tissues coated to plastic surfaces. The difference in calculated 
sensitivity between the different ODC preparations (purified ODC, cell homogenate) might be 
due to variations in the amount of ODC epitope that became attached to the plastic surfaces.
In contrast to immunochemical procedures, e.g. ELISA, immunocytochemical staining 
procedures take place in a chemically far more complex matrix. Model systems using artificial 
matrices have proven to be valuable tools to study the complexity of (immuno)cytochemical 
processes (Van der Ploeg and Duijndam 1986). By gradually increasing the complexity of the 
models studied (artificial models, cultured cells, tissues) the reliability of immunocyto­
chemical staining procedures can be analyzed and improved.
To study the preservation of the ODC-epitope in immunocytochemical processes we used the 
DASS system as artificial model (Streefkerk et al. 1975; Capel 1975). This model has the 
advantage that antigens are covalently bound to Sepharose beads. These beads have 
microscopical dimensions and can easily be manipulated to imitate actual conditions in cells 
and tissues (Van der Ploeg and Duijndam 1986).
Results with the DASS system and cultured cells showed that P16/ODC antigenicity is 
sufficiently preserved in beads and cells fixed with cross-linking fixatives.
In contrast, if  coagulating fixatives were used the intensity of immunostaining diminished. 
A frequently occurring problem with coagulative fixatives is that antigens are precipitated and 
extracted from biological matrices (Larsson 1993; Polak and Van Noorden 1997). Since in our 
DASS experiments the antigens are covalently immobilized to the beads, we assume that the 
coagulant fixatives may have altered or destroyed the P16/ODC epitope structure preventing 
binding of the MP16-2 antibody. Interestingly, the epitope remains preserved if, following 
fixation with cross-linking fixatives, cells are exposed to coagulating fluids used for 
permeabilization of cells.
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Table 3. Localization pattern o f ODC obtained with immunostaining in rat tissuesa
Tissue ODC immunoreactivity Cellular localization
Kidneyb proximal tubules cytoplasmic
Prostateb acinar cells cytoplasmic
Adrenalb adrenal medullary cells cytoplasmic
Pancreas 1 d Langerhans islets, some exocrine cells cytoplasmic
14 d exocrine cells cytoplasmic/nuclear
Small 1 d no staining
intestine
7 d villi/crypts perinuclear
14 d villi/crypts perinuclear
21 d villi/crypts perinuclear/cytoplasmic
28 d cells in crypts cytoplasmic
100 d cells in crypts cytoplasmic
a Tissues fixed with Bouin ’s fixative overnight at 4 0 C. Immunoreactivity was visualized using the ABC technique. d = days 
after birth.b Animals treated with testosterone.
Intact cells have to be made permeable to antibodies especially after fixation with cross­
linking fixatives that are known to create diffusion barriers (Larsson 1993). The results of our 
study confirm these findings, i.e. if  permeabilization was not carried out after the use of a 
cross-linking fixative the staining pattern was completely different. Acetone, ethanol and 
methanol are widely used to permeabilize cells for flow cytometric studies and are thus also 
applicable to permeabilize cells for immunocytochemical studies (see for example Cattaneo 
et al. 1983). To permeabilize cells these substances were tested. Methanol was the only 
alcohol that provided good permeabilization of the cultured WISH cells.
The preservation of the epitope by fixatives containing both 4% formaldehyde and 0.05% 
glutaraldehyde opens perspectives for the application of MP16-2 in electron microscopical 
studies.
On the basis of the results obtained in the model studies we tested the MP16-2 antibody on 
rat tissues fixed with 4 % paraformaldehyde or Bouin's fixative. Initial experiments resulted in 
a rather low and poorly reproducible immunostaining of the tissues. With the addition of SDS 
to the antibody-containing solution staining was dramatically increased. This observation is 
compatible with reports from the literature showing that immunogenicity of a number of 
antigens is retrieved after SDS treatment of cell and tissues (Brown et al. 1996). Citrate 
buffer-treatment, another antigen retrieval step, further improved the intensity of ODC 
staining and decreased background staining. A possible hazard of this heat-induced antigen 
retrieval step is the increased prominence of plasma cell immunoglobulins or endogenous 
biotin that can react with the secondary antibody or the ABC reagent, respectively. Therefore, 
the stained cells that were observed in the lamina propria of intestinal villi could be due to non­
specific staining of plasma cells. Non-specific staining due to endogenous biotin is not likely 
in our studies since the use of the indirect immunoperoxidase method without the
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streptavidin-biotin reagent gave similar localization patterns (data not shown).
These observations illustrate the increasing complexity of biological matrices in tissues 
compared to single cells and artificial models. Antigens in tissues, although well preserved 
after fixation, might be masked or linked to other components (for instance by means of 
hydrogen or disulfide bonds) and therefore hardly accessible to antibodies.
Although the present study was not primarily meant to investigate the intracellular localization 
of ODC in cultured cells, interesting results were obtained. Under optimal conditions ODC 
showed a similar localization pattern in all tested cell lines. In resting cells ODC staining was 
moderate and predominantly in the perinuclear region whereas mitotic cells were strongly and 
homogeneously stained. Previous studies on stimulated murine macrophage-like RAW 264 
cells (Greenfield et al. 1986) and ODC-overproducing CHO cells (Anehus et al. 1984) 
reported that ODC was localized exclusively or predominantly in the cytoplasm of cells. 
However, in a murine cell line of epidermal origin (JB6), immunoreactive ODC protein was 
found both in the cytoplasm and nucleoplasm but not in nucleoli (Greenfield et al. 1986). In 
growing cell fractions of human keratinocytes ODC showed a perinuclear and nuclear 
distribution pattern. When cell growth was arrested ODC distribution became more diffuse 
and cytoplasmic (Pomidor et al. 1995).
The optimized immunocytochemical method was also applied to various rat tissues. In 
testosterone-treated rats intense staining of ODC was detected in proximal tubules of kidney 
and acinar cells of prostate which is in agreement with previous biochemical, enzyme 
cytochemical and hybridocytochemical studies (Persson et al. 1983; Zagon et al. 1984, 
Koibuchi et al. 1993, Pegg et al. 1970; Dorn et al. 1985, Blackshear et al. 1989). Testosterone 
treatment did not change the intensity of staining in other tissues tested, e.g. small intestine 
and pancreas (dates not shown).
ODC expression has been shown to change during growth and maturation of developing 
tissues. In developing rat pancreas and small intestine we observed age-related localization 
patterns which might reflect the changes of ODC expression during growth and maturation of 
these organs (Romain et al. in preparation).
In conclusion, the present study describes conditions required for an optimal detection of 
ODC with the MP16-2 monoclonal antibody in homogenates, intact cells and tissue sections. 
Using optimized techniques we demonstrated high ODC immunoreactivity in cells and tissues 
that are engaged in growth or differentiation processes. Moreover, the ELISA technique 
provides a new valuable quantitative assay for ODC protein in homogenates of cells and 
tissues.
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Localization ofPolyamine oxidase activity
Abstract
Data concerning the substrate specificity and the exact intracellular localization of the 
polyamine-catabolizing enzyme polyamine oxidase are conflicting. Biochemical studies have 
shown that N1 -acetylation of spermine and spermidine dramatically increases the specificity 
of these compounds for peroxisomal polyamine oxidase to produce spermidine and 
putrescine, respectively. On the other hand, polyamine oxidase activity was demonstrated 
histochemically both in peroxisomes and in cytoplasm of several tissues using spermidine 
and/or spermine as substrate. To elucidate the in situ substrate specificity of polyamine 
oxidase and the localization of its activity, enzyme activity was detected in rat liver, kidney, 
and duodenum at the light and electron microscopic levels. For this purpose, unfixed cryostat 
sections were applied to avoid changes in enzyme activity owing to chemical fixation. 
Spermine, spermidine, their N1 -acetylated forms, and putrescine were used as substrates and 
cerium ions as capturing agent for H2O2. Control reactions were performed in the absence of 
substrate or in the presence of substrate and specific oxidase inhibitors. At the light 
microscopic level, final reaction product specifically generated by polyamine oxidase activity 
was found exclusively in a granular form in hepatocytes, epithelial cells of proximal tubules 
of the kidney, and epithelial cells of duodenal villi with N1 -acetylspermidine or N1 - 
acetylspermine as substrates. Final reaction product was not observed in any of the tissues 
after incubation in the presence of putrescine, spermidine, or spermine. Formation of specific 
final reaction product was prevented by incubation in the presence of a specific polyamine 
oxidase inhibitor but it was not affected by a diamine oxidase inhibitor. Ultrastructural 
studies revealed that polyamine oxidase activity is localized exclusively in the matrix of 
peroxisomes of kidney and liver and in microperoxisomes of the duodenum. The localization 
patterns obtained with unfixed tissues are in agreement with biochemical data. Strong 
intraperoxisomal, interperoxisomal, and intercellular heterogeneity in polyamine oxidase 
activity was found in liver, kidney, and duodenum.
Key WORDS: polyamine oxidase activity / substrate specificity / peroxisomes / N'-acetylation / 
unfixed cryostat sections / cerium salt capture method
I ntroduction
The polyamines spermidine (Spd) and spermine (Spm) play an important role in the regulation 
of growth and development of animal and plant cells (Féray et al. 1994; Tabor and Tabor 
1984; Heby 1981). Polyamine concentrations and enzymes involved in polyamine metabolism 
were found to be increased in proliferating cells, whereas induction of polyamine synthesis is 
related to increased rates of DNA, RNA and protein synthesis (Sjoerdsma and Schechter 
1984; Tabor and Tabor 1984; Jänne and Morris 1984; Pegg and McCann 1982; Heby 1981).
A key enzyme in polyamine synthesis is ornithine decarboxylase, which catalyzes the 
conversion of ornithine into putrescine (Put). Put is converted into Spd and Spd into Spm by 
Spd-synthase and Spm-synthase, respectively (see Figure 2, chapter 1) (Pegg 1986; Seiler et al. 
1985; Tabor and Tabor 1984; Heby 1981). Although the synthesis of polyamines is well 
understood, discrepancies exist in the literature with respect to degradation of polyamines. 
Biochemical studies have shown that polyamines can be oxidized by polyamine oxidase 
(PAO) in peroxisomes only (Heby 1981; Hölttä 1977). However, oxidation of Spd and Spm in 
vivo is described to occur only after N 1-acetylation by spermidine/spermine N 1-acetyltrans- 
ferase (SSAT) present in the cytoplasmic matrix (Pegg 1986; Matsui et al. 1981; Pegg et al.
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1981) (see also Figure 2, chapter 1). This would mean that only N 1-acetylspermidine 
(NAcSpd) and N 1-acetylspermine (NAcSpm) are true substrates for PAO, although Spd and 
Spm may act as substrates under certain artificial conditions (Bey et al. 1985; Bolkenius et al. 
1985; Morgan 1985; Bolkenius and Seiler 1981). Beard and co-workers (1985) claimed in an 
ultrastructural study that PAO activity could be detected with non-acetylated Spm as substrate 
in peroxisomes after chemical fixation of rat liver and kidney. Furthermore, it has been 
described that polyamines can also be oxidized by other, non-peroxisomal, amine oxidases. 
For example, diamine oxidase (DAO), which is localized in the cytoplasmic matrix, or bovine 
serum amine oxidase, which is present in serum, are believed to be able to oxidize Put, Spd, 
Spm, NAcSpd, and NAcSpm (Seiler et al. 1985). The discussion on the substrate specificity 
of PAO became even more confusing when Robinson et al. (1991) postulated that PAO and 
DAO are one and the same enzyme. Recently, Nakos and Gossrau (1994) tried to reproduce 
the ultrastructural findings of Beard et al. (1985) at the light microscopic level. Instead of a 
granular distribution of the precipitate they detected final reaction product throughout the 
cytoplasm of various cell types.
To obtain a clearer insight into the in situ substrate specificity and localization of PAO, we 
studied the in situ substrate specificity and the intracellular localization of PAO by incubation 
of unfixed cryostat sections of rat liver, duodenum, and kidney for PAO activity. Unfixed 
cryostat sections were used to avoid alterations of the enzyme by chemical fixation. PAO 
activity was detected with the cerium salt capture method (Briggs et al. 1975), which enabled 
the localization of enzyme activity at both the light and the electron microscopic level 
(Frederiks et al. 1994; Van den Munckhof et al. 1994a, Van Noorden and Frederiks 1993; 
Schellens et al. 1992). For light microscopy, polyvinyl alcohol (PVA) was added to the 
incubation medium to avoid diffusion of enzyme molecules into the medium. For 
ultrastructural studies, the semipermeable membrane technique was used (Van den Munckhof 
et al. 1994a; Schellens et al. 1992). Incubations were performed in the presence of different 
possible substrates for PAO and DIOX and several specific inhibitors of these enzymes (Bey 
et al. 1985; Bolkenius et al. 1985; Schuler 1952).
Materials and methods
Male Wistar rats weighing 200-250 g were sacrificed under ether anesthesia. Liver, kidney, 
and duodenum were removed and cut into pieces up to 5 mm3. The tissue was immediately 
frozen in liquid nitrogen and stored at -80 °C.
The cerium method according to Briggs et al. (1975) to localize oxidase activities was 
performed in two ways. Substrate specificity of PAO was studied at the light microscopic 
level using PVA-containing incubation media, whereas the semipermeable membrane 
technique was applied for study of the ultrastructural localization of PAO activity.
Substrate specificity
Unfixed cryostat sections (8 pm thick) of rat liver, kidney, and duodenum were mounted on 
glass slides and air-dried. The substrate specificity of PAO was studied by incubating sections 
for 30-90 min at 37 °C with a medium consisting of 300 mM Tris-maleate buffer, pH 8.5, 30 
mM CeCl3, 100 mM NaN3 (Van den Munckhof et al. 1994a; Frederiks and Marx 1993; 
Schellens et al. 1992; Angermüller and Fahimi 1988), 1-50 mM substrate (Put, Spd, Spm, 
NAcSpd, or NAcSpm), and 10% PVA (Frederiks et al. 1994; Nakos and Gossrau 1994; Kooij 
et al. 1991). Control reactions were performed by incubating sections in the absence of
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substrate, in the presence of substrate and 0.1-10 mM 1,4-butanediamine-N,N'-bis(2,3- 
butanedienyl) (MDL 72527, a specific inhibitor of PAO (Bey et al. 1985; Bolkenius et al. 
1985), which was a kind gift of Dr. S. Sarhan and Dr. P. Casara of Marion Merrell Dow 
Research Institute (Strasbourg, France). Control reactions in the presence of substrate and 0.1­
25 mM aminoguanidine, a specific inhibitor of DAO (Schuler 1952) were also performed. 
Moreover, incubations in the presence of 50 mM NAcSpd or NAcSpm were performed on 
cryostat sections pre-fixed with 2.5% glutaraldehyde in 100 mM Na-cacodylate buffer, pH 
7.4, for 5 min at room temperature (RT). After incubation, the electron dense water-insoluble 
reaction product, cerium perhydroxide, was visualized in a second step incubation with a 
medium containing 1.4 mM 3,3'-diaminobenzidine, 100 mM NaN3, 42 mM CoCl2, and 2.3 
pM H2O2 in 50 mM Na-acetate buffer, pH 5.3, for 30 min at RT (Gossrau et al. 1989, 
Angermüller and Fahimi 1988). After rinsing thoroughly in water, the sections were 
embedded in glycerol jelly.
Ultrastructural localization
For localization of PAO activity at the ultrastructural level, the semipermeable membrane 
technique was used ( Van den Munckhof et al. 1994a,b; Frederiks and Marx 1993; Schellens 
et al. 1992; Frederiks et al. 1990; McMillan 1967). The incubation medium consisted of 300 
mM Tris-maleate buffer, pH 8.5, 30 mM CeCl3, 100 mM NaN3 (Van den Munckhof et al. 
1994a; Frederiks and Marx 1993; Schellens et al. 1992; Angermüller and Fahimi 1988), 5 mM 
NAcSpd or NAcSpm, and 1% agar noble. Cryostat sections (8 pm thick) were mounted on the 
semipermeable membrane and incubated for 90 min at 37 °C. The specificity of the reactions 
was investigated by performing incubations in the absence of substrate. After incubation, the 
gelled incubation media were removed and the inner side of the membrane was cleaned. The 
piece of semipermeable membrane containing the incubated section was cut out and fixed 
immediately in a mixture of 1% glutaraldehyde and 4%formaldehyde in 100 mM Na- 
cacodylate buffer, pH 7.4, for 60 min at RT. Subsequently, sections were post-fixed in for 60 
min in 1% OsO4 in 100 mM Na-cacodylate buffer, pH 7.4, at 4 °C, dehydrated according to 
standard procedures for electron microscopy, and embedded in LX-112 epoxy resin. Ultra-thin 
sections were cut on a LKB Ultrotome III, collected on copper grids carrying a Formvar film, 
and investigated with a Zeiss EM-10c transmission electron microscope. Both unstained ultra- 
thin sections and sections stained with uranyl acetate and lead citrate were investigated
RESULTS
Substrate specificity
Final reaction product was generated when unfixed cryostat sections of rat liver, kidney, and 
duodenum were incubated for 90 min at 37 °C in the presence of 5 mM NAcSpd or NAcSpm 
(Figures 1D, 1E, 2B, and 2D). Higher concentrations of substrate did not give rise to higher 
amounts of final reaction product. Final reaction product was exclusively present in a granular 
form. In liver, the granules were heterogeneously distributed in hepatocytes (Figures 1D and 
1E). Some hepatocytes contained hardly any precipitate, whereas various amounts of granules 
were found in others. No distinct differences were observed between hepatocytes in periportal 
and pericentral areas. In kidney, epithelial cells of some proximal tubules in the cortex showed 
large amounts of final reaction product, but epithelial cells of most tubules did not contain 
any final reaction product (Figure 2B). In duodenum, epithelial cells of the villi but not of the
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crypts contained a granular final reaction product (Figure 2D). These small granules were 
present at the apical part of epithelial cells. Various amounts of granules were found in the 
different villi . Incubations with either NAcSpd or NAcSpm resulted in a similar distribution 
pattern in all tissues, although the amounts of final reaction product generated after incubation 
with NAcSpd appeared to be somewhat lower than after incubation with NAcSpm
Ultrastructural localization
Ultrastructural investigation of cryostat sections of different tissues revealed that PAO activity 
was present in (micro)peroxisomes (Figures 3 and 4). In liver parenchymal cells, electron 
dense reaction product was present in the matrix of peroxisomes, whereas crystalline cores 
were free of electron dense precipitate (Figures 3B and 3C). Different peroxisomes showed 
various amounts of final reaction product (Figures 3B and 3C). In kidney, final reaction 
product was distributed homogeneously throughout the peroxisomal matrix in epithelial cells 
of proximal tubules (Figures 4A and 4B).
Figure 1. Light microscopic photographs o f PAO activity as demonstrated in unfixed cryostat sections o f rat liver. 
Incubations were performed (A) in the absence o f substrate and in the presence o f B) Spd C) Spm, D) NAcSpd, and E) 
NAcSpm. Granular final reaction product is present only after incubations with acetylated polyamines (NAcSpd or 
NAcSpm). Bars: A-D = 50pm; E  = 25 pm
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Spd
A
Spd
Figure 2. Light microscopic photographs o f PAO activity as demonstrated in unfixed cryostat sections o f (A,B) rat kidney 
and (C,D) duodenum. Incubations were performed in the presence o f Spd (A,C) and NAcSpd (B,D). Only acetylated Spd 
(NAcSpd) gives rise to a granular final reaction product (arrows) in rat kidney and duodenum. Lpr, lamina propria; muc, 
mucus; PMN, polymorphionuclear leukocyte. Bars = 25 pm.
However, various amounts of reaction product were present in different peroxisomes 
(Figures 4A and 4B). Microperoxisomes in epithelial cells of duodenal villi showed electron 
dense precipitate (Figures 4C and 4D). Reaction product was mainly present at the periphery of 
microperoxisomes, whereas the centers of the organelles contained less precipitate (Figures 4C 
and 4D). In all tissue investigated, crystalline deposits were found exclusively in peroxisomes. 
Other organelles, as well as the cytoplasmic matrix, were completely free of reaction product. 
Incubations performed in the absence of substrate did not give rise to any electron dense 
precipitate in the tissues investigated. Incubations performed in the presence of 1-50 mM Put, 
Spd, or Spm did not result in formation of any (granular or cytoplasmic) final reaction product 
(Figures 1B, 1C, 2A, and 2C). Similar results were obtained when incubations were performed 
in the absence of substrate (Figure 1A). Formation of final reaction product was prevented 
completely when 0.5 mM MDL 72527, a specific PAO inhibitor, was added to NAcSpd- or 
NAcSpm-containing incubation media (data not shown). Addition of up to 25 mM 
aminoguanidine, a specific inhibitor of DIOX, to substrate-containing media did not affect the 
amount of final reaction product generated. Pre-fixation of cryostat sections completely 
prevented formation of final reaction product in all tissues investigated.
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Figure 3. Electron micrographs o f PAO activity as demonstrated in unfixed cryostat sections o f rat liver after incubation 
(A) in the absence o f substrate, and (B,C) in the presence o f NAcSpm. Reaction product is present in matrix (M) but not in 
cores (C) ofperoxisomes (per). The amount o f electron dense reaction product is variable in different peroxisomes. Sections 
were counterstained with lead citrate and uranyl acetate. Bars: A, C = I pm; B  = 500 nm.
Discussion
In this study we have shown that specific NAcSpd- and NAcSpm-dependent PAO activity is 
localized solely in peroxisomes of liver, kidney, and duodenum when unfixed cryostat 
sections are used. The specificity of the reaction was proven by the absence of final reaction 
product after incubation in the absence of substrate or in the presence of substrate plus a 
specific PAO inhibitor. These results are fully in agreement with biochemical findings that 
NAcSpd- and NAcSpm-oxidizing PAO is present only in peroxisomes (Bey et al. 1985; 
Bolkenius et al. 1985; Morgan 1985; Bolkenius and Seiler 1981; Heby 1981). Incubations in 
the presence of up to 50 mM Put, Spd, or Spm did not lead to any formation of final reaction 
product in granules or cytoplasm, indicating that peroxisomal PAO specifically oxidizes N 1- 
acetylated polyamines. It shows that peroxisomal PAO has a very low specificity for Spd and 
Spm, whereas conversion into NAcSpd and NAcSpm by cytoplasmic SSAT leads to increased 
specificity (Pegg 1986). Our findings that (a) formation of granular reaction product is 
prevented completely by addition of a specific PAO inhibitor (MDL 72527) but not by the 
DAO inhibitor aminoguanidine, and (b) PAO is localized exclusively in peroxisomes, are in 
contrast with the following data. Beard and co-workers (1985) claimed to localize PAO 
activity in peroxisomes using Spd as substrate, cytoplasmic DAO appears to oxidize both 
acetylated and non-acetylated polyamines (Seiler et al. 1985), DAO and PAO are one and the 
same enzyme (Robinson et al. 1991), and Spd and Spm are oxidized in the cytoplasm by PAO 
(Nakos and Gossrau 1994).
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Figure 4. Electron micrographs o f PAO activity as demonstrated in unfixed cryostat sections o f (A,B) rat kidney and 
(C,D) duodenum after incubation in the presence NAcSpm. In kidney, electron dense final reaction product is 
homogeneously distributed within peroxisomes (per), but the amount o f final reaction product varies strongly in different 
peroxisomes (A,B). In doudenum, dense final reaction product is mainly present at the periphery o f microperoxisomes 
(mper) (C,D). mit, mitochondrion. Sections were counterstained with lead citrate and uranyl acetate. Bars: A  = I ppm; B  = 
200 nm; C = 2 pm; D = 500 nm.
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These contradictions between biochemical data and our data on the one hand and 
histochemical data obtained by others may be explained by the fixation procedures used the 
latter authors. Since aldehydes exert effects on polyamines (Fujiwara 1994) and polyamine 
oxidizing enzymes that are poorly understood (Hölttä 1977), formation of final reaction 
product might have been affected by chemical fixation. Our attempts to localize PAO activity 
in pre-fixed sections using a fixative according to Beard and co-workers (1985) completely 
prevented formation of final reaction product, which means that the enzyme is very sensitive 
to aldehyde fixation. For this reason, we have avoided chemical fixation before enzyme 
incubations but we have ensured precise localization by using a technique that combines the 
use of PVA with the cerium salt capture method. This procedure has shown to be valid for 
localization of peroxisomal and cytoplasmic matrix-bound oxidase activities in unfixed 
cryostat sections at the light microscopic level (Frederiks et al. 1994; Frederiks and 
Marx,1993; Frederiks et al. 1993; Patel et al. 1991). Ultrastructural localization of activity of 
peroxisomal oxidases in unfixed cryostat sections is possible when using the semipermeable 
membrane technique (Van den Munckhof 1994a,b; Schellens et al. 1992).
PAO activity is heterogeneously distributed over (micro)peroxisomes within cells in 
various tissues (Figures 3 and 4). This heterogeneity has also been demonstrated for other 
peroxisomal enzyme activities such as for catalase (Veenhuis and Wendelaar Bonga 1979; 
Fahimi et al. 1976; Roels et al. 1975; Herzog and Fahimi 1974), D-amino acid oxidase 
(Schellens et al. 1992), L-hydroxy acid oxidase (Veenhuis and Wendelaar Bonga 1979; Hand 
1975), and urate oxidase (Van den Munckhof et al. 1994a; Veenhuis and Wendelaar Bonga 
1979; Graham and Karnovsky 1965). Moreover, cells within one tissue compartment also 
show distinct differences in PAO activity (Figures 1 and 2). This heterogeneity was stronger 
for PAO than for any other peroxisomal oxidase investigated thus far.
From our results we conclude that physiological breakdown of polyamines occurs 
exclusively by peroxisomal PAO. Specific degradation of Spm and Spd occurs via an 
interconversion pathway in which the polyamines are N1-acetylated first before they are 
oxidized by peroxisomal PAO into Spd and Put, respectively (Figure 2, chapter 1). 
Acetylation of polyamines enhances strongly the oxidation of polyamines by peroxisomal 
PAO. Although cytoplasmic DAO has been described to oxidize polyamines as well (Nakos 
and Gossrau 1994; Robinson et al. 1991; Seiler et al. 1985) to form various aldehydes, either 
the specificity of the enzyme for (non-)acetylated polyamines or its activity is too low to 
substantiate an important role for DAO in physiological polyamine turnover. Therefore, 
terminal degradation of acetylated and non-acetylated polyamines by cytoplasmic DAO may 
be only of secondary importance for the regulation of intracellular polyamine levels. To our 
knowledge, this study is the first histochemical study that is in agreement with extensive 
biochemical literature (Pegg 1986; Bey et al. 1985; Bolkenius et al. 1985; Morgan 1985; 
Seiler et al. 1985; Tabor and Tabor 1984; Bolkenius and Seiler 1981; Heby 1981), probably 
because we have used unfixed biological material.
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ABSTRACT
In many western countries prostate cancer is one of the most frequent types of malignancies in 
males. Present methods for the detection of prostatic malignancy are inadequate to predict 
tumor behavior. Standard treatments of disseminated prostatic carcinoma are rarely curative. 
Therefore, new classes of agents that interfere with the malignant behavior of prostatic cancer 
cells are needed. Epithelial cells in the prostate of human and rat produce a substantial amount 
of polyamines. Polyamines are crucial factors for cell proliferation and differentiation and are 
considered increasingly important as targets for cancer therapy. Present review gives a survey 
of the literature on the role of polyamines in normal and malignant growth of prostatic cells. 
These studies show that differences in biological behavior of prostatic (cancer) cells are 
accompanied with changes in polyamine levels and/or the activity of their metabolic enzymes. 
Furthermore, the effects of interference with polyamine homeostasis on the in vitro and in 
vivo growth of several prostatic cancer cell lines are described. Treatment of prostatic cancer 
cells with inhibitors of polyamine metabolic enzymes or polyamine analogs induces cell 
growth arrest or (apoptotic) cell death. Overall, these studies show that polyamines may serve 
as important biomarkers of prostatic malignancy and provide a promising target for 
chemotherapy of prostate cancer.
General aspects of prostate cancer
Prostate cancer, is an increasingly important health issue in many countries because of its high 
incidence and mortality rate of this disease in men (Parker et al. 1997). At autopsy, undetected 
prostatic carcinomas are frequently found especially in older patients. In spite of this frequent 
occurrence the number of patients evolving large, invasive tumors with metastasis is 
comparatively low (Stamy 1993). If discovered early, prostate cancer can be cured with 
surgery in about 90% of cases. Therefore, currently much emphasis is led on early diagnosis. 
Unfortunately, markers to detect patients with a high risk for progressive growth of prostatic 
cancer are lacking.
A substantial number of men are diagnosed at a time when the disease already has 
disseminated outside the prostate. These patients eventually require androgen ablation therapy 
(i.e. surgical or medical castration). Androgen ablation induces an active process of 
programmed cell death or apoptosis in the androgen-dependent prostatic cancer cells 
(Kyprianou et al. 1990). Unfortunately, this therapy is rarely curative (Lepor et al. 1982). The 
major reason for the failure of androgen ablation to cure the disease is that in each patient 
cancer cells are heterogeneous, including both androgen-dependent and androgen-independent 
prostatic cancer cells, even before therapy is initiated. Thus, therapy targeted at the androgen­
independent prostatic cancer cells is necessary to eliminate the cancer cells completely. At 
present such therapy is not available. Therefore, there is a need for new classes of agents to 
eliminate androgen-independent prostatic cancer cells.
POLYAMINES AND THE PROSTATE
The three most commonly occurring natural polyamines are putrescine, spermidine and 
spermine. These aliphatic amines have a low molecular weight, a simple chemical structure and 
are highly charged cations at physiological conditions. Polyamines are multifunctional organic 
bases which play an essential role in cell growth, differentiation and malignant development.
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A comprehensive overview of the biochemistry and physiology of polyamines is described in 
Chapter 1 of this thesis. For a more detailed description, the reader is referred to the books 
recently published by Cohen (1998) and Bardocz and White (1999).
The prostate and prostatic secretions have played an important role in our current 
understanding of polyamines. The initial identification of one of the polyamines, i.e. 
spermine, was reported in human semen as early as the 17th century by Van Leeuwenhoek. 
Following the elucidation of the chemical structure of polyamines, about 200 years later, the 
biochemical mechanism of action of polyamines in semen has been studied extensively.
Apart from this historical perspective, the prostate has one of the highest polyamine 
concentrations of any tissue. In rats, the amount of polyamines is highest in the ventral 
prostate followed by the dorsal and lateral prostate, whereas the coagulating glands and 
seminal vesicles show low values (Fjosne et al. 1990). In rat prostate, spermidine is the 
predominant polyamine whereas in the human prostate spermine is present in high amounts.
Studies on castration-induced regression and testosterone-stimulated regrowth of the rat 
prostate showed that prostatic polyamines are under the control of androgens (Pegg et al. 
1970; Fjosne et al. 1990, 1992; our unpublished work). Concomitantly to castration-induced 
apoptosis of prostatic epithelial cells, ODC activity and polyamine levels dramatically 
decrease, whereas SSAT activity progressively increases (Figure 1). Regeneration of the 
prostate by suppletion of androgens coincides with a marked increase in ODC activity and 
recovery of polyamine concentrations to normal limits.
ODC-mRNA and activity are induced by androgens and ODC expression is particularly 
high in the epithelial cells of the prostate (Pegg et al. 1970; Blackshear et al. 1989; Jänne et al. 
1991; Crozat et al. 1992; Fjosne et al. 1992). Studies on the murine ODC gene revealed that 
the ODC promoter contains an androgen-responsive element-like sequence that can bind to 
the androgen receptor in vitro (Crozat et al. 1992).). Differential display studies in LNCaP 
cells showed that androgen regulation of ODC is directly mediated through the androgen 
receptor with kinetics of induction also operational for prostate specific antigen (Betts et al. 
1997). Inhibition of ODC activity with difluorom ethyl ornithine (DFMO) reduces the size of 
prostatic acini in the developing prostate, retards testosterone-induced regrowth of the prostate 
in castrated rats and inhibits insuline-like growth factor 1 (IGF-1)- induced growth of the 
prostate (Torring et al. 1997).
ODC has been localized immunocytochemically in rat prostatic gland revealing a 
heterogeneous cytoplasmic staining of acinar cells (Dorn et al. 1985; Müller et al. 1986; 
Chapter 2,4). Three types of ODC-immunoreactive cells were observed, i.e. strongly positive, 
weakly positive and negative cells, probably representing different cell types in the prostatic 
epithelium. In addition, ODC occurs in the human prostatic fluid, seminal plasma and sperm 
(Jänne et al. 1973; Mohan et al. 1999).
It is apparent that functions of ODC and polyamines in the prostate are related to cellular 
proliferation and secretory activities. It has been postulated that spermine is involved in the 
maintenance of the functional secretory state of prostatic epithelium (Ahmed and Goueli, 
1992, and references herein). Interestingly, the prostate contains an androgen-regulated protein 
that has high affinity towards spermine, i.e. spermine binding protein (SBP) (Chang et al. 
1987). SPB is phosphorylated by cyclic-AMP-independent protein kinases, suggesting being a 
phosphoprotein in vivo (Goueli et al. 1985).
The functional significance of seminal polyamines is still unclear. The highly cationic 
polyamines would encounter difficulties in penetrating into the spermatozoa before being 
utilized. Proton magnetic resonance spectroscopy (1HMRS) studies of human prostatic fluids
91
Polyamines and Prostate cancer
indicate that spermine is linked to citrate, also present in remarkably high concentrations in 
the prostate (Lynch and Nicholson 1997). Complex formation with the negatively charged 
acid citrate would enable polyamines to penetrate in spermatozoa. Spermine has been 
localized in the middle and top parts of the acrosome and possibly modulates sperm 
fertilization competence and the acrosome reaction (Rubinstein and Breitbart 1994). However, 
spermine present in sperm cells may be also originating from endogenous polyamine 
biosynthesis since ODC has been shown to be involved in spermatogenesis (Hakovirta et al. 
1993). Seminal polyamines may have other functions in regulation of seminal clotting or 
prevention of bacterial growth in the urinary tract (Romijn et al. 1990).
The importance of polyamines in prostatic growth and differentiation has prompted studies 
to evaluate the clinical relevance of the ODC/polyamine system in prostate cancer. The use of 
polyamines as biological markers for malignant behavior and as a modality for chemotherapy 
in prostate cancer are discussed in the following two paragraphs.
POLYAMINE AS BIOMARKERS IN MALIGNANT BEHAVIOR IN PROSTATE CANCER
Polyamines are required for cell proliferation and in tumor cell growth increase of the 
polyamine pools and the regulating enzymes in polyamine biosynthesis was demonstrated 
(Pegg, 1986). Moreover, ODC is now considered as a putative protooncogen since 
transfection as well as inhibition studies show that ODC and polyamines are essential for 
transformation (Auvinen et al. 1992, 1997; Tamori et al. 1995; O’Brien et al. 1997; Shantz et 
al. 1998; Tabib and Bachrach, 1998). Therefore, monitoring polyamines and their metabolic 
enzymes in prostatic tissue may be useful in the diagnosis and prognosis of prostate cancer.
ODC and prostatic tumor growth
Studies on the rat prostate-derived Dunning tumors showed that ODC activity was 
substantially higher in the fast growing sublines (Heston et al. 1982). Our studies in human 
prostatic cancer cell lines further substantiate a role of polyamines in the kinetic behavior of 
prostatic cells. We examined polyamine homeostasis in cultured cells of four human prostatic 
cell lines, e.g. PC-3, TSU-pr1, DU-145 and JCA-1. In this panel, PC-3 and TSU-pr1 cells are 
considered to possess a higher degree of malignancy since they are less differentiated and 
have metastatic ability. Notably, these more malignant cell lines possess higher basal levels of 
polyamines consistent with their high ODC and low SSAT activity (Chapter 8).
Recently, we have determined the expression of ODC and the concentration of polyamines 
in a newly developed panel of xenograft models for human prostatic cancer as described by 
Van Weerden et al. (1996). Immunoblot analysis of ODC protein using the MP16-2 antibody 
(Chapter 3) was performed in tissue specimens of tumors with different doubling time (Td), 
i.e. PC-339 (Td = 20 days), PC-295 (Td = 18 days), PC-82 (Td = 18 days), PC-374 (Td = 10 
days) and PC-346C (Td = 7 days). Results show that the amount of ODC protein is highest in 
the relatively fast growing tumor lines PC-374 and PC-346C (Figure 2). The MP16-2 antibody 
has also been used for immunoblot analysis of tissue specimens of patients with prostate 
cancer. These studies show a significant elevated protein expression of ODC in the cancerous 
tissues as compared to the benign tissues (Mohan et al. 1999). Moreover, studies on the 
expression levels of the ODC gene in a series of 23 human prostate cancers dissected from 
radical prostatectomy specimens revealed significantly higher ODC-mRNA levels in tumors 
compared to the benign tissue (Saverio et al. 2000).
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Figure 1. Apoptosis and proliferation index, and parameters o f polyamine homeostasis in castration-induced involution 
and testosterone-induced regrowth o f the rat prostate. A) The apoptosis index was expressed as the fraction o f in situ nick 
translation (ISNT) positive glandular epithelial cells, ibid the proliferation index as the fraction o f BrdU positive cells. B) 
Activities o f the polyamine biosynthetic enzyme ornithine decarboxylase (ODC) and the polyamine catabolic enzyme 
Spd/Spm N1-acetyltransferases (SSAT) C) Concentrations o f putrescine (Put), spermidine (Spd) and spermine (Spm).
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F ig u re  2 .  Western blotting o f ODC in xenograft models o f human prostatic cancer with different doubling time (Td), i.e. 
PC-339 (Td = 20 days), PC295 (Td = 18 days), PC-82 (Td = 18 days), PC-374 (Td = 10 days) and PC-346 (Td = 7 days). 
Note that the amount o f ODC protein is highest in the relatively fast growing tumor lines PC-374 and PC-346.
Spermine as possible biomarker for malignant behavior in prostate cancer
Polyamine measurements in the newly established panel of human xenograft models 
showed that the xenografts PC-295, PC-310 and PC-374, which resemble the most to the 
original prostatic tissue with respect to differentiation characteristics (androgen-dependency, 
prostatic acid phosphatase, prostate specific antigen and androgen receptor) contained clearly 
more Spm than xenografts from less differentiated cell lines, e.g. PC-324, PC-339 (Figure 3). 
We found a similar correlation between spermine levels and the degree of differentiation in 
biopsies from prostates of patients (Chapter 7). Comparison of polyamine levels in normal, 
benign and malignant tissues of human prostate indicated that normal and benign hyperplastic 
prostatic tissues have a high content of spermine whereas in tumor tissue, especially in 
prostatic carcinoma with metastases spermine levels are reduced.
These observations prompted us to search for a non-destructive tool to evaluate polyamine 
levels in biopsies and in vivo in the prostate (Chapter 7). Such a tool would be of great value 
to determine the predictive value of the polyamine content in prostate cancer as a marker for 
its biological behavior. Proton magnetic resonance spectroscopy (1H MRS) has been applied 
for metabolic studies of prostate cancer in animal models and in humans. This technique is 
particular attractive as it is possible to obtain metabolic information non-invasively from 
multiple, distinct regions of prostatic tissue in situ or from intact biopsy material. In vitro 1H 
NMR on extracts of prostatic tissue or cells gives an immediate overview of numerous 
compounds present in these tissues or cells. In some of these extracts certain signals 
tentatively have been attributed to polyamines (Kurhanewicz et al. 1990). We are now 
definitely able to assign signals in 1H NMR spectra from extracts of the human prostate to 
spermine/spermidine. Moreover, in 2D 1H NMR studies of human prostate biopsy tissue we 
obtained evidence for the presence of large amounts of spermine/spermidine (Chapter 7).
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Figure 3. Polyamine levels in newly developed xenograft models o f human prostate cancer. Note that the 
xenografts PC-295, PC-310 and PC-374, which resemble the most to the original prostatic tissue with respect to 
differentiation characteristics (androgen-dependency, prostatic acid phosphatase, prostate specific antigen and 
androgen receptor) contained clearly more Spm than xenografts from less differentiated cell lines, e.g. PC-324, 
PC-339.
Recently, we explored the applicability of a newly developed NMR technology, i.e. High­
resolution magical angle spinning (HRMAS) to investigate intact “ex vivo" prostatic tissue 
material. These studies show that with HRMAS a far higher sensitivity and resolution can be 
achieved as compared to conventional ex vivo NMR methods. The high sensitivity of HRMAS 
even allows the detection of polyamines and other metabolites in fine needle biopsy material 
in a relative short measuring time enlarging the clinical potential of magnetic resonance 
spectroscopy. Moreover, improved analysis by adding J-resolved NMR becomes feasible in 
routine use since this analysis requires only little time.
Circulating polyamines as markers and tracers for prostatic malignancies
Polyamines or their acetylated forms can also be secreted by cells. Subsequently, these 
circulating polyamines and their acetylated intermediates can be taken up and reused by 
polyamine-demanding cells. Transport of polyamines from one cell to another via body fluids 
is believed to be carrier-mediated by either proteins (e.g. anti-polyamine antibodies, 
lipoproteins) or by cells (peripheral blood cells). Moulinoux et al. showed that more than 95% 
of circulating spermidine and spermine are transported by red blood cells (RBC’s) and that 
RBC polyamine levels correlate with tumor progression in tumor-grafted animals. Results 
from these animal studies and investigations in patients suggest that RBC polyamine levels 
reflect the proliferation status of normal tissues and tumors including prostate carcinomas 
(Cipolla et al. 1994; Moulinoux et al. 1996).
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As demonstrated by these studies, interorgan polyamine transport is realized by means of 
circulating polyamines, which participate in supporting normal and malignant cell 
proliferation. Since neoplastic growth also requires high concentrations of polyamines 
radioactive-labeled polyamines have been used as tracers for imaging and characterization of 
cancers. Clark and Fair (1975) reported that 14C-putrescine, when intravenously injected in 
rats, preferably accumulated in the prostate. In vitro and in vivo uptake of radiolabeled 14C- 
polyamines by rat prostate-derived Dunning tumor lines was investigated by Heston et al. 
(1984, 1986). These studies indicated that both labeled putrescine and spermidine are 
imported in cultured cells while, in tumor-bearing animals, labeled putrescine and cadaverine 
but not spermidine and spermine were taken up by the tumor. Uptake of [14C]-putrescine by 
the rat prostatic tumor was higher than in the dorsolateral prostate. In contrast, in the ventral 
prostate uptake equals the amount taken up by the tumor. Pretreatment with DFMO and 
androgen stimulation enhanced accumulation of [14C]-putrescine in the tumor but not in other 
tissues.
More recently, the potential of labeled putrescine as tracer for cancers has been studied
using Positron Emission Tomography (PET). PET-scan imaging of the Dunning R3327H
prostatic carcinoma demonstrated a high tumor uptake of the labeled polyamine N-(3- 
18 11 [ F]fluoro-propyl)putrescine (Hwang et al. 1989, 1990). Uptake of [ C]-putrescine using
PET-scan imaging has also been examined in brain tumors showing similar results (Hiesiger
et al. 1992). However, PET studies in humans showed that the uptake of [11C]-putrescine in
the prostates of normal controls exceeds uptake in prostates of patients with localized
prostatic cancer (Wang et al. 1994). These results suggest that [11C]-putrescine is not useful to
trace human cancers, at least prostate adenocarcinoma.
Polyamine homeostasis as target for chemotherapy of prostate cancer
Since polyamine are important for prostatic cell growth and function, interference with 
polyamine homeostasis could provide a promising target for chemotherapy of prostatic cancer. 
Polyamine homeostasis can be perturbed by inhibitors of polyamine biosynthesis and by 
polyamine analogs.
Several compounds are able to inhibit the action of enzymes involved in polyamine 
biosynthesis. Their potential as antineoplastic has been investigated and extensively reviewed 
(Marton and Pegg, 1995, Kramer, 1996). Although they can suppress tumor cell growth in 
vitro, so far, they fail to be successful as anti-cancer agents in vivo. Besides lack of specificity 
and potency, also other factors related to polyamine homeostasis might be responsible, such 
as: (a) rapid turnover of the enzymes involved in the polyamine biosynthesis, (b) 
compensatory increase of the non-inhibited polyamine enzymes, (c) compensatory increase of 
polyamine uptake from extracellular sources and (d) compensatory retroconversion of the 
intracellular polyamine pools, since a single inhibitor can not deplete all three polyamine 
pools.
With the synthesis of polyamine analogs some of the problems discussed above have been 
circumvented, i.e. various analogs of polyamines down-regulate polyamine synthesis, up- 
regulate polyamine catabolism and, compared to the biosynthetic inhibitors mentioned before, 
result in a more profound depletion of the natural polyamines. Both polyamine biosynthetic 
inhibitors and polyamine analogs have been evaluated for their antitumor potential against 
prostatic cancer cells (See Figure 4 for the structural formulas of these compounds).
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Figure 4. Structure o f polyamine synthesis inihibitors and polyamine analogs. ODC inhibitors: DFMO, 
a-difluoromethylornithine; MAP, methylacetylenic putrescine. SAMDC inhibitor: CGP-84664, 4- 
amidinoindan-1-one 2 ’-amidinohydrazone. Polyamine analogs: AZP, monoaziridinylputrescine; BE-3-3-3, 
bisethylnorspermine (BENSpm) also known as N1, N11-diethylnorspermine (DENSpm); BE-4-4-4-4, 1,19-di- 
(ethyl-amino)-5,10,15-triazononadecane; BE-3-7-3, bis(ethylamino)-4,12-diazapentadecane. BIS, 1,12-diazi- 
ridinyl-4,9-diazadodecane; CPE-3-3-3, N1-ethyl-N11-((cyclo-propyl)-methyl)-4,8 diazaundecane; CHE-3-3-3, 
N1 -ethyl-N11-((cycloheptyl)methyl)-4,8-diazaundecane.
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Polyamine biosynthesis inhibitors
Difluoromethylornithine (DFMO), the most widely studied inhibitor of ODC, normally 
causes a depletion of putrescine and spermidine pools but has only minor or late effects on 
spermine levels. For example, treatment of cultured PC-3 cells with DFMO led to a depletion 
of putrescine within 24 hours, a 80-90 % reduction in spermidine levels after 4 days while 
spermine remained constant or even showed an initial rise (Romijn et al. 1991). We observed 
a similar change in spermine levels in rat prostate during the first days after castration (Figure 
1C). A temporary raise in spermine levels upon blocking of polyamine biosynthesis can be 
explained by the intracellular accumulation of dcSAM promoting the conversion of the 
remaining putrescine and spermidine into spermine. Low-dose DFMO treatment of patients 
scheduled for surgery to treat prostatic hyperplasia or neoplasia showed only a reduction of 
prostatic putrescine pools (Messing et al. 1999). In contrast, in a comparable group of patients 
Simoneau et al. (unpublished work) reported that DFMO treatment caused depletion of all 
polyamine pools, including spermine (Meyskens et al. 1999).
DFMO treatment has striking inhibitory effects on cell growth of cultured prostatic cancer 
cells (Heston et al. 1982; Romijn et al. 1992). DFMO-inhibited growth of PC-3, PC-82 and 
androgen-stimulated LNCaP cells could be reversed by exogenously added polyamines or 
their acetylated derivates (Romijn et al. 1991). Further experiments showed that the 
intracellular event leading to this polyamine-mediated restoration of growth was the ultimately 
recompensation of intracellular spermidine levels. These results suggest that spermidine may 
be the key polyamine in the regulation of cell growth of prostatic (cancer) cells. 
Unfortunately, DFMO failed to induce a dramatic effect on the growth of transplantable rat 
and human prostatic tumors probably due to compensatory uptake of polyamines from 
extracellular sources ( Heston et al. 1982; Dunzendorfer et al. 1984).
Combination treatment with methylglyoxal-bis-guanylhydrazone (MGBG), a competitive 
inhibitor of SAMDC, increased the in vivo antitumor effects of DFMO in xenografts derived 
from the androgen-independent Dunning R-3327G subline (Her and Kleinert, 1984) and 
xenografts from the human prostatic cancer cell lines PC 82 and PC93 (Romijn et al. 1984). 
However, this combination therapy proved to be disappointing in clinical trials of androgen 
refractory prostatic cancer (Hech, unpublished results).
In spite of the limited success so far, future studies on DFMO combined with other forms 
of therapy might still point out the effectiveness of DFMO as a therapeutic agent. 
Furthermore, the growing awareness that ODC plays an important role in carcinogenesis has 
increased the interest in the development of DFMO as a possible chemoprevention agent 
(Meyskens et al. 1999).
The effects of methylacetylenic putrescine (MAP), another ODC-inhibitor, have been 
studied in PC-3 cells and some other non-prostatic cancer cell lines (Palyi et al, 1999). In all 
cell lines tested, including PC-3 prostatic carcinoma cells, MAP caused inhibition of growth, 
the slowest growing cells being the most sensitive. The mechanism of cell death occurring 
was found to be a rare form of programmed cell death, called Clarke III type non-apoptotic 
programmed cell death (Clarke, 1990). In breast cancer cell lines putrescine and spermidine 
levels decreased after treatment with MAP, however, spermine levels increased markedly. The 
effect of MAP on polyamine levels in the PC-3 cell line was not tested in this study.
The recently developed SAMDC inhibitor 4-amidinoindan-1-one 2’-amidinohydrazone 
CGP-48664 has reported to be an effective antitumor agent in several tumor models 
(Regenass et al. 1994). PC-3, LNCaP and DU-145 cells were similarly sensitive towards 
CGP-48664 with IC50-values ranging from 1-5 ^M. The effects of CGP-48664 on polyamine
98
Chapter 6
metabolism were compared under conditions of 50% growth inhibition. SAMDC-activity was 
reduced by ~ 50%, while ODC-activity increased 3-fold. Due to increased ODC-activity, 
putrescine pools increased substantially, spermine and spermidine pools decreased by at least 
50%. The authors suggested that growth inhibition was unrelated to the differentiation state or 
the androgen-responsiveness, because of the similar sensitivity of all three cell lines.
Other agents, which can affect the polyamine formation in prostatic carcinoma cells in vitro 
have been described (Pinto et al. 1997). Naturally occurring garlic derivatives and related s- 
cysteinyl compounds have an inhibitory effect on the growth of LNCaP cells. Growth 
inhibition was most effective with compounds containing a disulfide or an active diallyl 
moiety. Three days after treatment with S-allylmercaptocysteine the levels of putrescine and 
spermine decreased, while the spermidine levels increased. Growth inhibition and changes in 
the polyamine levels suggest that this agent inhibits ODC, probably by reacting directly with 
its nucleophilic thiol moiety.
Tea polyphenols show chemopreventive activity in various animal tumor models and in 
some human epidemiological studies (Katiyar and Mukhtar, 1996). Gupta et al. (1999) found 
that green tea polyphenols inhibited ODC activity in testosterone-induced growth of both 
cultured LNCaP cells and rat ventral prostate. The authors hypothesized that testosterone­
mediated induction of ODC is important in prostatic carcinogenesis and that ODC can be used 
as target for chemoprevention of prostate cancer.
Polyamine analogs
Initially, polyamine analogs were developed to investigate the regulatory mechanisms that 
control polyamine homeostasis. Subsequently, research was done to find polyamine analogs 
that down-regulate the biosynthetic enzymes, deplete intracellular polyamine pools and inhibit 
cell growth by failing to substitute for the depleted natural polyamines in functions required 
for proliferation. In vitro as well as in vivo studies showed that polyamine analogs have 
significant antitumor activity in several human solid tumor models. The antitumor effects of 
polyamine analogs on prostate carcinoma cells in vitro as well as in vivo are summarized in 
Table 1 and Table 2, respectively.
As discussed earlier, systemic putrescine is preferentially taken up by the prostate and this 
uptake can be enhanced by DFMO. Putrescine analogs could therefore have chemotherapeutic 
potential, especially in combination with DFMO. Monoaziridinylputrescine (AZP), one of the 
first analogs tested, inhibited growth of PC-3 human prostatic carcinoma cells while co­
treatment with DFMO increased the growth inhibitory effect (Heston et al. 1987). Since 
putrescine itself had no effect on growth the inhibitory effect of AZP was ascribed to the 
possible alkylating activity of AZP. AZP may act like a lysomotropic amine shown to inhibit 
intralysosomal processing of growth factors, resulting in the prevention of the growth factor­
mediated induction of DNA-synthesis (Widelitz et al. 1984). Another possibility for the mode 
of action of AZP is its interference in polyamine homeostasis. However, the effect of AZP on 
polyamine pools was not investigated by Heston et al.
Symmetrically substituted bis(ethyl) analogs of spermine, and to a lesser extent of 
spermidine appear to be highly potent in cell growth inhibition (see for review Kramer, 1996). 
Currently, some of these analogs, e.g. N 1, N 11-diethylnorspermine (BE-3-3-3, also know as 
BENSpm or DENSpm) are evaluated in clinical trials. BE-3-3-3 has been tested in various rat 
and human prostatic carcinoma cell lines (McCloskey et al. 1996a, 2000; Jeffers et al. 1997; 
Mi et al. 1998; Zagaja et al. 1998; Chapter 8). Results of these studies are not in all detail
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identical probably due to the different analytical methods and experimental conditions used in 
the studies. Nevertheless, it was concluded that BE-3-3-3 has differential effects on cell 
growth and polyamine homeostasis in different prostatic carcinoma cells, i.e. the androgen­
independent DU-145 cells were the most sensitive, the androgen-dependent whereas well- 
differentiated LNCaP cells were relatively insensitive. Treatment with BE-3-3-3 evoked 
intracellular accumulation of the analog and various regulatory responses, e.g. down- 
regulation of the polyamine biosynthesis, the induction of the catabolic enzyme 
spermidine/spermine N 1-acetyltransferase (SSAT), and the depletion or decrease of the natural 
polyamines. Mostly the degree of cell growth inhibition correlated with SSAT induction. Cell 
growth inhibition and the intracellular accumulation of the analog were not correlated. In 
contrast to other tumor models, BE-3-3-3 did not down-regulate polyamine uptake implying 
that polyamine homeostasis is differently regulated in prostatic (cancer) cells (Mi et al. 1998). 
We investigated the in vivo antitumor potential of BE-3-3-3 in two groups of nude mice 
bearing small or more developed xenografts of the DU-145 cell line (Chapter 8). Notably, BE- 
3-3-3 clearly prevented tumor growth in both size groups indicating that the tumor starting 
size did not affect the ultimate response.
Compared to BE-3-3-3, the polyamine analog 1,19-di-(ethyl-amino)-5,10,15-triazonona- 
decane (BE-4-4-4-4) was dramatically more effective (IC50 values 4 to 86 times higher) in 
inhibiting the growth of cultured DU-145, Tsu-Pr-1 and DuPro-1 cells. BE-4-4-4-4 had a high 
antitumor activity in DuPro-1 and DU-145 xenografts but not in PC-3 tumor xenografts 
(Zagaja et al. 1998). In a study by Jeffers et al. (1997) another analog, i.e. bis(ethylamino)- 
4,12-diazapentadecane (BE-3-7-3) appeared equally effective as BE-3-3-3 and BE-4-4-4-4 on 
the in vitro growth of DU-145, LNCaP and PC-3 cells although PC-3 cells required 10 to 100 
times more of each analog to inhibit cell growth to a similar extent. Polyamine depletion 
occurred in a dose-dependent manner whereas the levels of intracellular BE-4-4-4-4 after 
treatment varied between the cell line. In DU-145 cells levels were higher than in LNCaP and 
PC-3-cells), and remained high throughout the experiment.
BE-4-4-4-4 was also tested in vivo, using nude mice bearing xenograft tumors derived from 
DU-145 cells. In all tumors treated the analog BE-4-4-4-4 was taken up and inhibited tumor 
growth. Levels of spermidine and spermine were found to decrease whereas levels of 
putrescine were not affected. We observed similar effects of BE-3-3-3 on polyamine levels in 
DU-145 xenografts (Chapter 8). A possible explanation for the lack of polyamine depletion in 
vivo is the uptake of polyamines from extracellular sources, present in an in vivo system (See 
Figure 3, chapter 1), in particular via polyamine uptake from the gastrointestinal tract. These 
results support the idea that polyamine analogs act on cell growth not merely by depleting the 
natural polyamines but by exerting their own dysfunctional effects on cell growth as well.
The effects of non-symmetrically substituted alkylated analogs, N 1-ethyl-N11-((cyclo- 
propyl)methyl)-4,8 diazaundecane (CPE-3-3-3) and N 1-ethyl-N11-((cycloheptyl)methyl)-4,8- 
diazaundecane (CHE-3-3-3) were examined in LNCaP, DU-145 and PC-3 cells (McCloskey 
et al, 2000). Both analogs inhibited the growth of these cells, DU-145-cells being the most 
sensitive. Both analogs accumulated to high levels in each of the cell lines. However, CPE-3­
3-3 but not CHE-3-3-3 caused a significant decrease in intracellular spermidine and spermine 
levels. The activity of SSAT was strongly induced by CPE-3-3-3, but not by CHE-3-3-3. 
ODC- and SAMDC-activity were not affected by both analogs.
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Table 1. In vitro effects o f  polyamine analogs on human prostatic cancer cell lines
DU-145 PC-3 LNCaP JCA-1 TSU-PR1 DuPro-1 Reference
Analog
IC50-value
(MM) AZP - 18 - - - - Heston et al. 1987
BE-3-3-3 0.01-0.05 0.5-10 0.1 - - - Jeffers et al. 1997
3.2 - - - 1.6 6 Zagaja et al. 1998
1 28 >1,000 - - - Mi et al. 1998
0.3-1 1-3 1-3 - - - McCloskey et al. 2000
3 65 - 21 62 - Schipper et al. 2000
BE-4-4-4-4 0.01-0.05 0.5-10 0.1 - - - Jeffers et al. 1997
0.7 - - - 0.4 0.07 Zagaja et al. 1998
BE-3-7-3 0.01-0.05 0.5-10 0.1 - - - Jeffers et al. 1997
BIS 1.2 0.7 - - - - Eiseman et al. 1998
CPE-3-3-3 0.3-1 1-3 1-3 - - - McCloskey et al. 2000
CHE-3-3-3 0.3-1 1-3 3 - - - McCloskey et al. 2000
Apoptosis
BE-3-3-3 no - - - no no Zagaja et al. 1998
no no no - - - Mi et al. 1998
no no + - - - McCloskey et al. 2000
no no - no no - Schipper et al. 2000
BE-4-4-4-4 no - - - no no Zagaja et al. 1998
CPE-3-3-3 + + + - - - McCloskey et al. 2000
CHE-3-3-3 + + + - - - McCloskey et al. 2000
BIS + + - - - - Eiseman et al. 1998
Polyamine
pools BE-3-3-3 4 4 4 - - - Mi et al. 1998
Î 4 4 - - - McCloskey et al. 2000
4 4 - 4 4 - Schipper et al. 2000
BE-4-4-4-4 4 4 4 - - - Jeffers et al. 1997
BE-3-7-3 4 4 4 - - - Jeffers et al. 1997
CPE-3-3-3 4 4 4 - - - McCloskey et al. 2000
CHE-3-3-3 nsa 4 nsa - - - McCloskey et al. 2000
BE-3-3-3 4 4 4 4 Schipper et al. 2000
ODC/
SAMDC
activity BE-3-3-3 4 4 4 - - - Mi et al. 1998
nsa nsa nsa - - - McCloskey et al. 2000
4 4 - 4 4 - Schipper et al. 2000
CPE-3-3-3 nsa nsa nsa - - - McCloskey et al. 2000
CHE-3-3-3 nsa nsa nsa - - - McCloskey et al. 2000
SSAT
activity BE-3-3-3 Î Î Î - - - Mi et al. 1998
Î Î Î - - - McCloskey et al. 2000
Î Î - Î Î - Schipper et al. 2000
BE-4-4-4-4 nsa - - - nsa nsa Zagaja et al. 1998
CPE-3-3-3 Î Î Î - - - McCloskey et al. 2000
CHE-3-3-3 nsa. nsa nsa - - - McCloskey et al. 2000
IC5 0 , , drug concentrations which inhibited growth 50 % o f control; -, data not available; + , induced; no, not observed; 
nsa, not significantly affected; f  , increased, 4 , decreased
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Table 2. Effects of polyamine analogs on prostatic cancer tumor xenografts
DU-145 PC-3 DuPro-1
Effect on growth
Polyamine pools
ODC activity 
SSAT activity
Putrescine
Spermidine
Spermine
Analog
BE-3-3-3
BE-4-4-4-4
BIS
BE-3-3-3
BE-4-4-4-4
BE-3-3-3
BE-4-4-4-4
BE-3-3-3
BE-4-4-4-4
BE-3-3-3
BE-3-3-3
inhibition a 
inhibition 
inhibition c
b
unchanged b
decease a 
decrease b
b
decrease a 
decrease
decrease a 
increase a
inhibition c
inhibition c
a
a-c. Data from a, Schipper et al. 2000; b) Jeffers et al. 1997; c) Zagaja et al. 1998
Recently, a novel spermine analog, 1,12-diaziridinyl-4,9-diazadodecane (BIS), has been 
tested on in vitro and in vivo growth of DU-145- and PC-3 cells (Eiseman et al. 1998). BIS 
exhibited a dose-dependent cytotoxic effect against prostatic cancer cells in vitro. It was 
shown that cytotoxicity was accomplished via an apoptotic pathway. Furthermore, combined 
treatment of BIS and radiotherapy markedly increased the number of apoptotic cells measured. 
In vivo it was also shown that BIS had an inhibitory effect on the growth of tumor xenografts. 
So tumor-targeted apoptosis by BIS results in therapeutic efficacy and enhanced 
radiosensitivity of human prostate cancer.
Recently, we tested newly developed compounds, which are based on BE-4-4-4-4 but are 
restricted in their chain flexibility. So far we studied the activity of some of these compounds 
in our panel of prostatic cancer cell lines in vitro (DU-145, PC-3, LNCaP and PC-346C). All 
compounds had considerable cytotoxicity against all cell lines tested. The hormone- 
unresponsive DU-145 was the most sensitive cell line, whereas the hormone-responsive cell 
lines LNCaP and PC-346C were less sensitive. The sensitivity of PC-346C cells for the 
polyamine analogs increased in the absence of androgens in the culture medium. These 
preliminary results suggest that these analogs might have chemotherapeutic potential in 
prostate cancer in case hormone-therapy has failed. We are currently testing two of these 
conformationally restricted polyamine analogs that have negligible toxicity in rodents, in vivo 
on xenografts of human prostate cancer with varying degrees of differentiation and 
malignancy.
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Possible action mechanism ofpo/yamine analogs
Until now, the exact mode of action of polyamine analogs remains unclear, but inhibition of 
cell respiration and interaction with chromatin, probably resulting in dysfunctional changes, 
have been suggested as possible mechanisms. The huge induction of SSAT, which is directly 
or indirectly related to the sensitivity of the cells for the drugs, can have potential 
chemotherapeutic benefits. Several working mechanisms by which SSAT induction inhibits 
cell growth have been suggested, e.g. increased excretion and/or catabolism could rapidly 
deplete the intracellular polyamine pools, and acetylation of the polyamines could reduce their 
positive charges and therefore reduce their ability to interact with negatively charged 
macromolecules, such as DNA. However, the relationship between induction of SSAT and 
inhibition of cell growth is not yet fully understood since BE-4-4-4-4 and CHE-3-3-3, in 
contrast to BE-3-3-3, exert their growth inhibitory effects without apparent induction of SSAT 
activity (Nolan et al. 1994, McCloskey et al. 2000).
Some research groups have investigated the mechanism of cell death induced by polyamine
analogs and found that cytotoxicity of some of these analogs is actually based on their ability
1 12to induce apoptotic cell death. In human breast or lung cancer cells, N ,N -bis(ethyl)spermine 
(BE-3-4-3) and CPE-3-3-3 led to induction of apoptosis as revealed by DNA fragmentation 
(McCloskey et al. 1995, 1996b). CHE-3-3-3 induced apoptosis in NCI H157 cells, as 
observed by cytochrome-c release, loss of mitochondrial membrane potential, caspase-3 
activation, PARP-cleavage, G2M arrest, and DNA and nuclear fragmentation. As studied by 
quantitation of DNA fragmentation, both CPE-3-3-3 and CHE-3-3-3 were found to be 
effective inducers of apoptosis in prostatic cancer cells, although the two varied in the ability 
to decrease polyamine levels (McCloskey et al. 2000). BIS induced apoptosis, as measured by 
TUNEL, and enhanced radiosensitivity of the human prostatic cancer cell lines PC-3 and DU- 
145 (Eiseman et al. 1998.). Similar results were obtained in PC-3 and DU-145 xenografts in 
SCID.
BE-4-4-4-4 and BE-3-3-3 show cytoxicity without apparent induction of apoptosis 
(McCloskey et al. 1996a, 2000; Jeffers et al. 1997; Mi et al. 1998; Zagaja et al. 1998; Chapter
8) except in LNCap cells where BE-3-3-3 was found to induce apoptotic cell death after a 
long treatment period (McCloskey et al, 2000). Using an in vitro cell system, we examined 
whether polyamine metabolism and intracellular levels of polyamines were changed during 
cell growth and calcium-ionophore induced apoptosis of prostatic cancer cells (Schipper et al. 
1995; Chapter 11). In addition, we investigated the effect of DFMO and BE-3-3-3 on cell 
growth or apoptosis of these cells. Polyamine biosynthesis and polyamine levels were 
increased during cell growth of AT-3 cancer cells. DFMO en BE-3-3-3 had cytostatic effects 
on cell growth at millimolar and micromolar concentrations, respectively. MDL72527, an 
inhibitor of the retroconversion of polyamines, had no effect on cell growth in millimolar 
concentrations. In AT-3 cells treated with ionomycin a pronounced increase of apoptotic cells 
was observed. ODC activity was augmented under these conditions. Putrescine levels 
increased whilst spermidine and spermine levels decreased. Subsequently, cells were treated 
with DFMO, BE-3-3-3 or MDL-72527 in combination with ionomycin to induce apoptosis. 
These studies showed that if  putrescine biosynthesis is blocked (by DFMO) and/or 
polyamines are depleted (by BE-3-3-3) cells cease to proliferate but also fail to undergo 
apoptosis after treatment with ionomycin. An explanation for these findings might be the fact 
that a cell needs to traverse through the cell cycle to undergo apoptosis. Since polyamine 
depletion blocks cell cycle progression also apoptosis is inhibited. However, studies of Isaacs 
(1991) showed that prostatic cancer cells do not have to proliferate to undergo apoptosis.
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Therefore, ODC activity and/or polyamines themselves might be involved in the induction 
and/or progression of apoptosis in prostatic cancer cells
The observed apoptosis-inducing effects of some polyamine analogs are in agreement with 
the merging evidence that polyamines are actively involved in apoptotic cell death (Chapter
9). Changes in polyamine homeostasis have been reported during cell death of nerve cells, in 
programmed cell death of embryonic cells and in various in vitro models of apoptosis. 
Furthermore, interference with polyamine homeostasis modulate processes of cell death in a 
cell-type specific way. Much ambiguity exist in the working mechanisms by which polyamine 
mediate apoptosis since they have been shown to act as promoting, modulating or protective 
agents in apoptosis..
Since many of the structural analogs of spermine exert cytotoxic effects in vitro as well in 
vivo, we investigated whether spermine per se can influence cell growth of rat and human 
prostatic cancer cells. The effects of exogeneously added spermine, as compared to 
spermidine and putrescine, were studied in cultured cells of the rat prostatic cancer cell line 
AT-3 as well as the human prostatic cancer cell lines TSUpr1, DU145 and JCA. Results 
indicate that spermine as well as spermidine had differential effects on cell growth. All cell 
lines displayed a greater sensitivity towards spermine-mediated growth inhibition. Putrescine 
was not inhibitory at all, in most cases even little stimulatory to cell growth. Exogenously 
addition of spermidine led to the accumulation of spermidine in the cell, and induced SSAT 
activity enabling the conversion of spermidine via N 1-acetylated spermidine to putrescine. 
Interestingly, in the more malignant cell lines AT-3 and TSUpr1, SSAT was less inducible by 
Spd. Surprisingly, in all tested cell lines, increased spermine levels did not markedly induce 
SSAT activity and subsequent production of acetylated spermine. Spermine may exert its 
inhibitory effects on cell growth by down-regulating the activity of the polyamine biosynthetic 
enzyme ornithine decarboxylase (ODC). Measurements showed that ODC activity was less 
than 2% of control under these conditions.
These observations support the data, recently described by Smith et al. (1995) who found 
that spermine inhibited the growth of prostatic carcinoma in vitro as well as in vivo. Hence, 
the comparatively slow growth of prostatic carcinoma at its primary site, the prostatic gland, 
may be attributed to the high spermine levels (10-12 mM) present within the prostatic 
microenvironment. Escape from this regulation may emerge from altered inducibility of 
enzymes regulating polyamine biosynthesis in tumor cells and/or an acquired insensitivity 
towards spermine. Recent evidence for this opposition has been reported in a study of Koike 
et al. (1999) showing a differential sensitivity of rat prostatic cancer cell lines towards 
spermine. Exposure to spermine induced cell cycle arrest and apoptosis in the poorly 
metastatic AT2.1 cell line but not in the highly metastatic AT3.1. A possible explanation for 
the resistance to spermine may be found in the different induction of ODC-antizyme in 
spermine-sensitive and spermine-resistant cells. ODC antizyme is a unique regulatory protein 
that is induced by polyamine-mediated translational frame-shifting and that promotes 
proteolytic degradation of ODC (for a review see Hayashi et al. 1996). In the spermine- 
insensitive cells, ODC-antizyme levels were not up-regulated, hereby failing to inhibit and 
degrade ODC. Because antizyme levels were reduced in other carcinomas as well, antizyme 
may regulate tumor growth in vivo (Koike et al. 1999).
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Concluding remarks
The studies reviewed here clearly show that polyamines are of crucial importance for the 
regulation of cell proliferation and differentiation of prostatic glandulare epihelial cells. Our 
preliminary studies as well as data from others show that alterations in cell kinetic behavior of 
prostatic (cancer) cells are accompagnied with changes of polyamine levels and/or their 
metabolic enzymes. Prostatic cancer cell proliferation requires an increased rate of polyamine 
biosynthesis, in particular increased levels of the polyamines putrescine and spermidine. On 
the contrary, spermine seems to influence the functional, secretory state of the prostatic 
epithelium. This is in accordance with previous suggestions that a decrease in spermidine 
level and/or an increase in spermine usually indicates a shift of cells from a proliferation state 
into a state with a higher degree of differentiation. The prostate has a large glandular epithelial 
cell volume with large lumina where secretory products, like spermine and citrate, are 
concentrated. Consequently, changes in the cell organization resulting in decreased luminal 
volumes reduce the amount of secreted compounds. In line with this, normal and benign 
hyperplastic prostatic tissues are characterized by high levels of spermine while in human 
prostatic carcinoma spermine levels are low. Hence, a strong decrease in the concentration of 
spermine in the prostate could indicate a conversion of prostatic cells from a benign into a 
malignant phenotype. Based on these considerations, it seems appropriate to further explore 
the potential of polyamines as biomarkers for malignant behavior in prostate cancer. 
Preliminary data show that magnetic resonance spectroscopy provides a powerful, non­
invasive and spatially resolved method for the in vivo detection of polyamines and other 
metabolites in prostatic tissue. We anticipate that magnetic resonance spectroscopy techniques 
will mature into valuable diagnostic tools in prostatic cancer and that the high resolution 
magical angle spinning methodology will be useful to monitor polyamines in ex vivo tissue 
specimens.
Interference with polyamine homeostasis as a tool to inhibit tumor growth has been studied 
with various polyamine biosynthesis inhibitors and polyamine analogs. Inhibition of 
polyamine biosynthesis proved to be mostly cytostatic, since growth inhibition could be 
reversed by inhibitor withdrawal or polyamine repletion. These reversible cytostatic effects 
explain the limited success of these compounds in tumor growth inhibition in vivo attributed 
to the presence of exogenous polyamines allowing tumor cells to proliferate at a normal rate 
even if endogenous de novo production of polyamines is blocked. Most likely, specific 
inhibitors that will block the entry of exogenous polyamines into cells may provide better 
possibilities for therapeutic intervention in the polyamine metabolism. Manipulation of 
polyamine body pools, for instance by dietary means, may have additional value in the 
chemotherapy and chemoprevention of prostate cancer.
Compared to polyamine biosynthesis inhibitors, polyamine analogs may have even more 
clinical value, since these compounds can be cytotoxic. As shown by our group and others it is 
evident that polyamine analogs are effective growth inhibitors of different phenotypes of 
human prostatic carcinoma cells and, furthermore, are able to inhibit the in vivo growth of 
small as well more developed prostatic tumors. Currently, some of the analogs are under 
phase I or II clinical investigation with promising results.
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Detection of Spermine by MRS
ABSTRACT
To investigate whether polyamines may be valuable diagnostic and prognostic markers in 
prostate cancer, the presence of polyamines was studied in various human prostatic tissues 
using both proton magnetic resonance (MR) spectroscopy and high-pressure liquid 
chromatography (HPLC). The HPLC results showed that normal and benign hyperplastic 
prostatic tissues were characterized by a high content of spermine. Spermine levels were 
reduced in tumor tissue, especially in prostatic carcinoma with metastases, and in xenografts 
of human prostatic carcinoma cells. These preliminary results indicate that spermine may be 
used as a biomarker for malignant behavior. The MR spectroscopy study showed that it is 
possible to detect spermine resonances in prostatic biopsy material by one-dimensional and 
2D J-resolved MR spectroscopy at high field (600 MHz). Localized one-dimensional in vitro 
MR spectra obtained at the clinical field strength of 1.5 T showed spermine signals in the 
region between 3.0 and 3.3 ppm. In in vivo MR spectra of the human prostate, however, these 
signals were obscured by resonances of choline (3.2 ppm) and creatine (3.0 ppm).
Keywords: spermine / polyamine / magnetic resonance spectroscopy / prostate / cancer
I ntroduction
Although prostate cancer is one of the most frequently diagnosed malignancies in males 
(Parker et al. 1997), the number of patients developing large invasive tumors with metastases 
is comparatively low (Stamey 1993). The natural polyamines putrescine (Put), spermidine 
(Spd) and spermine (Spm) play an important role in the regulation of cell proliferation and 
differentiation (Jänne et al. 1978; Heby 1981). With respect to the prostate, the high 
concentration of spermine present in prostatic tissue (10-20 mM) may be responsible for the 
relatively slow growth of cancer cells in the prostate (Smith et al. 1995). Prostate cancer cell 
proliferation requires an increased rate of polyamine biosynthesis and increased levels of the 
two other polyamines Put and Spd (Romijn 1991). This is in accordance with previous 
suggestions that a decrease in Spd level and/or an increase in Spm level usually indicates a 
shift of cells from a proliferation state into a state with a higher degree of differentiation 
(Jänne et al. 1978). Furthermore, spermine seems to be a marker for the functional secretory 
state of prostatic epithelium (Takyi et al. 1977). The prostate is a secretory organ with a large 
glandular and ductal volume where secretary products, like spermine and citrate, are 
concentrated. Morphologic changes in cell organization which result in decreased ductal 
volume consequently reduce the detection of secreted compounds. Hence, a dramatic decrease 
of the prostatic spermine content could indicate changes in cellular metabolism and/or 
changes in ductal morphology as a result of a conversion of prostatic tissue from a benign to a 
malignant phenotype. As disseminated prostatic carcinoma is hard to cure completely, much 
emphasis is put on early diagnosis. Prostate cancer can be identified by the detection of 
decreased levels of citrate using in vivo proton magnetic resonance spectroscopy (MRS) 
(Kurhanewicz et al. 1995; Heerschap et al. 1997a; Costello et al. 1999). Unfortunately, 
markers to detect patients with a high risk for progressive growth of prostatic cancer are 
lacking. In vivo measurement of prostatic polyamine levels could provide a valuable new tool 
in early diagnosis and in predicting the biological behavior of prostatic cancer.
In the present study, we determined the polyamine content of various human prostatic 
tissues by high-pressure liquid chromatography (HPLC). In addition, we explored the 
possibilities of using MRS for the detection of prostatic polyamines, especially spermine, in a 
non-invasive way.
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Materials and M ethods
Prostatic tissue specimens were obtained from patients undergoing radical cystoprostatectomy 
(n=2) radical prostatectomy (n=9) and transurethral resection of the prostate (n=3). Three 
prostatectomized patients had disseminated prostate cancer. Tissue samples were harvested 
using a 5-mm skin biopsy punch, snap frozen in liquid nitrogen and stored at -80°C until 
further use. One tissue specimen was immediately subjected to MR spectroscopy before 
freezing and storage. Tissue specimens of xenografts derived from three human prostate 
carcinoma cell lines, i.e. LNCaP (Horoszewicz et al. 1983), DU-145 (Stone et al. 1978), and 
PC-3 (Kaighn et al. 1979) were also included in the study. Concentrations of Put, Spd and 
Spm were measured by HPLC using a method modified from Kirschbaum et al. (1994). In 
short: Tissue homogenates were deproteinized with sulfosalicylic acid (60% V/V in water). 
After centrifugation supernatant was collected and neutralized with 6 M NaOH. After 
derivatization with n-9-fluorenylmethoxycarbonyl succinimide in borate buffer, metabolites 
were separated by reversed phase HPLC (MicroSpher 3 C18, 100x4.6 mm I.D., particle size 3 
^m, Varian Chrompack Benelux, Bergen op zoom, The Netherlands). The mobile phase 
consisted of a gradient from 0 to 30 min starting with buffer A (50 % 0,1 M NaAc and 50% 
acetonitrile) and changing to buffer B (100% acetonitrile). Eluting analysis was performed 
with a Waters 470 fluorescence detector at an excitation and emission wavelength of 265 nm 
and 315 nm, respectively. Experiments were performed twice in duplo. Polyamine 
concentrations are expressed as nmol per mg protein and presented as means ± standard 
deviation. Comparison of polyamine levels between normal prostate and other prostatic 
tissues were statistically analyzed using Dunnett's Multiple Comparison post-test after one 
way-ANOVA.
High-resolution proton MR experiments in one and two dimensions were performed at 
25 °C on a Bruker AMX 600 spectrometer. Measurements were carried out on five samples 
with predominantly healthy biopsy material of the human prostate and on solutions mimicking 
prostatic fluid. The biopsy material was put into the MR tube without being crushed and it 
was covered with phosphate buffered saline (PBS), pH = 7.2, with 10% D2O and a small 
amount of sodium 3-trimethylsilyl-(2,2,3,3- H4) propionate (TSP) for referencing purposes. 
All samples with biopsy material were studied by one-dimensional MR and of three samples a 
2D J-resolved MR spectrum was also recorded. The solutions mimicking prostatic fluid 
contained 90 mM citrate, 18 mM spermine, 61 mM KCl, 18 mM CaCl2, 15 mM MgCl2, and 9 
mM ZnCl2 (pH ~ 7.0) (Kavanagh 1985). In the sample used for a 2D J-resolved experiment, 9 
mM choline and 12 mM creatine were also present. All solutions contained 10% D2O, and a 
small amount of TSP. Acquisition parameters of one-dimensional pulse-acquire experiments 
comprised a spectral width of 6667 Hz, a nominal flip angle of 50-60°, 2 dummy scans, and 
16 to 128 scans of 32K data points. Water suppression was performed by frequency-selective 
irradiation during the relaxation delay of 6 s. Two-dimensional (2D) J-resolved MR 
experiments (Aue et al. 1976a,b) were performed with a spectral width of 6667 Hz in the F2- 
dimension, and a spectral width of 100 Hz in the F 1-dimension, 2 dummy scans, 12 to 16 
scans and 64 t1-increments of 4K data points. The water resonance was suppressed by 
frequency-selective irradiation during the relaxation delay of 2 s. One-dimensional high­
resolution proton MR data were processed using the Bruker WIN-NMR software and 2D J- 
resolved MR data were processed using NMRI software (New Methods Research, Inc., 
Syracuse, NY).
It was also tested whether spermine could be detected at the clinical field strength of 1.5 T 
using localized MR spectroscopy. In vivo and in vitro MR experiments were carried out on a
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Siemens Magnetom SP or Vision spectrometer. Measurements were performed in vitro on a 
phantom containing a solution with 90 mM citrate, 18 mM spermine, 61 mM KCl, 18 mM 
CaCl2, 15 mM MgCl2, and 9 mM ZnCl2 (pH ~ 7.0) or a solution in which 9 mM choline and 
12 mM creatine were also present. In vivo measurements were performed on the human 
prostate. In vitro proton MR spectra of the two solutions were obtained by single-voxel 
spectroscopy with a CP head coil both for excitation and signal reception. A volume of 24.4 
cm3 (29 x 29 x 29 mm) was selected using a PRESS localization scheme [90°- t  - 180°- ^T E  - 
180°- ( ^ T E - t ) - Acq] (Ordidge et al. 1985; Bottemley et al. 1987) with a delay t  of 11 ms and 
various echo times (TE). After four dummy scans, 64 scans of 1024 data points were acquired 
with a spectral width of 1000 Hz and a repetition time (TR) of 1.5 s. In vivo proton MR 
spectra of the prostate were obtained from spectroscopic imaging (SI) data sets that were 
acquired using the body radio-frequency coil for excitation and a disposable endorectal coil 
(Medrad, Pittsburgh, PA) for signal reception (see Heerschap et al. 1997a,b). A PRESS 
localization scheme (t  = 11 ms and TE = 120 ms) was used for pre-selection of an axial slab 
through the prostate. The selected volume was generally 10 mm thick, 40 mm in the left-right 
and 30 mm in the anterior-posterior direction. TR was 1.2 s and three acquisitions were made 
for each of the 16 x 16 phase encoding steps in the two directions within the field of view of 
144 mm. For the acquisition of both in vitro and in vivo proton MRS metabolite spectra, 
chemical shift selective (CHESS) water suppression (Haase et al. 1985) was used. In addition, 
reference spectra without water suppression were acquired for eddy-current correction 
according to Klose (1990). Data were processed using the Siemens spectroscopy post­
processing software LUISE.
100-,
NP BPH PCa PCa Met PCa Xen
Prostatic tissue
Figure 1. Average polyamine concentrations (nmol/mg protein) with standard deviations in various prostatic 
tissues as determined by HPLC. *p<0.05, **p<0.01 compared to control (NP). NP = normal prostate; BPH = 
benign prostatic hyperplasia; PCa = prostate cancer; PCa Met = prostate cancer with metastases; PCa Xen = 
human xenograft models o f prostate carcinoma.
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As established by histology, the prostatic tissue specimens exhibited normal morphology (n = 
4), benign hyperplasia (n = 3) and prostate carcinoma with a Gleason pattern score ranging 
from 5 to 8 (n = 7). Polyamine levels in the various prostatic tissues as determined by HPLC 
are displayed in Figure 1. Comparing healthy with tumor tissue, a decrease of Put and Spm 
levels can be observed, while Spd levels were rather variable. Especially in tissue of tumors 
with metastases and in the panel of xenograft models, Spm content was dramatically reduced.
One-dimensional 600 MHz proton MR spectra of spermine solutions and five samples with 
prostatic biopsy material were acquired to gain insight into the possibilities of using proton 
MRS for the detection of spermine in prostatic tissue. The in vitro MR spectrum presented in 
Figure 2A shows that spermine proton MR signals consisting of several multiplets are present 
around 1.8, 2.1, and 3.1 ppm. Further, a strongly coupled AB-type multiplet of citrate can be 
observed around 2.6 ppm. This spectrum closely resembles a 500 MHz proton MR spectrum 
of expressed prostatic fluid presented by Lynch and Nicholson (1997), in which resonances of 
citrate, spermine and myo-inositol are present. A proton MR spectrum of prostatic biopsy 
material (Figure 2B) shows more broadened spermine and citrate resonances. Spermine 
resonances are present between the singlets of (phospho)choline (3.2 ppm) and 
(phospho)creatine (3.0 ppm), and around 2.1 and 1.8 ppm. The spermine signal at 2.1 ppm 
partly overlaps with resonances of glutamine and/or glutamate. In addition, various other 
signals can be observed, which are assigned to choline, creatine, lactate, inositol, taurine, 
glutamine/glutamate (glx), and alanine. The spectrum shown was obtained from fresh 
prostatic biopsy material that had not been frozen.
Figures 3A and 3B show 1.5 T MR spectra of a solution with citrate and spermine 
obtained by a PRESS localization scheme with echo times of 30 ms and 120 ms, respectively. 
These two figures clearly illustrate the effect of J-modulation on the multiplet signals of 
citrate and spermine. The spectrum obtained with the short TE of 30 ms (Figure 3A) shows all 
spermine resonances with dispersive line shapes. However, when using a TE of 120 ms 
(Figure 3B), the spermine resonances between 3.0 and 3.3 ppm appear with an absorption-like 
line shape, while the spermine resonances in the region around 1.8 and 2.0 ppm are barely 
visible. In addition, the two outer lines of the citrate multiplet have disappeared at TE = 120 
ms, which phenomenon has been described previously (Van der Graaf et al. 1997). Figure 3C 
shows a spectrum of a solution of 90 mM citrate, 18 mM spermine, 9 mM choline, 12 mM 
creatine and various salts measured with the same TE as the spectrum shown in Figure 3B. 
Although the spermine resonances in the spectral region between 3.0 and 3.3. ppm were 
clearly visible in Figure 3B, they are not resolved from the resonances of choline (3.2 ppm) 
and creatine (3.0 ppm) in the spectrum shown in Figure 3C. An in vivo proton MR spectrum of 
the human prostate (Figure 3D) obtained with identical timing of the PRESS localization 
sequence (t  = 11 ms and TE = 120 ms) shows a comparable resonance pattern in the region 
between 3.0 and 3.3 ppm. Generally, the peaks present at 3.0 and 3.2 ppm are assigned to 
creatine and choline. However, as the resonances of spermine also appear in this region (see 
Figure 3B), some part of the signal intensity may have to be assigned to spermine. The 
resonance at 2.1 ppm in the in vivo MR spectrum is situated at a position where a spermine 
multiplet resonates in the high-resolution MR spectrum (Figure 2A), but where hardly any 
signal intensity is present in the in vitro 1.5 T MR spectrum (Figure 3B). Therefore, this signal 
is expected to arise from another metabolite than spermine, e.g. from lipid or 
glutamine/glutamate.
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Figure 2. A) 600 MHz proton MR spectrum of 90 mM citrate and 18 mM spermine in a solution with various 
salts (see Materials and Methods). The spermine resonances are labeled A1-3 and B1-2, which assignments 
correspond to various proton positions in the spermine molecule as indicated. B) 600 MHz proton MR spectrum 
o f260 mg fresh prostatic biopsy material in PBS (pH 7.2). Glx = glutamine and/or glutamate
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As shown above it is difficult to measure spermine resonances in the prostate by localized 
single voxel spectroscopy due to J-modulation and overlap with choline and creatine 
resonances. For that reason, it was tested on biopsy material whether spermine resonances 
could be observed by 2D J-resolved proton MR spectroscopy, which technique has been 
shown to be applicable in vivo (Ryner et al 1995a,b; Thomas et al. 1996). In a 2D J-resolved 
MR spectrum the multiplet pattern of each resonance along the F1-axis is separated from its 
chemical shift along the F2-axis. 2D J-resolved MR experiments were successfully carried out 
at high field on a solution with 90 mM citrate, 18 mM spermine, 9 mM choline and 12 mM 
creatine (Figure 4A) and on biopsy material of the human prostate (Figure 4B). The spectrum of 
the solution shows the resonance patterns of spermine, citrate, choline and creatine (all labeled 
in Figure 4A). The 2D J-resolved MR spectrum of the biopsy material shows besides these 
resonances also signals of several other metabolites like inositol, taurine, lactate and 
glutamine or glutamate. As this spectrum is very crowded, only the resonances of citrate and 
spermine were labeled in Figure 4B. In addition, a homonuclear-decoupled spectrum (Figure 
4C) was obtained by summation of the subspectra of the 2D J-resolved spectrum of the biopsy 
material. In this spectrum individual multiplet peaks are combined into one resonance (e.g. a 
single peak at 4.1 ppm corresponds to the quartet of lactate), which results in higher resolution 
and S/N as compared with a conventional one-dimensional MR spectrum. However, the line 
widths in this spectrum are relatively broad as resonances in a 2D J-resolved MR spectrum are 
displayed in magnitude mode.
Discussion
In this preliminary study the polyamine content in various prostatic tissues was determined by 
HPLC and it was investigated whether the presence of spermine in prostatic tissue could be 
measured by proton MR spectroscopy. Although it has been shown that prostate cancer is 
characterized by a decreased level of citrate and an increased level of (phospho)choline (e.g), 
(Kurhanewicz et al. 1996; Heerschap et al. 1997a) we only focused on polyamines in the 
present study. The reason for this was that the polyamines directly play a role in the regulation 
of cell proliferation and differentiation (see Introduction). It may be investigated in a future 
study how changes in spermine concentrations correlate with differences in citrate and 
choline.
Although only a limited number of tissue specimens have been examined, these results as 
well as data from others (Dunzendorfer et al. 1978) show that normal and benign hyperplastic 
prostatic tissue contain high Spm levels, which are decreased in tumors. This reduction in 
Spm may result from shifts in polyamine homeostasis and/or from morphologic changes 
reducing the ductal volume. Comparing the three polyamines, the Spm concentration is the 
highest and shows the largest variation. Therefore, the spermine content may be a valuable 
marker to discriminate prostate cancer from benign prostate hyperplasia and normal prostate. 
The number of tumor specimens studied was too limited to correlate Spm levels with the 
degree of malignancy. However, the lowest Spm levels were found in tissue derived from 
primary tumors that were metastasized and in the human xenograft models, which rarely form 
ducts. Recent studies in new xenograft models of human prostate carcinoma (Van Weerden et 
al. 1996) also showed low Spm levels, in particular in the less differentiated tumors (personal 
communication with Dr. J.C. Romijn).
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Figure 3 . Proton MR spectra measured at 1.5 T using a PRESS sequence with TE = 30 ms (A) and TE = 120 
ms (B,C,D). Spectra were obtained from a solution with 90 mM citrate and 18 mM spermine (A,B), from a 
solution with 90 mM citrate, 18 mM spermine, 9 mM choline and 12 mM creatine (C), and in vivo from healthy 
tissue in the peripheral zone of a human prostate (D). Spm = spermine, Cit = citrate, Cho = choline and Cr = 
creatine.
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The results of the one-dimensional high-resolution MR experiments show that resonances 
of citrate and spermine can be observed in spectra of prostatic biopsy material. However, the 
relative signal intensities of the citrate and spermine resonances clearly differ from those in 
the spectrum obtained from a solution with 90 mM citrate and 18 mM spermine. The relative 
concentrations of citrate to spermine in this solution (5:1) had been chosen in agreement with 
values reported for human prostatic fluid (Kavanagh 1985; Lynch and Nicholson 1997). The 
relatively lower citrate resonance could be the result of a relatively lower amount of citrate 
present. Histological analysis of this sample indeed showed the presence of some tumor 
tissue. Another possibility is that the resonances of citrate are more broadened than those of 
spermine. In Figure 2B the chemical shift Scit of the midpoint of the citrate multiplet has a 
slightly higher ppm-value and the chemical-shift difference A between the two resonance 
groups is larger than in Figure 2A. It has been shown that the values of Scit and A increase by 
the binding of positively charged cations to the negatively charged groups of citrate (Van der 
Graaf and Heerschap 1996). Therefore, positively charged (possibly paramagnetic) cations 
may be bound to the negatively charged citrate in the biopsy material resulting in citrate lines 
which are more broadened than the resonances of the positively charged spermine. 
Biochemical analysis which determines both the amount of spermine and citrate is necessary 
to find out the real concentration ratio present in the biopsy material.
Also in the MR spectra measured at the clinical field strength of 1.5 T the shape of 
the citrate signal varies with the absence or presence of other metabolites. Although the field 
homogeneity was comparable during the measurement of the spectra shown in Figure 3B-D, 
the two central lines of the citrate multiplet become less well separated going from a solution 
with only citrate and spermine, via a solution with also choline and creatine present to the 
situation in vivo. Overall, the in vitro spectrum in Figure 3C closely resembles the in vivo 
spectrum in Figure 3D. Only the choline peak is increased compared with in vivo spectra of the 
healthy prostate, which suggests that the concentration of choline in the solution (9 mM) was 
relatively too high compared to the in vivo situation. The in vitro spectrum in Figure 3C was 
obtained from a solution in which 18 mM spermine was also present giving rise to signal 
intensity in the spectral region between 3.0 and 3.3 ppm (see Figure 3B). However, in this 
spectrum the spermine resonances are not resolved but they overlap with the resonances of 
choline and creatine. This may also be the case in the in vivo spectrum shown in Figure 3D. 
Peaks present at 3.0 and 3.2 ppm are generally assigned to creatine and choline, respectively, 
but some part of the signal intensity may have to be assigned to spermine. In a study by 
Vigneron et al. (1998) it was found that the intensity of the choline peak in in vivo MR spectra 
of prostate tumor tissue increases going from Gleason pattern score 5 to 8. However, the 
intensity of the choline resonance in spectra of prostate tumors with Gleason pattern score 5 
was slightly lower than in spectra of the healthy prostate. Cell densities can be lower in 
tumors of intermediate grade than in normal tissue due to mis-organization, but the reduction 
of the measured choline area may also be affected by changes in the underlying polyamine 
resonances.
Although we have been able to identify spermine resonances in MR spectra of prostatic 
tissue by 2D J-resolved spectroscopy, it is not trivial to extend these experiments to the 
prostate in vivo. Firstly, the resolution at the clinical field of 1.5 T is much lower than the 
resolution of the spectra obtained at 600 MHz (= 14.1 T). Secondly, the low sensitivity at 1.5 
T requires long measurement times. And finally, a 2D J-resolved MR measurement in vivo of 
the prostate is expected to be more complicated than that of the human brain (Ryner et al. 
1995a,b) as it resides in a less homogeneous environment and it is prone to increased
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mobility. Some of these problems may be solved with the advent of clinical MR spectrometers 
with a higher magnetic field strength.
As the spermine concentration in prostatic tissue is much higher than the concentrations of 
the two other polyamines Put and Spd, the polyamine resonances in the MR spectra shown are 
labeled as ‘spermine’. However, Put and Spd may give rise to some signal intensity at the 
same resonance positions. It has been shown to be possible to distinguish these three
1 13polyamines in cell extracts and biofluids by a H/ C inverse two-dimensional MR method at 
high field (Wilker et al. 1998; Cornel et al. 1993). For prostatic biopsy material, this 
discrimination may be more difficult or even impossible due to increased line widths.
Narrow linewidth spectra may be achieved by the use of extracts. The disadvantage of this 
method, however, is the sample preparation method. Metabolites may be lost or degenerated 
during the extraction procedure. E.g. polyamine signals were virtually absent in high­
resolution MR spectra of perchloric acid extracts of human prostate tissue measured by our 
group (Cornel et al. 1993), while signals of polyamines could be observed in high-resolution 
MR spectra of perchloric acid extracts of prostatic tissue reported by Kurhanewicz et al. 
(1995). Another possibility is the use of magic angle spinning (MAS) MR spectroscopy. It has 
been shown by Tomlins et al. (1998) and Cheng et al. (1999) that high-resolution MAS proton 
MR spectroscopy can be successfully applied to prostatic biopsy material to obtain narrow 
linewidth spectra with well resolved resonances. Presently, our group is studying the 
possibilities of this method.
Conclusions
Although only a limited number of tissue specimens were examined, the HPLC results 
indicate that normal and benign hyperplastic prostatic tissues are characterized by high levels 
of spermine while in human prostatic carcinoma spermine levels are low. This reduction in 
spermine level may result from shifts in polyamine homeostasis concomitant with changes in 
cellular behavior and/or morphologic changes reducing the ductal volume. Hence, a strong 
decrease in the high concentration of spermine in the prostate could indicate a conversion of 
prostatic cells from a benign into a malignant phenotype.
The results of the MR experiments show that spermine in prostatic tissue can be detected 
by MR, in particular by one- and two-dimensional high-resolution MR of biopsy material. 
Non-invasive determination of spermine in the prostate by in vivo MR is still very difficult 
but may be easier in the future. The presence of spermine resonance intensity between 3.0 and 
3.3 ppm in localized 1.5 T MR spectra complicates the interpretation of signal variations in 
this region. An increased intensity of the choline signal in spectra of tumor tissue may be 
obscured by a decreased underlying spermine signal.
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Figure 4 . Sections o f600 MHz 2D J-resolved proton MR spectra o f (A) a solution with 90 mM citrate, 18 mM 
spermine, 9 mM choline and 12 mM creatine, and of (B) 260 mg prostatic biopsy material. (C) 600 MHz 
homonuclear-decoupled proton MR spectrum derived from (B). Spm = spermine, Cit = citrate, Cho = choline 
and Cr = creatine.
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Antitumor potential o f DENSpm
Abstract
Recent studies indicate that N-terminally bis-ethylated-polyamine analogs have significant 
antitumor activity in several human solid-tumor models. In this study, the in vitro and in vivo 
antitumor potential of the polyamine analog N1, N11-diethylnorspermine (DENSpm) in human 
prostate carcinoma cells was examined. The antiproliferative and biochemical effects of 
DENSpm were tested in four human prostate cancer cell lines, i.e. PC-3, TSU-pr1, DU-145 
and JCA-1. The in vivo antitumor potential was explored in two groups of nude mice bearing 
small or more developed xenografts of the DU-145 cell line. The mice were treated with 40 
mg/kg DENSpm, three times per day for two cycles of 6 days, on days 1-6 and 8-13. In vitro 
studies showed that all four tested human prostate carcinoma cell lines were sensitive to 
DENSpm in micromolar concentrations. In tumor-bearing mice, DENSpm clearly prevented 
tumor growth in both size groups, which became significant after day 17. Treatment with 
DENSpm evoked intracellular accumulation of the analog and various regulatory responses, 
e.g., downregulation of the polyamine biosynthesis, the induction of the catabolic enzyme 
spermidine/spermine N1-acetyltransferase (SSAT), and the depletion or decrease of the 
natural polyamines. The cellular sensitivity to growth inhibition by DENSpm only correlated 
with the degree of ODC inhibition and SSAT induction. DENSpm has sustained inhibitory 
effects on the growth of human prostate carcinoma cells in vitro as well in vivo. DENSpm 
may provide a new tool in the chemotherapy of prostate cancers with various phenotypes.
KEY WORDS: prostate cancer / polyamine analogs / polyamines / spermidine/spermine N'-acetyl- 
transferase / ornithine decarboxylase
I ntroduction
Prostate cancer is one of the most frequent types of malignancies in males (Denmeade and 
Isaacs 1997). If discovered early enough, prostate cancer is still localized and can be cured 
with surgery. However, disseminated prostate carcinoma is hard to cure. Androgen ablation, 
the standard therapy in the treatment of prostate cancer, is rarely curative for this type of 
prostate cancer. The major reason for the failure of androgen ablation to cure the disease is the 
existence or emergence of androgen-independent subpopulations of prostate cancer cells 
(Isaacs and Coffey 1981). Therapy, targeted at the androgen-independent cancer cells is 
necessary to eliminate also the hormone-insensitive cell populations present within an 
individual tumor. At present, such therapy is not available. Therefore, new classes of agents 
need to be developed to interfere with the growth of prostate cancer cells. Since polyamines 
are important for prostate cell growth and function, interference with polyamine metabolism 
could provide a promising target for chemotherapy of prostate cancer.
In mammals three types of polyamines have been described, i.e., putrescine (Put), 
spermidine (Spd) and spermine (Spm). These compounds have a low molecular weight, a 
simple chemical structure (aliphatic amines) and are highly charged cations at physiological 
conditions (Figure 1). It is now generally accepted that polyamines are of crucial importance 
for the regulation of cell proliferation and differentiation (Pegg and McCann 1982). The exact 
mechanism of the actions of polyamines on cell proliferation and differentiation is not well 
understood. Because of their basic character at physiological pH, in vitro, polyamines are able 
to bind to a variety of organic compounds, such as nucleic acids, proteins and phospholipids. 
Therefore, it has been suggested that in vivo polyamines are involved in the stabilization of 
these molecules and/or possibly facilitate their conformational shifts (Porter et al.1992).
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Figure 1. Structure o f the polyamines putrescine, spermidine and spermine and the polyamine analog DENSpm 
at physiological pH.
Since polyamines are important for (tumor) cell growth, the development of agents which 
can deplete the intracellular polyamine pools would lead to the development of an "universal" 
antineoplastic therapy. Several compounds are able to inhibit the action of the enzymes 
involved in polyamine biosynthesis. Their potential as antineoplastic has been investigated 
and extensively reviewed (Marton and Pegg 1985; Kramer 1996). Although they can suppress 
tumor cell growth in vitro, so far, they fail to be successful as anti-cancer agents in vivo. 
Besides a lack of specificity and potency, also other factors related to the polyamine 
homeostasis might be responsible, such as: (a) rapid turnover of the enzymes involved in the 
polyamine biosynthesis, (b) compensatory increase of the non-inhibited polyamine enzymes, 
(c) compensatory increase of polyamine uptake from extracellular sources, (d) compensatory 
retroconversion of the intracellular polyamine pools, since a single inhibitor can not deplete 
all three polyamine pools (Porter 1992).
With the synthesis of polyamine analogs some of the problems discussed above have been 
circumvented. Structural analogs of polyamines, e.g., N 1, N u -diethylnorspermine (DENSpm) 
(Figure 1), were shown to down-regulate polyamine synthesis and uptake, up-regulate poly­
amine catabolism and, compared tot the biosynthetic inhibitors mentioned before, result in a 
more profound depletion of polyamines (Marton and Pegg 1985; Kramer 1996). Recent 
studies indicate that the bis(ethyl)analogs of spermine have significant antitumor activity in 
several human solid tumor models (Chang et al. 1992; Bernacki et al. 1993; Porter et al.
1993). Currently, some of these analogs are undergoing clinical trials with promising results.
In the present study, we investigated the in vitro and in vivo antitumor potential of the 
polyamine analog DENSpm in human prostate cancer cells. In vitro effects of DENSpm were 
studied in four human prostate carcinoma cell lines with different malignant behavior. The in 
vivo antitumor potential was explored in athymic nude mice xenografted with one of the 
human prostate carcinoma cell lines. In these experiments, the effect of DENSpm on 
polyamine metabolism was examined by measuring the biosynthetic enzyme ornithine 
decarboxylase (ODC), the catabolic enzyme spermidine/spermine N 1-acetyltransferase 
(SSAT) and by determining the intracellular concentrations of the natural polyamines and the 
polyamine analog.
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Materials and methods
Materials
The spermine analogue N 1,N11-diethylnorspermine (DENSpm) was synthesized and purified 
as described by Bergeron et al. (1988). Purity was tested by proton nuclear magnetic 
resonance spectra and high-performance liquid chromatography (HPLC) analysis. Put was 
obtained from Sigma Chemica Co. (St. Louis, MO), Spd en Spm were bought from Serva 
(Heidelberg, Germany).
All human prostate carcinoma cell lines, i.e. PC-3 (Kaighn et al 1979)], TSU-pr1 (Iizumi et 
al. 1987), DU-145 (Stone et al., 1978), and JCA-1 (Muraki et al., 1990), are routinely 
maintained in our laboratory. PC-3 and TSU-pr1 are poorly differentiated and prone to 
metastasize. DU-145 and JCA-1 are moderately differentiated and have no metastatic abilities. 
All four human prostate carcinoma cell lines are androgen-unresponsive.
Cell culture
The human prostate carcinoma cell lines were passaged or grown in RPMI-1640 medium 
supplemented with 10 % heat-inactivated fetal calf serum (FCS, Integro BV; Zaandam, The 
Netherlands), glutamine and antibiotics. For growth inhibition assays, cells were plated in 96- 
well microtiter plates, incubated for 24 hrs and then treated with different doses of DENSpm. 
As a standard practice 1 mM aminoguanidine, an inhibitor of serum amine oxidases (Shore 
and Cohn 1960), was added to prevent oxidation of polyamines in the culture medium. Cell 
viability was measured in triplicate after 24, 48 and 72 hrs after the start of the treatment, 
using a tetrazolium-based colorimetric assay (Carmichael et al. 1987). Growth inhibition was 
assessed by dose-response curves, the IC50 value was defined as the 50 % inhibition of cell 
growth at 48 hrs.
To investigate the effect of DENSpm on polyamine homeostasis, cells were cultured in T- 
25 flasks and treated with 100 |iM DENSpm, a dose which produced profound cytostatic 
effects in all four cell lines. After 48 hrs, cells were harvested and assayed for enzymatic 
activity of ODC and SSAT, and for content of polyamines and analog as described below.
All cell lines were cultured in a humidified atmosphere containing 5% CO2 at 37 °C.
Xenografts
Cultured DU-145 human prostate cancer cells were subcuteanously injected (3-106 
cells/injection) into 20-22 g female BALB/c (Harlan Netherlands, Zeist, The Netherlands). 
The cells were co-injected with a reconstituted basement membrane gel (Matrigel) obtained 
from Collaborative Research Inc. (Bedford, MS, USA) to enhance the take rate of the tumor 
cells. After 3-4 weeks following inoculation the animals were selected for similar sized
3 3tumors (Size group A; 200-400 mm , Size group B; 700-1100 mm ) and divided in a group 
treated with DENSpm and a control group. The treated animals received intraperitoneal 
injections of a 10 mg/ml solution of DENSpm in saline (0,9% NaCl, pH 7.4) three times per 
day (8 hr apart) on days 1-6 and 8-13. The given dose was based on the results described by 
Bernacki et al. (1993). The control group received saline injections. Tumor size was 
determined by using bidimensional caliper measurements three times per week. The mice 
were sacrificed after 40 days (Size group A) or if tumor size exceeded 2000 cm (Size group 
B)
Tumors were removed and frozen immediately in liquid nitrogen. Subsequently samples 
were cut in smaller pieces and sonicated to homogeneity in 25 mM TRIS/HCl buffer
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containing 250 mM sucrose, 25 mM Tris buffer (pH 7,5), 0,1 mM EDTA, 1mM DTT, and the 
protease inhibitors PMSF, antipain, chymostatin, leupeptin and pepstatin. The homogenate 
was used for protein determinations, enzyme assays and polyamine determinations. Protein 
determinations were done using the Bradford method (Bradford 1977).
Polyamine enzyme activities
Activity of ODC was estimated according to Patterson & Maxwell (1980) measuring the 
formation of 14CO2 from 14C-ornithine. Enzyme activity of SSAT was determined by 
following the incorporation of acetyl-1-14C-CoA in spermidine according to a method 
described by Matsui and Pegg (1980). Enzyme activities are expressed as pmol/min/mg 
protein.
HPLC analysis ofpotyamines and DENSpm
The polyamine and analog content was measured using a method essentially the same as 
described by Kirschbaum et al. (1994). In short, cells were deproteinized with sulphosalicylic 
acid (60% v/v in water). After centrifugation supernatant was collected and neutralized with 
6N NaOH. After derivatization with Fmoc-ONSu in borate buffer, the samples were subjected 
to HPLC analysis. Polyamine concentrations are presented as nmol per mg protein.
Statistical assessment
In case of the biochemical measurements, data were analyzed using the unpaired Student’s t 
test. Results are presented as means ± standard deviation. Differences in the growth inhibitory 
effect of DENSpm between the treatment groups were statistically analyzed using the 
MANOVA test.
R e s u l t s  
In vitro Model
Cell Line sensitivity
For the determination of cellular sensitivity of the human prostate carcinoma cell lines PC-3, 
TSU-pr1, DU-145 and JCA-1, cells were cultured and treated with different doses of 
DENSpm. From the obtained dose-response curves, IC50 values were deducted at the 50 % 
difference between initial cell number and cell number after 48 hrs in control cultures.
Results, as depicted in Table 1, show that all tested prostate cancer cell lines display cellular 
sensitivity to DENSpm with IC50 values in the micromolar range. DU-145 cells were the most 
sensitive (IC50 = 2 |xM) followed by JCA-1 cells (IC50 = 18 |xM). PC-3 and TSU-pr1 were less 
sensitive with comparable IC50 values (65 and 62, respectively).
In each cell line, DENSpm had cytostatic effects except at higher concentrations (> 0.5 
mM) or after long treatment (>144 hrs) (results not shown).
Table 1. IC50 values o f  DENSpm in Human Prostate Carcinoma Cell L ines*
Cell line
t = 48 hrs PC3 TSU-pr1 DU-145 JCA-1
05CI 65 62 3 21
* IC50 value was defined as the 50 % inhibition o f cell growth at 48 hrs. Assays were done twice in triplicate.
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Polyamine metabolism
After 48 hrs treatment, polyamine metabolism was examined in control cells and in cells 
treated with 100 |xM DENSpm, a dose which produced profound cytostatic effects in all four 
cell lines. Figure 2 shows the results of the effects of DENSpm on the activity of ODC and 
SSAT (Figure 2A) and on the intracellular concentrations of polyamines and DENSpm (Figure 
2B).
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Figure 2. Effects on polyamine metabolism o f human prostate carcinoma cell lines treated for 48 hrs with 100 yM  
DENSpm: A) activity o f ODC, SSAT, and B) intracellular levels o f Put, Spd, Spm and DENSpm. Results are presented as 
mean ± SEM. All assays were performed twice in triplicate.
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The human prostate carcinoma cell lines show a differential basal activity of the polyamine 
enzymes ODC and SSAT. Compared to the DU-145 and JCA-1 cells, ODC activity tends to 
be higher and SSAT activity to be lower in PC-3 and TSU-pr1 cells. These cell lines also 
contain higher basal concentrations of the polyamines with relatively high levels of Spd.
Results show that treatment with DENSpm coincides with a decrease in ODC activity and 
a high induction of SSAT activity. The used enzyme assay also reveals the activity of other 
acetylating enzymes, so, the actual induction of SSAT is possibly higher than can be estimated 
from the data in Figure 2A. Interestingly, ODC inhibition as well as SSAT induction are higher 
in the more sensitive cell lines DU-145 and JCA-1 compared to PC-3 and TSU-pr1.
In all tested human prostate carcinoma cell lines, treatment with DENSpm resulted in a 
profound decrease in the natural polyamines and intracellular accumulation of the polyamine 
analog. Intracellular levels of neither DENSpm nor the decrease in the polyamines showed a 
correlation with the observed cellular sensitivity towards the polyamine analog. Notably, the 
polyamine analog accumulated more in the cells having higher basal polyamine levels (PC-3 
and TSU-pr1).
In vivo Model
Tumor growth
After 3-4 weeks following inoculation all mice had developed palpable tumors. The mice 
were divided in two size groups of similar-sized tumors (size group A; 200-400 m , size group 
B; 700-1100 m ). At the end of the experiment there were no significant differences in body 
weight of the mice indicating that the treatment had no overt toxic effects.
Results of the effect of DENSpm on the tumor growth of the DU-145 xenografts are depicted 
in Figure 3A (Size group A) and Figure 3B. (Size group B). Treatment with DENSpm clearly 
prevents the tumor growth in both size groups directly from the beginning of the treatment. 
Statistical analysis using MANOVA showed that the growth inhibitory effect becomes 
significant after day 17 in both size groups.
Polyamine metabolism
Tumors were analyzed for polyamine metabolism in size group A as well as size group B. The 
results of the effects of DENSpm on the activity of ODC and SSAT and on the intracellular 
concentrations of polyamines and DENSpm are shown in Table 2. These results show that 
treatment with DENSpm caused a decrease in ODC activity and high induction (30 to 50 
folds) of SSAT activity. Treatment with DENSpm resulted in an increase of Put levels and a 
decrease in Spd and Spm levels. In addition, DENSpm accumulated in concentrations 
comparable of the spermine levels present in the controls. No significant differences could be 
observed between the two size groups in the effect of DENSpm on polyamine metabolism.
131
Antitumor potential o f DENSpm
time (days)
time (days)
Figure 3. Effect o f DENSpm on the growth o f xenografts o f the human prostate carcinoma cell line DU-145 in athymic 
nude mice: A) initial tumor size 200-400 m3; B) initial tumor size 700-1100 m3. Treated animals received 40 mg/kg o f 
DENSpm, three times per day on days 1-6 and 8-13. The results are presented as means ± SEM, n =7-9.
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Table 2. Effects of DENSpm on polyamine metabolism in xenografts of DU-145*
Size
Group
Polyamine enzym es  
(pm ol/m in/m g protein)
Polyamine levels  
(nmol/mg protein)
T reatment ODC SSAT Put Spd Spm DENSpm
A control 2.8 ± 1.8 15.8 ± 4.8 0.8 ± 0.2 2.8 ± 1.4 1.4 ± 0.4 -
+ DENSpm 1.8 ± 1.4 476.5 ± 84.7 2.2 ± 1.0 1.6 ± 0,6 0.7 ± 0.1 1.2 ± 0.6
B control 1.3 ± 1.2 10.3 ± 3.21 0.7 ± 0.5 2.1 ± 0.6 1.6 ± 0.7 -
+ DENSpm 0.8 ± 0.7 345.6 ± 20.8 1.3 ± 1.1 1.2 ± 0.1 0.5 ± 0.1 1.5 ± 0.5
* Xenografted mice were treated with 40 mg/kg o f DENSpm, three times per day (8 hrs apart) on days 1-6 and 8-13. 
Results are presented as mean ± SEM, n = 5-7. All assays were performed twice in triplicate
Di s c u s s i o n
Polyamine analogs were initially developed to investigate the regulatory mechanism, which 
control polyamine homeostasis. Subsequently, research was done for polyamine analogs 
which downregulate the biosynthetic enzymes, deplete intracellular polyamine pools and 
inhibit cell growth by failing to substitute for the depleted natural polyamines in functions 
required for proliferation. From all the compounds synthesized so far, the most potent in cell 
growth inhibition are bis(ethyl)-analogs of spermine, and to a lesser extent, bis(ethyl)analogs 
of spermidine (Kramer 1996).
In the present study, we explored the antitumor efficacy of the polyamine analog N 1, N 11- 
diethylnorspermine (DENSpm) against human prostate carcinoma cells. For the in vitro 
studies, four human prostate cell lines, e.g. PC-3, TSU-pr1, DU-145 and JCA-1, with different 
degree of malignant behavior were examined. In this panel, PC-3 and TSU-pr1 cells are 
considered to possess a higher degree of malignancy since they are less differentiated and 
have metastatic ability. Notably, these more malignant cell lines possess higher basal levels of 
polyamines consistent with their high ODC activity and low SSAT activity. This observation 
seems to be in agreement with other studies showing positive correlations between polyamine 
overproduction and prostate malignant growth (Heston 1991). Another difference between the 
more malignant cell lines PC-3 and TSU-pr1 and the two other cell lines DU-145 and JCA-1 
was observed with respect to the cellular sensitivity towards DENSpm and its biochemical 
effects on polyamine homeostasis. DENSpm was more effective in inhibiting cell growth of 
the DU-145 and JCA-1 cells. Furthermore, the decrease of ODC activity and the induction of 
SSAT were substantially higher in these cell lines after treatment of DENSpm. This suggests 
that the observed cellular sensitivity correlates with the decrease in ODC activity and the 
induction of SSAT. On the contrary, sensitivity did not seem to relate to the concentration of 
accumulated analog compared to the basal polyamine concentrations nor to the degree in 
which polyamines were depleted.
To investigate the in vivo effects of DENSpm, nude athymic mice were xenografted with 
DU-145 cells, which were, in vitro, the most sensitive to DENSpm treatment. Results show
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that DENSpm rapidly inhibited cell growth in small tumors (size group A) as well as in more 
developed tumors (size group B).
SSAT activity was highly induced after DENSpm treatment whereas ODC was only 
moderately and not significantly inhibited. Remarkably, polyamine concentrations in the 
treated xenografts were not depleted in the same degree as seen in vitro. Spd and Spm content 
were moderately decreased whereas the Put level was even increased. This shift in the 
polyamine distribution by DENSpm can be explained by the increased SSAT activity, which 
promotes the degradation of spermine and spermidine into spermidine and putrescine, 
respectively. The lack of profound depletion of polyamines as seen in vitro could be explained 
by insufficient excretion and/or breakdown of intracellular polyamines or be due to uptake of 
polyamines from extracellular sources (Seiler et al. 1990).
The observed effects of DENSpm on polyamine metabolism in human prostate carcinoma 
cells are comparable with those seen with polyamine analogs in other tumor models (Kramer 
1996; Chang et al. 1992; Bernacki et al. 1993; Porter et al. 1991, 1993; Fogelpetrovic et al.
1996). In these studies, the cellular responses to these compounds were (a) down-regulation of 
polyamine biosynthesis (b) high increase of SSAT activity and (c) decrease of the natural 
polyamine pools. The mechanisms of action of these compounds have been investigated (Basu 
et al. 1989, 1992; Vertino et al. 1991; He et al. 1994) but the exact mode of action remains 
unclear. The huge induction of SSAT, which is directly or indirectly related to the sensitivity 
of the cells for the drugs, can have potential chemotherapeutic benefits. However, the 
relationship between induction of SSAT and the inhibition of cell growth is not yet fully 
understood. Several working mechanisms have been suggested, e.g. increased catabolism 
and/or excretion of polyamines could rapidly deplete the intracellular polyamine pools, and 
acetylation of the polyamines could reduce their positive charges, and therefore reduce their 
ability to interact with macromolecules (Casero and Pegg 1993).
In the course of this work, three other research groups reported on the in vitro and in vivo 
sensitivity of prostate carcinoma cells to polyamine analogs, DENSpm included (Jeffers et al. 
1997; Zagaja et al. 1998; Mi et al. 1998; McCloskey et al. 2000). Results of these studies are 
not in all detail identical probably due to the different analytical methods and experimental 
conditions used in the studies. Nevertheless, it was concluded that DENSpm has differential 
effects on cell growth and polyamine homeostasis in different prostatic carcinoma cells, i.e., 
the androgen-independent DU-145 cells were the most sensitive, whereas the androgen- 
dependent, well-differentiated LNCaP cells were relatively insensitive. In addition, these 
studies showed that the antitumor effect of DENSpm was not caused by the increased 
induction of apoptosis as observed with some other polyamine analogues (McCloskey et al., 
1995, 1996; Ha et al. 1998; Eiseman et al. 1998) except in LNCaP cells where DENSpm was 
found to induce apoptotic cell death after a long treatment period (McCloskey et al. 2000). 
Also, we could not find evidence of induction of apoptosis by DENSpm, neither in vitro nor 
in vivo (unpublished observations).
In conclusion, DENSpm might be an important tool in the chemotherapy of prostate 
cancers with different degree of malignant behavior, since our studies indicate that DENSpm 
is an effective growth inhibitor of different phenotypes of human prostate carcinoma cells and, 
furthermore, is able to inhibit prostate tumor growth in vivo, irrespective of the initial tumor 
size. Although DENSpm is currently the only analog that is undergoing clinical trails, recent 
newly developed polyamine analogs have become available which might be more potent in 
inhibiting prostate tumor growth (Jeffers et al. 1997; Zagaja et al. 1998; Eiseman et al. 1998; 
McCloskey et al. 2000). Conformationally restricted tetra- and pentamines have been 
developed (manufactured by Prof. Dr. Marton, Dr. H. Basu and Dr. B. Frydman of the SLIL
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Biomedical Corp., Madison, WI, USA), which show high cytotoxicity against human prostatic 
cancer cells but have negligible toxicity in rodents. We are currently testing these analogs in 
vivo on xenografts of human prostate cancer with varying degrees of differentiation and 
malignancy.
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Polyamines and Apoptosis
ABSTRACT
The natural polyamines (putrescine, spermidine, spermine) are ubiquitous low-molecular 
aliphatic amines that play multifunctional roles in cell growth and differentiation. Recently, 
evidence is merging that polyamines are actively involved in cell death. Changes in polyamine 
homeostasis have been reported during cell death of nerve cells, in programmed cell death of 
embryonic cells and in various in vitro models of apoptosis. Polyamines and many of their 
structural analogs exert cytotoxic effects in vitro as well in vivo. Furthermore, polyamine 
analogs and inhibitors of the polyamine anabolic/catabolic pathways modulate processes of 
cell death in a cell-type specific way. Much ambiguity exist in the working mechanisms by 
which polyamine mediate apoptosis since they have been shown to act as promoting, 
modulating or protective agents in apoptosis. Nevertheless, from the studies reviewed here it 
can be concluded that polyamines are critically involved in cellular survival which makes 
them suitable targets for therapeutic intervention that is specifically directed to cell death 
pathways.
KEYWORDS: polyamines / ornithine decarboxylase / polyamine oxidation/ neuronal cell death / 
apoptosis / programmed cell death / transglutaminase
INTRODUCTION
Histidine decarboxylase and ornithine decarboxylase have several biological functions in 
common.(Medina et al. 1999) In this study we will focus on the role of the ornithine 
decarboxylase and its reaction products, the polyamines in relation to apoptosis.
The natural polyamines putrescine (Put), spermidine (Spd) and spermine (Spm) are widely 
distributed in living organisms. These compounds have a low molecular weight, a simple 
chemical structure (aliphatic amines) and are highly charged cations at physiological 
conditions (see Figure 1, chapter 1). The metabolic pathways and homeostasis of polyamines 
are well established and have been summarized in several reviews (Seiler et al. 1996; Persson 
et al. 1996; Seiler & Douaud 1998). Cells have developed a complex regulatory machinery, 
which controls intracellular polyamine pool sizes in a fast and accurate manner by the 
combined action of de novo synthesis, retroconversion, terminal degradation, secretion, and 
uptake of polyamines (Figure 1).
Put, Spd and Spm are derived from a common precursor, ornithine, which is 
decarboxylated by the rate-limiting enzyme ornithine decarboxylase (ODC) to yield Put. S- 
adenosylmethionine decarboxylase (SAMDC), another rate-limiting enzyme in polyamine 
biosynthesis, converts S-adenosylmethionine (SAM) into decarboxylated S-adenosyl- 
methionine (dcSAM). In turn, dcSAM acts as an aminopropyldonor in the production of Spd 
and Spm catalyzed by Spd synthase and Spm synthase, respectively. In the retroconversion 
pathway, Spm and Spd are first acetylated by Spd/Spm N 1-acetyl transferase (SSAT) to N 1- 
acetyl spermine (N1-AcSpm) and N 1-acetylspermidine (N1-AcSpd) respectively. N 1-AcSpm 
and N 1-AcSpd can be excreted from the cell. Alternatively, these substances can be oxidized 
by the FAD-dependent polyamine oxidase (PAO) to Spd and Put respectively, and the 
oxidation products 3-acetamidopropanol and hydrogen peroxide. Polyamines can also be 
irreversibly degraded (terminal degradation) by oxidative deamination catalyzed by copper 
containing amine oxidases (CuAO’s). The products of this degradation of polyamines are 
unstable and toxic and are subsequently further degraded into urea, carbon dioxide and water. 
In addition, cells are equipped with an efficient transport system for uptake of polyamines
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from extracellular sources (Seiler et al. 1996). This energy-dependent carrier-mediated 
system can transport natural polyamines, and BENSpm as well as other not related agents, e.g. 
paraquat. The role of polyamines in cell proliferation and differentiation has been extensively 
studied, e.g. by interference with polyamine homeostasis using enzyme inhibitors of the 
metabolic pathway or polyamine analogs (Marton & Pegg 1995). These compounds not only 
have profound effects on cell growth and function but even cause cell death, depending on the 
cell type or pharmacological compound used. In present review, the involvement of 
polyamines in (apoptotic) cell death will be discussed.
(Other cells, diet, 
bacterial flora)
Figure 1. Polyamine homeostasis in mammalian cells. In the biosynthetic branch o f the interconversion cycle, ornithine is 
decarboxylated to yield putrescine. DcSAM acts as an aminopropyldonor in the production o f spermidine and spermine. In 
the catabolic branch o f the interconversion cycle, spermine and spermidine are first acetylated to N1-acetylspermine (N1- 
AcSpm) and N1-acetylspermidine (N1-AcSpd) respectively. N1-AcSpm and N1-AcSpd can be excreted from the cell or finally 
oxidized to form spermidine and putrescine respectively. Polyamines can also be irreversibly degraded by oxidative 
deamination catalyzed by copper containing amine oxidases (CuAO ’s). In addition to the metabolic apparatus to synthesize 
and convert polyamines, cells can regulate intracellular polyamine pools by transport o f polyamines across the membrane. 
Extracellular polyamines can be derived from other cells that secrete polyamines or their acetylated conjugates. Polyamines 
can also be derived from dietary or microbial polyamines which are take up by the gastrointestinal tract. The enzymes 
involved are (1) ornithine decarboxylase, (2) S-adenosylmethionine decarboxylase, (3) spermidine synthase, (4) spermine 
synthase, (5) spermidine/spermine N1-acetyltransferase, (6) polyamine oxidase
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Polyamines and apoptotic cell death
Eukaryotic cells possess a genetic program to commit cellular suicide, a phenomenon also 
known as apoptosis. Apoptosis plays a role in e.g. the proper removing of cells or tissues 
during development (also referred as programmed cell death), selection of competent clones 
during negative selection of T-lymphocytes and in the removal of genetically damaged cells to 
avoid the onset of hyperplasia. In contrast to necrosis, apoptosis is not accompanied by an 
inflammatory response. The molecular pathways leading to apoptosis have been published 
frequently (Fadeel et al. 1999), and are therefore not discussed here. There is a merging body 
of literature indicating the involvement of polyamines in apoptotic cell death. Table 1 
summarizes the changes in ODC activity and/or the levels of the three polyamines observed in 
apoptosis induced by a variety of experimental conditions in several cell systems. 
Furthermore, as shown in Table 2, the effects of interference with polyamine homeostasis 
using polyamine enzyme inhibitors or polyamine analogs on the process of apoptotic cell 
death strengthens the idea that polyamines are important factors in the control of apoptotic cell 
death.
Necrosis, also called accidental or pathological cell death, is considered to result from 
extreme environmental conditions (e.g. hyperthermia, hypoxia, exposure to toxic agents) and 
is not genetically controlled as in apoptotic cell death. The involvement of polyamines in 
necrosis has not been extensively explored and will only be briefly discussed in the present 
review. The cytotoxicity of polyamines and their analogs and their assumed role in neuronal 
cell death are mostly assigned to the necrotic type of cell death. However, it is most likely that 
in some of the older studies cells actually died by apoptosis since this relatively newly 
established type of cell death was not well recognized and/or investigated at that time.
Both up-regulation and down-regulation of polyamine levels were reported during 
apoptosis. These rather contradictory results will be discussed separately in the next 
paragraphs
Up- regulation of polyamine levels in  apoptosis 
I nvolvement of ODC
First reports on the involvement of ODC in cell death processes emerged from studies on 
neuronal cell death induced by transient hypoglycemia, seizure, lesions, neurotoxic agents and 
traumatic brain injury (see for review Bernstein & Muller 1999). These studies showed a 
marked increase in ODC gene expression, de novo ODC protein synthesis and Put levels. 
Whether the increased Put production has real pathological consequences or merely is a 
trophic response to stress or is even just a epiphenomenon, remains yet to be established. The 
close relationship between Put levels and the extent of neuronal necrosis argue for a role for 
Put in the contribution to the pathological process of cell injury. Recent findings, however, 
favor the idea that ODC activation and Put accumulation should be considered as an attempt 
towards neuroprotection in stressed brain. In line with this assumption is the observation that 
in ODC-overexpressing mice the extent of neuronal damage after ischemia was increased by 
the highly specific ODC inhibitor a-difluoromethylornithine (DFMO) whilst Put protected the 
CA1 neurons from the insult. In transient focal ischemia, a long-lasting up-regulation of ODC 
was found in brain regions were usually no neuronal death occurs.
Various studies using different cell systems show a fast and marked increase of ODC 
activity after inducing apoptotic cell death suggesting an active role for ODC in apoptosis (see 
Table 1). A direct role of ODC as a mediator of apoptosis was suggested by Cleveland et al.
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who showed that enforced expression of ODC enzyme activity rapidly induced apoptosis in 
interleukine-3-dependent cells following cytokine deprivation (Packham & Cleveland 1994). 
These authors suggest that c-myc induces ODC-mediated apoptosis and proliferation by 
different, yet overlapping, pathways (Packham et al. 1996). This is in line with the idea that 
apoptosis and proliferation are connected and that the apoptotic and cell cycle machinery 
share common regulators. Cell cycle regulators such as c-myc, cyclin D3, p53, pRb, and E2F 
have also been implicated in apoptosis (King & Cidlowski 1998).
Table 1. Ornithine decarboxylase (ODC) activity and/or polyamine levels in apoptosis
C ells /t is su e Inducer
apoptosis
ODC
a ctiv ity
Put
Polyamine levels 
Spd Spm
R eferen ce
Human fibroblasts tumor necrosis factor * * * * (Donato et al. 1991)
Human cervical 
cancer cells
tumor necrosis factor * (Manchester et al. 1993)
Rat/mouse T-cell 
hybridoma cells
tumor necrosis factor * (Penning et al. 1998)
Human promyeloma 
leukaemia cells
etoposide * (Lindsay & Wallace 1999)
Human lung and 
colon cancer cells
selenomethionine nd (Redman et al. 1997)
Mouse T-cells interleukine-3
withdrawal
nd nd nd (Packham & Cleveland 
1994)
interleukine-2
withdrawal
nd (See Schipper et al. 1999)
Human lymphocytes PHA nd nd nd (Grassilliet al. 1991)
Pancreatic cells quinone nd nd nd (See Schipper et al. 1999)
Rat hepatoma cells hepatocyte growth 
factor
* * * * (Yanagawa et al. 1998)
Rat prostate hormone withdrawal (See Schipper et al. 1999)
Rat prostate 
cancer cells
ionomycine * * (Schipper et al. 1995)
Rat thymocytes dexamethasone * (Desiderio et al. 1995)
radiation-or heat- 
shock treatment
* (Grassilli et al. 1995)
ODC-overproducing 
L1210 cells
hyposmotic shock * * * nc (Poulin et al. 1995)
ODC-overproducing 
mouse myeloma 
cells
ornithine * * nd nd (Tobias & Kahana 1995)
ODC-deficient 
Chinese ovary 
hamster cells
putrescine +
cycloheximide
np * nc nc (Xie et al. 1997)
ODC-overproducing
HTC-cells
ornithine * * nd (Tome et al. 1994, 1997)
t ,  increased; \A, decreased; nc, not changed; nd, not determined; np, not present; ODC, ornithine decarboxylase; Put, 
putrescine; Spd, spermidine; Spm, spermine; TNF, tumor necrosis factor
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Table 2. Effect o f  pharmacological intervention o f  polyamine metabolism on apoptosis
T arg e t Rate of 
apoptosis
Reference
Enzyme inhibitor
DFMO ODC decreased
unchanged
(Piacentini et al. 1991) (Manchester et 
al. 1993) (Packham & Cleveland 
1994) (Das et al. 1997) (Schipper et 
al. 1995) (Monti et al. 1998) (Penning, 
et al. 1998) (Yanagawa et al. 1998)
(Lin et al. 1997) (Noda et al. 1998)
MGBCP SAMDC induced (Mori et al. 1997) (Kaneko et al. 
1998) (Satoh et al. 1999) (Hashimoto 
et al. 1999)
MGBG SAMDC induced
increased
(Redman et al. 1997) (Davidson et al. 
1998)
(Penning et al. 1998)
CGP48664a SAMDC increased (Penning et al. 1998)
MDL72527 PAO unchanged
decreased
(Schipper et al. 1995) (Poulin et al. 
1995) (Penning et al. 1998) (Xie et al. 
1997)
(Ha et al. 1997) (Hu & Pegg 1997)
polyamine analog
BE-3-3-3 polyamine homeostasis/ 
function
decreased (Schipper et al. 1995)
BE-3-4-3, CPENSpm polyamine homeostasis/ 
function
induced (McCloskey et al. 1996)
BE-3-3-3, BE-3-4-3, BE-
3-7-3, BE-4-4-4, BE-4-4-
4-4
polyamine homeostasis/ 
function
induced (Hu & Pegg 1997)
BE-3-3-3, BE-3-4-3 polyamine homeostasis/ 
function
induced (Kramer et al. 1997)
BE-3-3-3 polyamine homeostasis/ 
function
increased (Penning et al. 1998)
BIS polyamine homeostasis/ 
function
induced (Eiseman et al. 1998)
BE-3-3-3, N1,N11-bis(ethyl)norspermine; BE-3-4-3, N1,N12-bis(ethyl)spermine; BE-3-7-3, N,N'-bis[3-(ethylamino)-popyl- 
1,7-heptane diamine; BE-4-4-4, 3,8,13,18,tetra-azaeicosane; BE-4-4-4-4, 1,19-bis(ethylamino)-5,10,15-triazanoadecane; 
BIS, 1,12-diaziridinyl-4,9-diazadodecane; CGP48664a, 4-amidinoindan-1-one 2'-amidinohydrazone; CPENSpm, N1-ethyl- 
N  -[cyclopropyl)methyl]-4-8,-diazaundecane; DFMO, a-difluoromethylornithine; MGBCP, methylglyoxal bis(cyclo- 
pentylamidinohydrazone); MGBG, methylglyoxal bis(guanylhydrazone); MDL 72527, N1-N4-(2,3-butadienyl)butane-1,4- 
diamine; ODC, ornithine decarboxylase; PAO, polyamine oxidase ; SAMDC, S-adenosylmethionine decarboxylase
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Some recent studies support the idea that polyamines, cell cycle events and apoptosis are 
closely connected. Polyamine depletion protected human promyelogenous leukemia cells 
(HL-60) from sugar-induced apoptosis (Monti et al. 1998). A following study showed that this 
protection was due to a cell cycle arrest in G1 and cell cycle progression by spermidine was a 
necessary event for the activation of apoptosis by the sugar (Monti et al. 1999). In human 
melanoma cells, polyamine-analog treatment activated the p53/p21/Rb cell cycle regulatory 
pathway leading to cell cycle arrest in MALME-3M containing the wildtype p53 but inducing 
massive apoptosis in p53-mutated SK-MEL-28 cells (Kramer et al. 1998). These studies 
implicate that cell cycle progression mediated by ODC or inappropriate expression of ODC in 
growth arrested conditions may facilitate the activation of apoptosis.
If ODC plays an active role in apoptosis, decreased ODC enzyme activity should inhibit the 
induction or progression of apoptosis. Indeed, forced degradation of ODC prevented low 
serum-induced apoptosis in human gingival fibroblasts (Tewari et al. 1998). Furthermore, 
blocking of ODC activity with the highly specific ODC inhibitor a-difluoromethylornithine 
(DFMO) inhibits apoptosis in almost all systems tested (see Table 2). It should be mentioned 
however, that DFMO treatment up-regulates other rate-limiting enzymes of polyamine 
metabolism, and that, although Put and Spd levels are decreased by DFMO, Spm levels are 
often increased.
Recent studies imply that a change in ODC activity per se is not obligatory for apoptosis. 
In anti-IgM-induced growth inhibition and apoptosis of Burkitt's lymphoma cells, ODC 
activity was increased, however, treatment with DFMO or putrescine had no effect on 
apoptosis (Lin et al. 1997). In a study by Noda et al. (1998) ischemia-perfusion damage in rat 
intestinal mucosa was accompanied by elevated ODC activity and DNA fragmentation. 
DFMO prevented the increase in ODC activity, but did not affect DNA fragmentation 
indicating that the rate of apoptosis was independent of ODC activity. In our studies on the 
role of ODC activity in TNF-induced apoptosis we found that ODC activity was increased by 
TNF. However, sensitization towards the apoptotic effect of TNF clearly was independent of 
ODC activity per se but depending on the intracellular level of spermine (Penning et al. 1998).
Cytotoxic effects of polyamines and their analogs
Polyamines have toxic effects on cells under certain conditions, i.e. in case cells are subjected 
to culture medium with high levels of polyamines or if  cells have high intracellular 
concentrations of polyamines. The in vitro cytotoxicity of Spd and Spm has been recognized 
for many years (Gahl & Pitot 1979; Allen et al. 1979). It was demonstrated that the cytotoxic 
effect of polyamines on cultured cells only occurred if ruminant serum was present in the 
culture medium, i.e. was absent if  serum from other sources was used (Allen et al. 1979). The 
cytotoxic effects of polyamines in culture medium containing ruminant serum could be 
abolished by aminoguanidine, an inhibitor of copper amine oxidases. Further research showed 
that cytotoxicity was due to serum amine oxidase, highly present in ruminant serum, which 
degrades Spd and Spm into amino aldehydes, ammonia and hydrogen peroxide, substances 
that have potential detrimental effects on cells (Tabor & Tabor 1984; Seiler 1987). 
Intracellular accumulation of polyamines stimulates polyamine catabolism and can give rise to 
the production of the cytotoxic metabolites, which in lack of detoxifying regulators can cause 
cell death. Thus, polyamine oxidation catalyzed by PAO (see Figure 1) and its subsequent 
product hydrogen peroxide have been implicated in inducing apoptotic cell death (see next 
section). However, our own studies on the in situ localization of PAO in several rat tissues 
suggest that the enzyme is present exclusively in peroxisomes in which hydrogen peroxide
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can be neutralized by peroxisomal peroxide and oxygen-radical detoxifying enzymes (Van- 
den-Munckhof et al. 1995). It has also been suggested that intracellular polyamines can be 
metabolically eliminated by cellular amine oxidases such as diamine oxidase to produce 
cytotoxic by-products (Smith et al. 1983; Seiler 1987). However, we found no in situ activity 
of a polyamine-oxidizing enzyme in rat liver, kidney and colon using non-acetylated 
polyamines as substrates (Van-den-Munckhof et al. 1995).
Several recent studies suggest that polyamines themselves and not their oxidative 
metabolites can exert toxic effects on cells (Brunton et al. 1990, 1991; Mitchell et al. 1992). 
For example, Spm was cytotoxic to baby-hamster kidney cells although the cells were cultured 
in horse serum. Aminoguanidine could only partially prevent Spm toxicity whereas inhibition 
of PAO had a potentiating effect (Brunton et al. 1991). In another study, exposure of ODC- 
overproducing HTC cells to micromolar levels of Spd and Spm caused protein inhibition and 
cell lysis, effects that were independent of oxidation processes (Mitchell et al. 1992). The 
research group of Zetter observed cell lysis of prostate carcinoma cells by in vitro 
administration of micromolar concentrations of Spm, which could be relieved up to 
millimolar levels by the use of aminoguanidine (Smith et al. 1995). In our study, we observed 
Spm toxicity in the millimolar range in human prostate carcinoma cells cultured in the 
presence of aminoguanidine and MDL72527, an inhibitor of PAO. Interestingly, cell lines 
with a more malignant phenotype were less sensitive to Spm toxicity. Also Spd appeared to be 
cytotoxic, although in a one log higher molar range (unpublished observations).
Polyamines have also been shown to be toxic in vivo (for review see Seiler 1991) but it is 
yet unclear whether polyamines themselves or their metabolites cause the toxic events. Smith 
et al. (1995) showed that injection of Spm in xenografts of a prostate carcinoma cell line 
inhibited the growth of the solid tumor. The authors concluded that the Spm, highly abundant 
in prostate, could act as an endogenous inhibitor of prostate carcinoma.
More of interest are the synthetic structural analogs of polyamines of which many have 
shown to be cytotoxic to tumor cells but relatively non-toxic to normal cells (for reviews see 
Marton & Pegg 1995; Kramer 1996). These compounds interfere with polyamine homeostasis 
by down-regulating polyamine biosynthesis and uptake, and by up-regulating polyamine 
catabolism causing a decrease of the polyamine content below levels possibly needed for cell 
survival. However, the cytotoxicity of these compounds seems to correlate better with the 
intracellular accumulation of the analogs rather than their effects on polyamine homeostasis. 
Until now, the exact mode of action of polyamine analogs remains unclear, but depletion of 
mitochondrial DNA, inhibition of cell respiration and interactions with chromatin, probably 
resulting in dysfunctional changes, have been suggested as possible mechanisms. Most 
probably these analogs replace polyamines from their cellular binding sites without being able 
to perform the survival functions of the natural polyamines. Recent studies indicate that the 
cytotoxicity of some of these analogs is actually based on their ability to induce apoptotic cell 
death (see Table 2). Treatment of human breast or lung cancer cells with the alkylated 
polyamine analogs N 1,N12-bis(ethyl)spermine (BESpm) and N 1-ethyl-N11-[(cyclopropyl)- 
methyl]-4,8-diaza-undecane (CPENSpm) led to induction of apoptosis as revealed by DNA 
fragmentation (McCloskey et al. 1996). A comparable analog N 1-ethyl-N11-[(cycloheptyl)- 
methyl]-4,8-diaza-undecane (CHENSpm) induced apoptosis in NCI H157 cells, as observed 
by cytochrome-c release, loss of mitochondrial membrane potential, caspase-3 activation, 
PARP-cleavage, G2M arrest, and DNA and nuclear fragmentation.(Ha et al. 1998a) 
Overexpression of bcl-2 completely inhibited cytochrome-c release, caspase-3 activation and 
PARP cleavage without affecting CHENSpm-induced apoptosis. A novel Spm analog, 1,12- 
diaziridinyl-4,9-diazadodecane (BIS), induced apoptosis, as measured by TUNEL, and
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enhanced radiosensitivity of the human prostate cancer cell lines PC-3 and DU-145 (Eiseman 
et al. 1998). Similar results were obtained in PC-3 and DU-145 xenografts in SCID mice.
Some studies in prostate cancer models show also cytoxicity of polyamine analogs without 
apparent induction of apoptosis. The polyamine analogs 1,9-bis(ethylamino)-5,10,15- 
triazanoadecane (BE-4-4-4-4) and bis(ethyl)norspermine (BE-3-3-3 or BENSpm, also known 
as di(ethyl)norspermine, DENSpm), were studied in prostate cancer cells in vitro (AT3.1, 
AT6, DU-145) and in vivo (PC-3 xenografts in nude mice) (Zagaja et al. 1998). Both analogs 
were cytotoxic without activation of the apoptotic pathway. In vivo, BE-4-4-4-4 inflicted an 
inflammatory response. Mi et al. (1998) tested BE-3-3-3 treatment on the growth of the 
human prostate cancer cell lines LNCaP, DU-145 and PC-3, and found no evidence of 
apoptosis on basis of the analog growth-curve kinetics. In a recent study, we measured the 
effect of BE-3-3-3 on the human prostate cancer carcinoma cell lines (JCA-1, TSU-pr1, PC-3, 
DU-145) and DU-145 xenografts (Schipper et al. 2000, chapter 8) BE-3-3-3 prevented tumor 
growth in vitro as well as in vivo, but did not induce apoptosis.
A direct role of high polyamine levels in the induction of apoptotic cell death has yet to be 
established, but excessive polyamine production can clearly cause apoptosis, at least in some 
cell systems. For instance, in ODC-overproducing L1210 cells, Spd over-accumulation 
triggered by hyposmotic shock led to the induction of apoptosis (Poulin et al. 1995). Exposure 
to ornithine and subsequent excessive accumulation of Put caused apoptotic cell death in 
ODC-overproducing mouse myeloma cells (Tobias & Kahana 1995) and rat hepatoma HTC- 
cells (Tome et al. 1994,1997). Recent studies with cycloheximide treated CHO cells showed 
that deregulated uptake of Put (Xie et al. 1997) or polyamine analogs (Hu & Pegg 1997) 
rapidly induced apoptosis irrespective of ODC activity. It has also been suggested that excess 
Put induces apoptosis by inhibition of the synthesis of the modified eukaryotic initiation factor 
5 (eIF-5A) (Tome et al. 1997; Tome & Gerner 1997). Increased levels of cytosolic Spm can 
also directly activate apoptosis independent of PAO (Stefanelli et al. 1998,1999). Exposure of 
HL60 cells to Spm triggered caspase activation accompanied by the proteolytic processing of 
procaspase-3, PARP and gelsolin and an accumulation of cytochrome-c in the cytosol. These 
effects were not blocked by antioxidants or inhibition of PAO but could be abolished by 
polyamine acetylation.
Decrease of polyamine levels in  apoptosis 
Down-regulation of ODC
In the previous paragraph we presented data indicating that accumulation of polyamines can 
trigger apoptosis. However, decrease of polyamine levels, especially of Spd and Spm, seems 
to be a more common feature in apoptosis (see Table 1). In this paragraph we will summarize 
evidence that decreased levels of polyamines can be due to down-regulation of polyamine 
biosynthesis.
A decline in ODC activity has been observed during apoptosis in rat prostate following 
castration, in quinon-treated rat pancreatic cells, and in interleukin-2 dependent mouse T-cells 
after cytokine withdrawal (See Schipper et al. 1999, and references herein). In most of the 
studies depicted in Table 1 ODC increases early during apoptosis but eventually polyamine 
levels mostly decreased. The inability of ODC to maintain elevated polyamine levels may be 
due to a precocious degradation of ODC during the cell death process. Proteolytic degradation 
of ODC is regulated by a unique protein, the so-called antizyme, which binds to ODC and 
facilitates its breakdown by the cytosolic 26S proteosome (Hayashi & Murakami 1995).
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Preservation of ODC activity by inhibition of the 26S proteosome prevented dexamethasone- 
induced apoptosis in thymocytes (Grassilli et al. 1998). In several mouse and human 
malignant cell lines, ectopic expression of antizyme induced tumor cell death associated with 
a rapid decline in polyamine levels (Iwata et al. 1999). Interestingly, some antizyme protein 
has been shown to be located and processed in mitochondria (Mitchell & Judd 1998) The 
function of antizyme in this organelle is puzzling since there is no ODC present. Mitochondria 
have been shown to the most important executioners of apoptosis (Wilson 1998; Susin et al.
1998). Possibly, the release of antizyme by mitochondria may facilitate degradation of ODC 
during apoptosis. Consistent with this is that the proteolytic activity observed during apoptosis 
mostly affects proteins needed for cell cycle and survival. Since polyamines are critically 
involved in cell cycle control, ODC may be one of this group of proteins that are degraded by 
apoptosis-related proteases. No evidence has yet been found for the proteolysis of ODC by 
apoptosis-related cysteine proteases known as caspases. However, a potential cleavage site 
(YVAD) for caspase-1 is present in ODC in most animals. Interestingly, the amino acid 
sequence of the very stable ODC of Trypanosoma brucei contains HVAD, a site less 
vulnerable to caspase-mediated proteolysis. It is therefore tempting to speculate that ODC is a 
potential caspase-1 target. In an in vitro assay we added purified human caspase-1 and in vitro 
transcribed/translated human ODC and subsequently analyzed ODC degradation. Under 
conditions where caspase-1 was active, ODC remained intact excluding ODC as possible 
caspase-1 target (unpublished observations). This does, however, not exclude ODC as a 
potential target for other caspases.
Involvement of polyamine catabolism
Another mechanism by which intracellular polyamine levels can be decreased is by the action 
of polyamine catabolic enzymes (see Figure 1). The rate-limiting step in polyamine catabolism 
is the acetylation of Spd or Spm catalyzed by Spd/Spm N 1-acetyltransferase (SSAT). 
Interestingly, SSAT is induced by various toxic agents and other stress stimuli (Xiao & Casero 
1995). The cell-specific cytotoxicity of polyamine analogs has been associated with SSAT 
that is highly induced by these drugs (Kramer et al. 1997). Increased expression of SSAT 
during apoptosis has also been reported (Desiderio et al. 1995; Ha et al. 1997) suggesting that 
stimulation of polyamine catabolism is a general cellular response in cell death.
Toxic compounds produced by the oxidation of polyamines might be the link between 
polyamine catabolism and apoptosis. First reports on the relationship between polyamine 
oxidation and apoptosis were made by Parchment & Pierce (1989). These authors clearly 
showed that a soluble extracellular factor triggered programmed cell death during blastocyst 
development of murine embryos. Because glutathion protected this process, it was speculated 
that H2O2 was the toxic agent herein, most likely produced as a result of polyamine oxidation. 
This means that polyamines may function as an extracellular non-toxic store for oxyradicals. 
Parchment proposed a model in which polyamines, as potential generators of oxyradicals, play 
an important paracrine role in tissue renewal, terminal differentiation and cell turnover 
(Parchment 1996). Generation of oxygen radicals can be a potential trigger of apoptosis but is 
not generally required for apoptosis (Clutton 1997). Furthermore, inhibition of polyamine 
oxidase has been effective in protecting against apoptosis in some studies but not all (Table 2).
The role of SSAT and PAO in etoposide-induced apoptosis was studied in human 
promyeloma leukemia (HL-60) cells (Lindsay & Wallace 1999). At the time of maximal 
apoptosis, enzyme activities of SSAT and PAO were not significantly changed although an 
increase of polyamine efflux and a decrease of total polyamine levels were observed. After
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long exposure with the drug, SSAT and PAO activities were augmented whilst polyamine 
efflux and the polyamine depletion further increased. We observed a similar, relatively late, 
induction of SSAT in calcium-ionophore induced apoptosis of prostate cancer cells (see 
chapter 11). These result suggest that polyamine catabolism is associated with the later, 
possibly necrotic, stages of apoptosis.
Transglutaminase-mediated actions
Several recent studies indicate that transglutaminase-mediated cross-linking of proteins is an 
important irreversible event in various cell death and apoptosis pathways (for reviews see 
Fesus et al. 1996; Melino & Piacentini 1998). The physiological role of transglutaminase 
activity in the dying cell is most obviously to cross-link cytoplasmic and membrane proteins 
into stable protein polymeric structures. The resistance to chemical attack or mechanical 
disruption of these protein structures can give dead cells their specialized function (in 
terminally differentiated cells) or prevent the leakage of potentially harmful cell contents (in 
cells dying by apoptosis). Polyamines have been shown to serve as physiological amine donor 
substrates for transglutaminases resulting in bis(-glutamyl) polyamine cross bridges between 
proteins and/or covalent incorporations of polyamines into proteins (Folk et al. 1980).
Data from Piacentini et al. (1990) suggest that polyamines are involved in the terminal 
differentiation program of epidermal cells and are incorporated in the cornified layers of the 
stratum corneum by transglutaminase. Interestingly, high levels of both ODC and polyamines
are found in the layers of the epidermis where apoptotic or terminally differentiated cells are
1 8located (Verrando et al. 1987). High levels of N -N -bis(-glutamyl)spermidine have been 
detected in the insoluble protein fraction isolated from cultured mouse keratinocytes 
(Piacentini et al. 1988), human callus (Beninati & Folk 1988), and in apoptotic bodies from
hepatocytes (Fesus et al. 1989). Piacentini et al. (1991) were able to show that retinoic acid
1 8increased apoptosis, tissue-type transglutaminase (tTGase) activity and the number of N -N - 
bis(-glutamyl)polyamine cross-links, while treatment with DFMO had the opposite effect on 
these parameters.
Based on this data it is tempting to speculate that polyamines and transglutaminase 
participate in a coordinated way in cell death. Increase of putrescine biosynthesis as observed 
in several death pathways (see Table 1) could precede the expression of transglutaminase and 
protein cross-linking in which polyamines are used as substrates. An extensive use of 
polyamines in the transglutaminase-mediated cross-linking of proteins could explain the 
decrease of polyamines, generally seen in cell death pathways (see Table 1).
Protective actions of polyamines against apoptosis
The down-regulation of polyamine levels observed in apoptosis models suggest a protective 
role against apoptosis of Spd or Spm or both. First evidence was reported by Gilad et al. 
(1985) who showed that polyamine treatment protected against programmed cell death in 
early development of the rat brain. Protection by polyamines was also observed in ischemia- 
induced neuronal cell death in gerbil forebrain (Gilad & Gilad 1991). In cultured rat cerebellar 
neurons polyamines protected against caspase-3 mediated apoptosis induced by decreasing the 
KCl concentration in the medium (Harada & Sugimoto 1997). The best protection was by 
Spm whereas Put was not effective. Activation of caspase-3 preceded apoptosis and Spm 
prevented this increase suggesting that Spm acts upstream of caspase-3 like proteases.
Exogenous Spm administration also protected against apoptosis in glucocorticoid-treated 
thymocytes (Desiderio et al. 1995), human tumor cells exposed to selenomethionine (Redman
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et al. 1997) and etoposide-treated human promyeloma leukemia cells (Lindsay & Wallace
1999). We have investigated the role of polyamines in anti-Fas- and TNF-mediated apoptosis 
in several human and murine cell lines and found that intracellular polyamine levels decreased 
during apoptosis whereas DFMO protected against the apoptotic effects of anti-Fas and TNF 
(Penning et al. 1998). This protection was not caused by an effect on ODC itself, but rather 
due to its increasing effect on intracellular levels of Spm. Exogenous addition of Spm also 
protected against apoptosis but only if Spm was added together or shortly after TNF treatment.
Studies with inhibitors of the Spm biosynthetic enzyme S-adenosylmethionine 
decarboxylase (SAMDC) support the idea that Spm has a role in the cellular resistance to 
apoptotic cell death (see Table 2). The SAMDC- inhibitors MGBCP and MGBG were able to 
induce apoptosis in cancer cell lines (Redman et al. 1997; Kaneko et al. 1998; Satoh et al. 
1999; Hashimoto et al. 1999) MGBCP inhibited tumor growth of MRK-nu-1 cells in a dose- 
dependent manner as the polyamine levels decreased (Kaneko et al. 1998). This was due to 
MGBCP-induced apoptosis as measured with membrane blebbing, chromatin condensation, 
and DNA fragmentation and flow cytometric analysis. Exogenously added Spm did only 
partially prevent MGBCP-induced apoptosis. As comparable drug, MGBG, induced apoptosis 
via a p53-independent mechanism in three cell lines (Raji, Ramos and Daudi) derived from 
Burkitt’s lymphoma, prostate carcinoma (PC-3) and breast cancer (MCF-7) (Davidson et al. 
1998). This synthetic polycarbonyl derivative causes uncoupling of oxidative phosphorylation. 
MGBG increased the sensitivity of thymocytes to apoptotic cell death (Brune et al. 1991), and 
MGBG or CGP48664a greatly sensitized TNF or anti-Fas-induced apoptosis in different 
human and murine cancer cells (Penning et al. 1998).
The nature of the protective effect of Spm is not well understood but several mechanisms 
have been suggested, e.g. inhibition of endonucleases (Ribeiro & Carson 1993), stabilization 
of DNA (Brooks 1995; Basu et al. 1997) or protection DNA against oxidative stress (Khan et 
al. 1992; Muscari et al. 1995; Dypbukt et al. 1994; Ha et al. 1998b). Conclusions based solely 
on DNA fragmentation as criterion for the effects of Spm on apoptosis might be less valid 
since Spm can artificially affect DNA fragmentation assays (Snyder et al. 1996).
Recently, polyamines were shown to act as endogenous modifiers of inward rectifying K+- 
channels. For recent reviews about this, the reader is referred to Williams (Williams 1997). 
The suggestion that Spm somehow protects by means of interfering in the K+-homeostasis is 
rather straightforward in view of the observations by Walev et al. (1995) and Perregaux and 
Gabel (1994). These two groups showed that depletion of intracellular K+ enhances 
proteolytic processing of pIL-1ß into the biologically active mIL-1ß. This suggests that a 
decrease of intracellular K+ activates interleukin-1ß converting enzyme, now called caspase-1, 
although the effect on other pIL-1ß processing enzymes cannot be excluded. Furthermore, 
several papers suggested that low potassium leads to the activation of caspase-3 as measured 
by procaspase-3 proteolysis and fluorometric assays (Bortner et al. 1997; Tanaka et al. 1998; 
Miller et al. 1997). Since the activation of caspases is a critical event in apoptosis, Spm- 
mediated interference in the K+-homeostasis may well affect apoptosis. We have recently 
shown that spermine modulates cytokine-induced apoptosis (Penning et al. 1998) and that 
lowering of intracellular potassium sensitizes human and rodent tumor cell lines towards 
TNF-induced apoptosis.(Penning et al. 2000). Therefore, it is well conceivable that TNF- 
receptor triggering leads to a reduction in intracellular spermine levels affecting intracellular 
potassium concentration, followed by enhanced caspase activity and finally increased cell 
death.
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A re polyamines metabolic regulators of apoptosis?
There is substantial evidence that polyamines are importantly involved in apoptosis. Changes 
in polyamine pools and the activities of their metabolic enzymes are consistent observations in 
studies of apoptotic cell death. In addition, manipulating polyamine homeostasis by either 
enzyme inhibitors, polyamine analogs or exogeneously added polyamines, has profound 
effects on the rate of cell death. However, it is difficult to draw general conclusions about the 
action mechanisms of polyamine in apoptosis since polyamines have been associated with 
induction, sensitization as well as protection against apoptosis. The difference in results of the 
studies reviewed here might be due to the variability that can exist between cell systems 
and/or their metabolic (and apoptotic) pathways. However, it is also possible that polyamines 
can perform multiple functions in the cell and can participate at several levels in the process 
of apoptosis. Derived from the studies reviewed here, a composite view by which polyamines 
and shifts in their cellular concentrations may contribute to apoptosis in connection with cell 
cycle events is presented in Figure 2.
Although the working mechanisms of polyamines in apoptosis are still inconclusive, it is 
obvious that excessive levels as well as extremely low levels of these highly charged 
molecules interfere with their specific cellular interactions and affect their important 
physiological activities. Subsequently, improper functioning of polyamines will interfere with 
the cell cycle and/or eventually lead to the activation of cell death programs depending on the 
biological settings. In a similar way, polyamine analogs may evoke apoptosis by interfering 
with the functional cellular sites of polyamines.
Although induction of ODC and accumulation of polyamines levels have been observed 
during apoptotic cell death, at least in some cell systems, the real physiological significance of 
polyamine synthesis may reside in cell cycle control and cell survival. Polyamine synthesis is 
normally rapidly and transiently increased as a result of growth promoting stimuli and 
essential for cell cycle transition. Therefore, the early induction of ODC during apoptosis may 
be related to the progression of the cell into a cell cycle phase until a checkpoint is reached 
from where apoptosis is triggered as a result of negative growth factors or cell death-inducing 
signals. Alternatively, in conditions where apoptosis is inhibited and/or in co-operation with 
genetic lesions, constitutive ODC expression can lead to cell transformation and deregulated 
cell growth as observed in recent studies (Auvinen et al. 1997; Shantz & Pegg 1998; Tabib & 
Bachrach 1998).
Polyamine levels may actually decrease during the apoptotic process. It would explain the 
paradoxical decrease of polyamines after initial induction of ODC activity and putrescine 
production as observed in several studies. The decrease of polyamine levels can be due to 
degradation of ODC, incorporation of polyamine into proteins by transglutaminase, polyamine 
catabolism and/or polyamine efflux. All these processes could actively or passively contribute 
to the execution of apoptotic cell death.
It is well conceivable that minor levels of polyamines may actually promote apoptosis for 
the following reasons. First, depletion of polyamines can lead to cell cycle arrest or apoptosis 
by affecting the p53/p21/Rb cell cycle regulatory pathway (Kramer et al. 1998; Li et al. 1999; 
Ray et al. 1999). Second, polyamines are important in regulation of ion transport and the 
stabilization of important cellular components such as cell membranes and chromatin 
structures. Therefore, depletion of polyamine levels might induce destabilization of important 
cell structures, leading to loss of cell integrity and finally inducing cell death. The observation 
made in several studies that exogeneously added polyamines protects against cell death favors 
the idea of polyamines being important in processes needed for cell viability and cell survival.
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Figure 2. Schematic presentation o f the possible different pathways by which polyamine levels can mediate apoptosis in 
connection with cell cycle events. See in text for details
Modulation of chromatin structure, regulation of ion channels, protection against oxidative 
stress as well as production of oxygen radicals are recurring themes in studies to elucidate the 
mechanisms by which polyamines might control the process of apoptosis. The variety of 
factors which can induce polyamine production and the multiple functions that polyamines 
display in cellular physiology makes them obvious candidates as important cellular regulators 
of cell proliferation as well as cell death. It is becoming more and more evident that the 
polyamine system is part of tightly regulated control machinery, which at any time takes final 
decisions in the choice between growth, survival, differentiation or death of a cell.
The growing awareness of the importance of polyamines in cell kinetic behavior will 
stimulate the interest in the polyamine system as a potential target for chemotherapeutic 
intervention in the treatment of cancer and other diseases.
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A bstract
Rat/mouse T cell hybridoma-derived PC60 R55/R75 cells were used as a model to study 
tumor necrosis factor (TNF)-induced apoptosis. The role of ornithine decarboxylase (ODC) 
activity and polyamines in this process was investigated. In PC60 R55/R75 cells, TNF- 
induced ODC activity was completely suppressed by externally added spermine (Spm). TNF 
decreased the intracellular levels of the three polyamines Spm, spermidine (Spd) and 
putrescine (Put). A reduction of the intracellular [Spm] with MGBG, CGP48644a, or 
DENSpm, clearly sensitized the cells towards the apoptotic TNF. Conversely, an increase in 
intracellular [Spm] with DFMO or externally added Spm reduced cellular sensitivity. Similar 
results were obtained with the human cell lines Kym 39A6 (rhabdomyosarcoma), HeLaH2I 
(cervix carcinoma) and U937 (histocytoma) after TNF treatment and after anti-Fas treatment 
of HeLaH2I, U937 and CEM-CM3 (human T-cell line). These results suggest that a decrease 
of intracellular Spm levels rather then ODC activity per se is involved in the apoptotic 
pathway induced by TNF or anti-Fas.
Keywords: tumor necrosis factor / anti-Fas / apoptosis/ polyamines / spermine / polyamine 
inhibitors
I ntroduction
Apoptosis or programmed cell death is a genetically regulated, self-destructive response of 
cells (recent reviews Martins and Earnshwa 1997; Nagata 1997). Characteristics of apoptosis 
include chromatin condensation, DNA fragmentation and membrane blebbing. Failure of 
apoptosis can lead to auto-immune diseases, or to carcinogenesis and further outgrowth of 
cancer and to chemotherapeutic-resistant cells. Apoptosis can be induced e.g. by cytokines, 
(lack of) growth factors or by different chemotherapeutics.
Tumor necrosis factor (TNF), mainly produced by activated macrophages, is a cytokine 
with a broad spectrum of biological activities. These effects range from defense against viral, 
bacterial and parasitic infections to immunoregulatory responses and the induction of cell 
death (reviewed in Beyaert and Fiers 1994). The pleiotropic character is due to the fact that 
virtually all cells express receptors for TNF. Two types of receptors have been cloned with 
molecular masses of about 55 kDa (R55) and about 75 kDa (R75), both belonging to the nerve 
growth factors superfamily (for reviews see Smith et al. 1994; Vandenabeele et al. 1995a). 
Most responses are mediated by R55, but in T-cells a role for R75 has been found (Tartaglia et 
al. 1993; Vandenabeele et al. 1992). There is strong evidence that receptor clustering is the 
mechanism of TNF action (Van Ostade et al. 1991; Declercq et al. 1995). Despite intensive 
research, the intracellular mechanisms leading to TNF-induced cell lysis or cytokine 
production are not fully understood (Beyaert and Fiers 1994).
The involvement of G-proteins, different phospholipases, sphingomyelinases, kinases, 
proteases and phosphatases in various TNF functions has been described (reviewed by Vande­
nabeele et al. 1995a; Tracey and Cerami 1994; Heller and Kroenke 1994). Another member of 
the TNF/NGF receptor superfamily is the Fas/APO-1 receptor, which is a major regulator of 
apoptosis in vivo. The Fas/APO-1 receptor cDNA encodes a 45 kD glycoprotein with three 
cysteine-rich domains. Upon crossreacting with the anti-Fas/APO-1 MoAb, or with Fas­
ligand, cell killing is induced in a large number of cells (Schulze-Osthoff 1994). Although the 
TNF receptor and Fas/APO-1 receptor belong to the same TNF/NGF receptor superfamily the 
mechanisms by which these receptors transduce their signals are not entirely overlapping.
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The activation of ICE-like proteases in both TNF and anti-Fas-induced apoptosis was 
published independently by four groups (Enari et al. 1995; Miura et al. 1995; Los et al. 1995; 
Tewari and Dixit 1995). On the other hand, studies in L929 fibrosarcomas overexpressing 
human Fas/APO-1, clearly showed that TNF and anti-Fas induced different patterns of cell 
death viz. necrosis and apoptosis respectively (Vercammen et al., submitted). Moreover, the 
signal transduction pathways leading to cell death were different (Schulze-Osthoff et al.
1994).
Because ornithine decarboxylase (ODC, EC 4.1.1.17) plays a role in c-myc-induced apoptosis 
(Packham and Cleveland 1994) and c-myc is involved in TNF-induced apoptosis of HeLa 
cells (Jaenicke et al. 1994; Klefstrom et al. 1994), we investigated the role of ODC activity in 
anti-Fas- or TNF-induced apoptosis. ODC catalyzes the first, and rate limiting, step in the 
biosynthesis of polyamines, i.e. the decarboxylation of ornithine to putrescine (see Figure 2, 
chapter 1). The role of ODC in transformation was demonstrated previously (Auvinen et al. 
1992) and ODC activity is increased in human breast, stomach and colon tumors (Tamori et 
al. 1995 and references therein). Polyamines are involved in many cellular functions including 
stimulation of DNA, RNA and protein synthesis, and stabilization of chromatin.
The addition of different drugs difluoromethylornithine (DFMO), methylglyoxal bis- 
(guanyl hydrazone) (MGBG), di(ethyl)norspermine (DENSpm), 4-amidinonidon-1-one 2'- 
amidinohydrazone (CGP48664a), known to affect ODC activity and/or intracellular polya­
mine levels, revealed that a decrease in intracellular Spm levels rather than the activity of 
ODC per se, was involved in apoptosis induced by either TNF or anti-Fas. Possible 
mechanisms of action are discussed.
Materials and M ethods
Chemicals
DFMO was purchased from Merrel Dow Chemicals (Strasbourg, France), Put and MGBG 
were obtained from Sigma (St. Louis, MO, USA). Spd and Spm are bought from Serva 
(Heidelberg, Germany). CGP48664a was obtained from Ciba-Geigy (Basel, Switzerland). 
DENSpm was synthesized according to Bergeron et al. (1988).
All chemicals were used without further purification.
Cytokines
Recombinant human and murine TNF were produced in Escherichia coli and purified to at 
least 99% homogeneity (Tavernier et al. 1987). Specific activities were 2.3 107 IU/mg and 1.4 
108 IU/mg protein, respectively, and contained less then 23 ng and 4 ng of endotoxin per mg 
of protein. Reference hTNF (code 87/650) and mTNF (code 88/532) were obtained from the 
National Institute for Biological Standards and Control (Potters Bar, UK). Anti-Fas (IgM-type 
directed against hFas-antigen, clone CH-11) was obtained from Immunotech (Marseille, 
France).
Cell lines
The mouse/rat T-cell hybridoma PC60 21.14.4 (PC 60) was provided by Dr. M. Nabholz 
(ISREC, Epalinges, Switzerland) (Conzelmann et al. 1982). PC60 R55/R75 clone 5, ex­
pressing human TNF-receptor R55 and human TNF-receptor R75, were cultured as described 
before (Vandenabeele et al. 1995b). Human HeLaH21 cells were grown in RPMI 1640
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medium supplemented with 10% newborn calfserum, Na-pyruvate, ß-mecraptoethanol and 
antibiotics. Similar culture medium was used for the other human cell lines Kym 39A6 
(rhabdomyosarcoma), U937 (histiocytoma) and CEM-CM3 (T-cell) cells. All cell lines were 
cultured in a humidified atmosphere containing 5% CO2 at 37 0C.
ODC activity
ODC activity was determined essentially the same as the procedure described before (Seely 
and Pegg 1983) on the basis of quantification of [14C]CO2 released from [14C]carboxyl- 
labeled L-ornithine.
Polyamine measurement
The [polyamine]i were determined according to Kirschbaum et al. (1994) with some 
modifications. In short, cells were deproteinized with sulphosalicylic acid (60% v/v in water). 
After centrifugation supernatant was collected and neutralized with 6N NaOH. After 
derivatization with Fmoc-ONSu in borate buffer, the samples were subjected to HPLC 
analysis.
Cell death assays
For PC60 R55/R75 cells the cell death was measured as % PI positive cells (Vandenabeele et 
al. 1995b). Cell death of HeLaH21 cells was measured with the cristal violet assay (Suffys et 
al. 1987). For Kym 39A6, U937 and CEM-CM3 cells the % of hypoploid DNA was measured 
by FACS-analysis after PI staining and freezing. All cell lines show apoptotic morphology 
(e.g. nuclear apoptotic bodies) after TNF or Fas-receptor stimulation and cleavage of PARP as 
detected on SDS-PAGE and subsequent western blotting.
Figure 1 . Polyamine biosynthesis and the sites o f drug interference. ODC (1) catalyzes the decarboxylation o f ornithine to 
Put, this enzyme is specifically inhibited by DFMO. S-adenosylmethionine is converted into decarboxylated-SAM by SAM 
decarboxylase (SAMDC) (2), which in turn is a substrate for Spd-synthase (5) and Spm-synthase (6) to form Spd and Spm 
resp. Two frequently used inhibitors o f SAMDC are MGBG and CGP48664a. The breakdown o f Spm and Spd is mediated by 
Spd/Spm N1-acetyltransferase (SSAT) (3), leading to N1-acetylspermine and N1-acetylspermidine, which are oxidized by 
polyamine oxidase (PAO) (4) to Spd and Put resp. The polyamine analog DENSpm down-regulates ODC and SAMDC 
activity and up-regulates SSAT activity.
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GM-CSF
GM-CSF concentrations were assayed in the FPCpl proliferation assay as described before 
(Vandenabeele et al. 1990). Reference GM-CSF was from the National Institute for Biological 
Standards and Control (Potters Bar, UK).
All experiments were carried out in at least two independent experiments. Standard errors 
were less then 12% for each independent experiment.
Results
In Figure 1 we have depicted the biochemical pathways leading from ornithine to Put and 
subsequently to the higher polyamines Spd and Spm. ODC (1) catalyzes the decarboxylation 
of ornithine to Put, this enzyme is specifically inhibited by DFMO. S-adenosylmethionine is 
converted into decarboxylated-SAM by SAM decarboxylase (SAMDC) (2), which in turn is a 
substrate for Spd-synthase (5) and Spm-synthase (6) to form Spd and Spm respectively. Two 
frequently used inhibitors of SAMDC are methylglyoxal bis-(guanyl hydrazone) (MGBG) and 
CGP48664a. The breakdown of Spm and Spd is mediated by Spm/Spd N 1-acetyl transferase 
(3), leading to N 1-acetylspermine and N 1-acetylspermidine, which are oxidized by polyamine 
oxidase (PAO) (4) to Spm and Put, respectively. In Table I  we have summarized the effects of 
the different drugs on ODC activity and [polyamine]i.
TNF enhances ODC activity and decreases polyamine concentrations
The effect of TNF treatment on ODC activity and intracellular polyamines levels was 
measured in PC60 R55/R75 T-cell hybridomas. TNF induced a transient increase in ODC 
activity, reaching a maximum at 4 hr treatment (Figure 2A). In the presence of 50 ^M  Spm, 
this activation is completely abrogated. The intracellular Put, Spd and Spm concentrations 
were decreased by TNF-treatment (Figure 2B). The decrease in [polyamine]i paralleled the 
induction of apoptosis. No decrease in [Spd]i and [Spm]i was observed after 4 hr TNF 
treatment, whereas an 24 hr treatment reduced the intracellular levels of Put and Spd to 
around 50% of untreated controls. The small transient increase of [Put]i by a 8 hours TNF 
treatment is most likely due to enhanced ODC activity.
I
§
200
150
100
50
0
0 4 18
Time of TNF treaiment (hrs)
I
200
150
100
50
0
□  Put □  Spd □  Spm
0 4 8 18 24 
Time of TNF treatment (hrs)
Figure 2. The effect o f TNF on (A) ODC activity and (B) polyamine concentrations o f rat/mouse PC60 R55/R75 T-cell 
hybridomas. ODC activity was measured as described in Materials and Methods. Spermine was added together with 300 
ng/ml TNF.
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Table 1. Effects on different drugs on ODC activity and intracellular polyamine concentrations
Inhibitor ODC activity [Put] [Spm ]
DFMO in h ib ited d ep le ted in c reased
DENSpm do w n reg u la ted d ep le ted d ep le ted
MGBG u p reg u la ted in c reased d ep le ted
CGP48664a u p reg u la ted in c reased d ep le ted
A decrease in [Spm], is correlated with apoptosis
To test the involvement of ODC activity in TNF-induced apoptosis, we incubated PC60 
R55/R75 T-cell hybridomas with the highly specific ODC inhibitor DFMO. This drug prote­
cted PC60 R55/R75 T-cell hybridomas against TNF-induced apoptosis (Figure 3). TNF 
treatment in the absence of DFMO resulted in about 50% apoptotic cells after 18 hours of in­
cubation. In the presence of DFMO, the amount of apoptotic cells decreased from around 40% 
(0.1 mM DFMO) to as low as 25% with the highest tolerated dose of 1 mM DFMO.
+ DFMO
T N F  (ng/ml) T N F  (ng/ml)
+ MGBG
■■is
■15
+ CGP48664a
TNF (ng/ml) TNF (ng/ml)
Figure 3. The effect o f drugs effecting ODC activity and/or intracellular polyamine concentrations on TNF-induced apoptosis 
o f PC60 R55/R75 T-cell hybridomas. Drugs were added at the same time and for the same period as TNF. Cell death was 
measured after 18 h incubation, as described in Materials and Methods
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Although DFMO is the most frequently used inhibitor of ODC activity, some other effects 
are known viz. a decrease in [Put]i and an increase in [Spm]i (Table I). Therefore we used 
DENSpm, a down-regulator of ODC activity, decreasing [Put]i, [Spd]i and [Spm]i (Table I). 
The Spm-analogue, DENSpm strongly enhanced TNF-induced apoptosis (Figure 3); con­
centrations as low as 100 ^M were sufficient to obtain 50% cell death at 20-fold lower TNF- 
concentrations. The DFMO and DENSpm studies suggested that changes in [Spm]i were 
important mediators of cellular sensitivity, rather then an increase in ODC activity. To further 
substantiate this idea, we tested other drugs effecting [polyamine]i. MGBG is an inhibitor of 
S-adenosylmethionine decarboxylase (SAMDC) and thereby reduces [Spm]i and increases 
[Put] (Regenass et al. 1994, Table I). Notably, ODC activity is increased by MGBG. As 
shown in Figure 3C, MGBG enhanced the susceptibility of PC60 R55/R75 cells to TNF- 
induced apoptosis. Half-maximal mortality was obtained with over twenty fold lower TNF- 
doses in the presence of 1 mM MGBG. CGP48664a is another inhibitor of SAMDC, and like 
MGBG, CGP48664a reduces [Put]i and increases ODC activity (Regenass et al. 1994, Table 
1). This SAMDC inhibitor clearly sensitized the cells to the apoptotic TNF-stimulus; LD50 
was decreased about 20 fold in the presence of CGP48664a to as low as 50 ^M  (Figure 3D). 
These two SAMDC inhibitors also increased the maximal amount of apoptotic cells from 
around 50% to as much as 70%. Taken together, these results suggested an important role for 
[Spm]i in cell survival, rather than the activity of ODC or a change in [Put]i.
In a final proof of this hypothesis, we tested the effect of the three different polyamines on 
TNF-induced apoptosis. Spm slightly protected against cytokine-induced apoptosis in PC60 
R55/R75 cells (Figure 4). At 50 ^M  Spm, apoptosis decreased from 50% to below 40% with 
the highest TNF-dose (300 ng/ml). At 30 ng/ml of TNF, apoptosis decreased from 20% (no 
Spm) to below 5% in the presence of 50 ^M  Spm. Spd was even less protective and Put did 
not protect at all against TNF-induced apoptosis (data not shown). Figure 5 shows that the 
protection with Spm against the TNF-induced apoptosis is only observed if Spm is added 
together with or shortly after (4hr) cytokine addition. If Spm was added later than 4 hr after 
TNF addition, the protective effects rapidly disappeared.
TNF(ng/ml)
Figure 4. The effect o f spermine on TNF-induced apoptosis o f PC60 R55/R75 T-cell hybridoma. Experiments were 
performed as described in the legend o f Figure 3.
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Sensitization caused by a decrease of[Spm]i is a general phenomenon
To test if  these observations were a peculiarity of PC60 R55/R75 cells, we repeated the 
experiments in other cell lines. Although less pronounced then in PC60 R55/R75 cells, 
sensitization with MGBG was observed in all three human cell lines treated with TNF: 
HeLaH21 cells, U937 cells and Kym 39A6 cells (Table 2). Sensitization with MGBG was not 
only observed in TNF treated cell lines but also in anti-Fas treated HeLaH21, U937 and CEM- 
CM3 cells. Like with MGBG, treatment with the other SAMDC inhibitor CGP48664a always 
resulted in enhanced cell death for all experimental setups. As a decrease in [Spm]i with 
MGBG or CGP48664a consistently sensitized the cells, we tested whether addition of Spm 
protected against TNF or anti-Fas treatment. This indeed turned out to be the case, as in 
HeLaH21 (both TNF and anti-Fas), U937 (both TNF and antiFas), Kym 39A6 (TNF) and 
CEM-CM3 cells (anti-Fas) reduced sensitivity was observed. These observations clearly 
showed that sensitization caused by a decrease in [Spm]i is a general phenomenon.
Time (hr) o f Spm addition a fter start TNF treatment
Figure 5. The effect time intervals between the addition o f TNF and spermine
TNF-induced cytokine production is mediated by a decrease in [Spm]i
Next to the apoptotic signal, the cytokine TNF leads to cytokine production in PC60 R55/R75 
cells. Therefore, we measured the effects of some [Spm]i-effecting drugs on TNF-induced 
GM-CSF release. Figure 5 shows that MGBG, DENSpm or CGP48664a enhanced TNF- 
induced GM-CSF release from PC60 R55/R75 cells. The strongest enhancement was caused 
by MGBG where the GM-CSF levels are doubled as compared to TNF-treatment alone. The 
effect of the other drugs was less pronounced, maximal stimulation was around 50%. 
Putrescine did not affect this release, whereas Spd, Spm or DFMO were too toxic in this 
bioassay. TNF-induced cytokine production can't be measured in U937, HeLaH21 and CEM- 
CM3 cells because apoptosis in induced in the presence of ActD.
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Discussion
TNF-induced activation of ODC has been reported before (Endo et al. 1988; Donato et al. 
1991). Based on the effects of DFMO the authors suggested that ODC has antiproliferative ac­
tivities. It was unclear what caused the antiproliferation: reduced proliferation or enhanced 
apoptosis. We investigated the role of ODC in apoptosis because ODC plays a role in c-myc- 
induced apoptosis (Packham and Cleveland 1994) and c-myc is known to be involved in TNF- 
induced apoptosis of HeLa cells (Jaenicke et al. 1994; Klefstrom et al. 1994). After TNF 
treatment, the ODC activity increased (Figure 2) and this increase was completely prevented 
by externally added Spm (Figure 2), comparable with previous results (Endo et al. 1988; 
Donato et al. 1991).
TNF(ngZm l)
Figure 6. The effect o f MGBG, BENSpm, CGP48664a on TNF-induced GM-CSF release from PC60 R55/R75 T-cell 
hybridoma. GM-CSF concentrations were measured after 40 h incubation in the presence o f TNF with the drugs.
To investigate the role of ODC activity in apoptosis, we added different drugs affecting 
ODC activity (Figure 3). The three sensitizing drugs, DENSpm, MGBG and CGP48664a had 
different effects on ODC activity (decreased, increased and increased, respectively). On the 
other hand, strong protection against the apoptotic triggering is observed with DFMO 
(inhibition of ODC), whereas complete inhibition of ODC activity with Spm resulted in a 
small protection. Thus, these observations clearly argued against an important role for ODC in 
TNF-induced apoptosis.
As shown here, and described before under completely different experimental conditions, 
apoptosis is accompanied by a decrease in polyamines levels (Grassilli et al. 1995; Desidero et 
al., 1995; Schipper et al., 1995 see Table 1, chapter 9). Whether the decrease was a result or a 
cause of apoptosis was further investigated in our experiments. A causal relationship between 
a decrease in [Put]i and apoptosis was excluded because DFMO and Spm decreased [Put]i and 
decreased cell death but DENSpm, which also decreased [Put]i, enhanced cell death. A 
decrease in [Spm]i with DENSpm, MGBG or CGP48664a always resulted in enhanced cell 
death. Moreover, an increase in [Spm]i (with DFMO or externally added Spm) always resulted 
in reduced cell death. Therefore, our cytotoxicity data showed that a decrease in [Spm]i rather 
than enhanced ODC activity per se, is correlated with apoptosis. The protection with Spm 
against cell death has been described in ischemia-induced damage (Brune et al. 1991; Gilad 
and Gilad 1992). To our knowledge, our observations are the first report in which Spm 
protected against apoptosis induced by naturally occurring immune-modulators. This protec­
tion is a rather general phenomenon, because the cells used in our study are of both human 
and rodent origin.
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Table 2. The effect o f spermine,CGP46884a or MGBG on cytokine-induced apoptosis in different cell lines
Cell line (species) T re a tm e n t Spm MGBG CGP48664a
PC60 R55/R75 (r/m) TNF + + - - -
HelaH21 (h) Anti-Fas/ActD + + - - -
HelaH21 (h) TNF/ActD + + - - -
U937 (h) Anti-Fas/ActD + + - _
U937 (h) TNF/ActD + + - _
Kym39A6 TNF + - - ND
CEM-CM3 Anti-Fas/ActD + - - ND
Cell death was measured after 18 h incubation in the presence o f cytokines. Spermine, MGBG or CGP48664a were present 
during the cytokine incubation. + + protection obtained with drug doses equal to or lower than 50 pM Spm; + protection 
obtained with doses between 50 pM  and 300 pM  Spm; - - sensitization obtained with doses equal to or lower than 25 pM  
MGBG or CGP46884a; - sensitization obtained with doses between 25 pM and 250 pM  MGBG or CGP46884a; ND , not 
determined
Our observations are in contrast to recently published work, which showed that 
overexpression of ODC (Packham and Cleveland 1994; Poulin et al. 1995) or intracellular 
accumulation of Put (Tobias and Kahana 1995) can lead to apoptosis. However, their 
conclusions are based upon data obtained in overexpression systems, that do not necessarily 
reflect in vivo processes. Evidence that the oxidation products produced from polyamine 
catabolism are associated with apoptosis has been described (Parchment 1993). Parchment 
proposed a model in which polyamines, as potential generators of reactive oxygen species, 
play an important paracrine role in tissue renewal, terminal differentiation and cell turnover. 
However, inhibition of polyamine oxidase has not been effective in protecting against 
apoptosis in studies so far (Poulin et al. 1995; Schipper et al. 1995). In our study, inhibition 
of polyamine catabolism with MDL72527 did not have a significant effect on TNF-induced 
apoptosis in PC60 R55/R75 cells (data not shown).
Conclusions solely based on the effects of externally added chemicals have certain 
drawbacks. First, little is known about the intracellular concentrations and, second, non­
specific side effects can occur. Concerning the first point of criticism, the polyamines and 
drugs used in this study are known to be taken up rapidly by cells (Regenass et al. 1994). Non­
specific side effects of the drugs can never be excluded completely, however, since we have 
used a total of 4 chemicals and 3 naturally occurring compounds, it is very unlikely that the 
sensitization would be caused by a so far unknown overlapping mechanism. We do not expect 
an artefact in the cell death assays induced by changes in [Spm]i (Snyder et al. 1996), because 
we have used three different methods to measure apoptosis, depending on the cell type 
studied.
The mechanism by which Spm reduced the cytotoxicity and, on the other hand, a reduction 
of [Spm]i sensitized apoptosis, is not clear. An altered interaction of the cytokine with its 
cellular receptor is unlikely for two reasons. First, in an in vitro binding study, we have shown 
that polyamines do not affect binding of TNF to its receptor (data not shown). In several cell 
lines, sensitization is observed in the presence of ActD (Table 2), thus independent of 
macromolecular synthesis. Therefore, it is unlikely that sensitizing drugs mediated their 
effects by increasing the level of receptor molecules. Because no causal relationship between 
ODC activity and cell death was observed, the protection caused by Spm is not mediated by 
an inhibition of ODC activity.
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Spm is important in stabilizing DNA and chromatin structure (Brooks 1994; Basu et al. 
1997). Therefore, a decrease in [Spm]i could induce an unstable and more open structure of 
the nucleosomal complex, making it more accessible for DNA fragmentation. Because DNA 
fragmentation is an early event in apoptosis, this could explain why protection is only 
observed if polyamines are present in the first hours of the induction of apoptosis (Figure 5). 
Interference of spermine with the DNA ladder measurements makes it impossible to directly 
test this hypothesis (Snyder et al. 1996). Recently, polyamines were shown to act as 
endogenous modifiers of inward rectifying K+-channels (Lopati et al. 1994; Ficker et al. 1994; 
Fakler et al. 1995; Forsythe 1995). Although there is no evidence for the existence of such 
channels in PC60 R55/R75 cells, these observations may offer another explanation for the 
protection by Spm. Recently, two papers clearly showed the involvement of cytochrome c 
release from the mitochondria into the cytoplasm as an important event in apoptosis (Yang et 
al, 1997; Kluck et al. 1997). The suggestion that Spm somehow protected by means of 
interfering in the K+-homeostasis or at the level of mitochondrial permeability transition pores 
is currently under investigation.
In summary, these results argue for an important role of Spm in cellular resistance against the 
cytotoxic effects of cytokine-receptor stimulation. Because cell death (Figures 3-5, Table 2) 
and GM-CSF (Figure 6) release are affected by MGBG, DENSpm or CGP48664a, it is 
expected that Spm is involved upstream from the point where TNF-triggered apoptosis and 
cytokine production diverge. This early effect would explain why Spm is only effective in 
suppressing apoptosis if  added together with, or shortly after TNF receptor stimulation. It 
remains to be seen if these sensitizing drugs will also affect the antitumor-effect of TNF on 
tumor-bearing nude-mice.
ACKNOWLEDGEMENTS
The authors wish to thank DW Eib, M Vandecasteele and W Burm for editorial and technical 
assistance. Dr. M. Nabholz (ISREC, Epalinges, Switzerland) is acknowledged for making 
available the T cell hybridoma PC60 21.14.4. DFMO and CGP48664a are kindly provided by 
Merell Dow and Ciba-Geigy resp. E. Otten and R. Rutten are acknowledged for HPLC 
analysis of the polyamines and for synthesis of DENSpm respectively.
References
Auvinen, M., A. Paasinen, L.C. Andersson, and E. Holtta. 1992. Ornithine decarboxylase activity is critical for 
cell transformation. Nature 360:355.
Basu, H.S., I.V. Smirnov, H.F. Peng, K. Tiffany, and V. Jackson. 1997. Effects of spermine and its cytotoxic 
analogs on nucleosome formation on topologically stressed DNA in vitro. Eur. J. Biochem. 243:247. 
Bergeron, R.J., A.H. Neims, J.S. McManis, T.R. Hawthorne, R. Bortell, and M.J. Ingeno. 1988. Synthetic 
polyamine analogues as antineoplastics. J. Med. Chem. 32:1183.
Beyaert, R., and W. Fiers. 1994. Molecular mechanisms of tumor necrosis factor-induced cytotoxicity; what we 
do understand and what we do not. FEBS Lett 340:9.
Bolkenius, F.N., P. Bey, and N. Seiler. 1985. Specific inhibition of polyamine oxidase in vivo is a method for the 
elucidation of its physiological role. Biochim. Biophys. Acta 838:69.
Brooks, W.H. 1994. Polyamine involvement in the cell cycle, apoptosis, and autoimmunity. Medical Hypotheses 
4:331.
Brune, B., P. Hartzell, P. Nicotera, and S. Orrenius. 1991. Spermine prevents endonuclease activation and 
apoptosis in thymocytes. Exp. Cell Res. 195:323.
169
Polyamines and TNF-induced apoptosis
Conzelmann, A., P. Corthésy, M. Cianfriglia, A. Silva, and M. Nabholz. 1982. Hybrids between rat lymphoma 
and mouse T cells with inducible cytolytic activity. Nature 298:170.
Declercq, W., P. Vandenabeele, and W. Fiers. 1995. Dimerization of chymeric erythropoietin/75 kDa tumour 
necrosis factor (TNF) receptors transduces TNF signals: necessity for the 75 kDa-TNF receptor transmem­
brane domain. Cytokine 7:701.
Desiderio, M.A., E. Grassilli, E. Bellesia, P. Salomoni, C. Franceschi. 1995. Involvement of ornithine 
decarboxylase and polyamines in glucocorticoid-induced apoptosis of rat thymocytes. Cell growth Diff 
6:505.
Donato, N.J., J. Rotbein, and M.G. Rosenblum. 1991. Tumor necrosis factor stimulates ornithine decarboxylase 
activity in human fibroblasts and tumor target cells. J. Cell Biochem. 46:69.
Enari, M., H. Hug, and S. Nagata. 1995. Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 
375:78.
Endo, Y., K. Matsushima, K. Onozaki, and J.J. Oppenheim. 1988. Role of ornithine decarboxylase in the 
regulation of cell growth by IL-1 and tumor necrosis factor. J. Immunol. 141:2342.
Regenass, U., H. Mett, J. Stanek, M. Mueller, D. Kramer, and C.W. Porter. 1994. CGP48664, a new S- 
adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity. 
Cancer Res. 54:3210.
Fakler, B., U. Brandle, E. Glowatzki, S. Wiedemann, H-P. Zenner, and J.P. Puppersberg. 1995. Strong voltage- 
dependent inward rectification of inward rectifier K+ channels by intracellular spermine. Cell 80:149.
Ficker, E., M. Taglialatela, B.A. Wible, C.M. Henley, and A.M. Brown. 1994. Spermine and spermidine as 
gating molecules for inward rectifier K+ channels. Science 266:1068.
Forsythe, I.D. 1995. A physiological function for polyamines? Current Biology 5:1248.
Gilad, G.M., and V.H. Gilad. 1992. Polyamines in neurotrauma. Ubiquitous molecules in search for a function.
Biochem. Pharmacol. 44:401.
Grassilli, E., M.A. Desiderio, E. Bellesia, P. Salomoni, F. Benatti, and C. Franceschi. 1995. Is polyamine 
decrease a common feature of apoptosis? Evidence from gamma-rays and heat shock-induced cell death.
Biochem. Biophys. Res. Commun. 216:708.
Hayashi, S., and Y. Murakami. 1995. Rapid and regulated degradation of ODC. Biochem. J. 306:1.
Heller, R.A., and M. Kroenke. 1994. Tumor necrosis factor receptor-mediated signaling pathways. J. Cell Biol. 
126:5.
Jaenicke, R.U., F.H.H. Lee, and A.G. Porter. 1994. Nuclear c-myc plays an important role in the cytotoxicity of 
tumor necrosis factor alpha in tumor cells. Mol. Cell. Biol. 14:5661.
Kirschbaum, J., B. Luckas, and W.D. Beinert 1994. Precolumn derivatization of biogenic amines and amino 
acids with 9-fluoronylmethyl chloroformate and heptylamine. J. Chromatogr. 661:193.
Klefstrom, J., I. Vaestrik, E. Saksela, J. Valle, M. Eilers, and K. Alitalo. 1994. c-Myc induces cellular 
susceptibility to the cytotoxic action of TNFa. EMBO J. 13:5442.
Kluck, R.M., E. Bossy-Wetzel, D.R. Green, and D.D. Newmeyer. 1997. The release of cytochrome c from 
mitochondria: a primary site for bcl-2 regulation of apoptosis. Science 275:1132.
Lopati, A.N., E.N. Makhina, and C.G. Nichols. 1994. Potassium channels block by cytoplasmic polyamines as 
the mechanism of intrinsic rectification. Nature 372:366.
Los, M., M. Van de Craen, L.C. Penning, H. Schenk, M. Westendorp, P.A. Baeuerle, W. Droege, P.H. Krammer, 
W. Fiers, and K. Schulze-Osthoff. 1995. Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated 
apoptosis. Nature 375:81.
Martins, L.M., and W.C. Earnshaw. 1997. Apoptosis: alive and kicking in 1977. Trends Cell Biol. 7:111.
Miura, M., R.M. Friedlander, and J. Yuan. 1995. Tumor necrosis factor-induced apoptosis is mediated by a 
CrmA-sensitive pathway. Proc Natl. Acad. Sci. USA 92:8318.
Nagata, S. 1997. Apoptosis by death factor. Cell. 88:355.
Packham, G., and J.L. Cleveland. 1994. Ornithine decarboxylase is a mediator of c-Myc-induced apoptosis. Mol. 
Cell. Biol. 14:5741.
Parchment, R.E. 1993. The implications of a unified theory of programmed cell death, polyamines, oxyradicals 
and histogenesis in the embryo. Int. J. Dev. Biol. 37:75.
170
Chapter 10
Poulin, R., G. Pelletier, and A.E. Pegg. 1995. Induction of apoptosis by excessive polyamine accumulation in 
ornithine decarboxylase-overproducing L1210 cells. Biochem. J. 311:723.
Schipper, R.G., A.A. Otten, R.G. Rutten, W.P. Lange, J.A. Schalken, A.A.J. Verhofstad. 1995. Role of 
polyamines in programmed cell death in prostatic cancer cells. Urol. Res. 23:249.
Schulze-Osthoff, K. 1994. The Fas/APO-1 receptor and its deadly ligand. Trends Cell Biol. 4:421.
Schulze-Osthoff, K., P.H. Krammer, and W. Droege. 1994. Divergent signalling via APO-1/Fas and the TNF 
receptor, two homologous molecules involved in physiological cell death. EMBO J. 13:4587.
Seely, J.E., and A.E. Pegg. 1983. Ornithine decarboxylase (mouse kidney) In Methods in Enzymol. Vol 94. H. 
Tabor and C.W. Tabor, eds. Academic Press, London p. 243.
Smith, C.A., T. Farrah, and R.G. Goodwin. 1994. The TNF receptor superfamily of cellular and viral proteins: 
activation, costimulation, and cell death. Cell 76:959.
Suffys, P., R. Beyaert, F. Van Roy, and W. Fiers. 1987. Involvement of a serine protease in tumor-necrosis- 
factor-mediated cytotoxicity. Eur. J. Biochem. 178:257.
Snyder, R.D., S.J. Vogelpohl, B.L. Baldwin, E.D. Deaton, E. Bade, and J.H. Carter. 1996. Apparent inhibition of 
apoptosis by polyamines and aminothiols in DNA fragmentation assays is artificial. Cell Death Diff. 3:323.
Tamori, A., S. Nishiguchi, T. Kuroki, N. Koh, K. Kobayashi, Y. Yano, and S. Otani. Point mutation of ornithine 
decarboxylase gene in human hepatocellular carcinoma. Cancer Res. 55:3500.
Tartaglia, L.A., D. Pennica, and D.V. Goeddel. 1993. Ligand passing: the 75-kDa tumor necrosis factor (TNF) 
receptor recruits TNF for signaling by the 55-kDa TNF receptor. J. Biol. Chem. 268:18542.
Tavernier, J., L. Franssen, A. Maremout, J. Van der Heyden, R. Mueller, M.R. Ruysschaert, A. Van Vliet, R. 
Bauden, and W. Fiers W. 1987. Isolation and expression of the genes coding for mouse and human tumor 
necrosis factor (TNF) and biological properties of recombinant TNF. In Lymphokines, Vol. 13. D.R. Webb 
and D.V. Goeddel eds. Academic Press, Orlando, FL, p 181.
Tewari, M., and V.M. Dixit. 1995. Fas- and TNF-induced apoptosis is inhibited by the poxvirus crmA gene pro­
duct. J. Biol. Chem. 270:3255.
Tobias, K.E., and C. Kahana. 1995. Exposure to ornithine results in excessive accumalation of putrescine and 
apoptotic cell death in ornithine decarboxylase overproducing mouse myeloma cells. Cell Growth Diff. 
6:1279.
Tracey, K.J., and A. Cerami. 1993. Tumor necrosis factor: A pleitropic cytokine and therapeutic target. Annu Rev 
Med. 45:491.
Vandenabeele, P., Y. Guisez, W. Declercq, G. Bauw, J. Vanderkerckhove, and W. Fiers. 1990. Response of 
murine cell lines to an IL-1/IL-2-induced factor in a rat/mouse T hybridoma (PC60): differential induction of 
cytokines by human IL-1a and IL-11 and partial amino acid sequence of rat GM-CSF. Lymphokine Res. 
9:381.
Vandenabeele, P., W. Declerq, D. Vercammen, M. Van de Craen, J. Grooten, H. Loetscher, M. Brockhaus, W. 
Lesslauer, and W. Fiers. 1992. Functional characterization of the tumor necrosis factor receptor p75 in a 
transfected rat/mouse T cell hybridoma. J. Exp. Med. 176:1015.
Vandenabeele, P., W. Declerq, R. Beyaert, and W. Fiers. 1995a. Two tumor necrosis factor receptors: structure 
and function. Trends Cell Biol. 5:392.
VandenAbeele, P., W. Declercq, B. Vanhaesebroeck, J. Grooten, and W. Fiers. 1995b. Both TNF receptors are 
required for TNF-mediated induction of apoptosis in PC60 cells. J. Immunol. 154:2904.
Van Ostade, X., J. Tavernier, T. Prange, and W. Fiers. 1991. Localization of the active site of human tumor 
necrosis factor (hTNF) by mutational analysis. EMBO J. 10:1015.
Yang, J., X. Liu, K. Bhalla, C.N. Kim, A.M. Ibrado, J. Cai, T.I. Peng, D.P. Jones, and X. Wang. 1997. 
Prevention of apoptosis by bcl-2: release of cytochrome c from mitochondria blocked. Science 275:1129.
171

Chapter 11
Polyamine metabolism and apoptosis 
in prostatic carcinoma cells
Raymond G. Schipper 1, Louis C. Penning 3,
Erwin A.C. Otten 1, Rob G. J. Rutten 1, Will P.H. Lange 1,
Jack A. Schalken 2 and Albert A.J. Verhofstad 1
1 2Department of Pathology and Urology , University Medical Centre Nijmegen,
Nijmegen, The Netherlands 
Division of Biopharmaceutics , LACDR, Sylvius Laboratory, University of Leiden,
Leiden, The Netherlands
To be  su b m itte d
Polyamines and Calcium ionophore-induced apoptosis
A bstract
Androgen ablation, the standard therapy in disseminated prostate cancer, fails to trigger 
apoptosis in androgen-independent prostatic cancer cells. Recent evidence indicates that 
polyamines, i.e. putrescine, spermidine and spermine, are associated with apoptotic cell 
death. In present study we investigated if  polyamine metabolism is involved in calcium 
ionophore-induced apoptosis in androgen-independent rat (AT-3) and human (DU-145) 
prostatic cancer cells. Treatment of cultured cells with ionomycin or thapsigargin induced 
apoptosis, which reached a maximal rate after 48 hours. Under these conditions the activity 
of ornithine decarboxylase, a key enzyme in polyamine biosynthesis, was augmented and 
intracellular levels of putrescine increased. Paradoxically, during the apoptotic process the 
levels of spermidine and spermine decreased. Treatment of prostatic cancer cells with 
ionomycin in combination with the ODC-inhibitor difluoromethylornithine DFMO or the 
polyamine analog N1,N11-di(ethyl)norspermine prevented apoptosis. The activity of the 
polyamine catabolic enzyme spermidine/spermine N1 -acetyltransferase increased relatively 
late (after 72 and 96 hours) and inhibition of polyamine degradation by MDL7252 7 had no 
effect on the rate of apoptosis suggesting that polyamine catabolism is associated with the 
late stages of apoptosis. Together, these results suggest an important role for polyamines in 
the induction and/or progression of apoptosis in prostatic cancer cells.
KEYWORDS : P olyam ines /  sp e rm in e  /  tu m o r  n ec ro s is  fac to r/ ap o p to sis  /  p ro s ta te  /  ca n ce r
I ntroduction
Disseminated prostate cancer is still a disease for which no effective therapy is presently 
available. The standard therapy used for the treatment of metastatic prostate cancer, androgen 
ablation, fails in long term due to the presence of androgen-independent prostatic cancer cells 
(Isaacs et Coffey 1981). In androgen-dependent prostatic cancer cells androgen ablation 
induces apoptosis (Kyprianou et al. 1990). Apoptosis is an active process which involves 
biochemical events (e.g. elevation of intracellular free Ca2+, expression of specific genes, 
induction of proteolytic enzymes) and morphological changes (condensation of nucleus and 
cytoplasm, fragmentation into small membrane bound apoptotic bodies) (for review see 
Fadeel et al. 1999). Androgen ablation fails to induce apoptosis in androgen-independent 
cells. However, in vitro, androgen-independent cells can be triggered by calcium ionophores 
to undergo apoptosis, i.e. the pathway needed for apoptosis is retained (Martikainen et al. 
1991). Therefore, a strong need is requested to search for a type of non-hormonal therapy 
enabling the induction of apoptosis in androgen-independent prostatic cancer cells in vivo as 
well.
Polyamines, i.e. putrescine (Put), spermidine (Spd) and spermine (Spm), are ubiquitous 
aliphatic amines that have a low molecular weight and are highly charged cations at 
physiological conditions. Evidence from in vitro as well as in vivo experiments shows that 
polyamines are intimately involved in cell proliferation and cell differentiation. Several recent 
publications now indicate that polyamines as well as compounds associated with polyamine 
catabolism are involved in apoptosis (for a review see Chapter 9). However, no unanimous 
effect of polyamine mediation has been described, i.e. they have been shown to act as 
promoting, modulating or protective agents in apoptosis. Nevertheless, it can be concluded 
that polyamines are critically involved in cellular survival which makes them suitable targets 
for therapeutic intervention that is specifically directed to cell death pathways.
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The aim of the present study is to investigate the significance of polyamine metabolism for the 
induction and/or progression of apoptosis in androgen-independent cancer cells. In these 
experiments, polyamine metabolism was examined by measuring the activity of the 
biosynthetic enzyme ornithine decarboxylase (ODC), the catabolic enzyme 
spermidine/spermine N 1-acetyltransferase (SSAT) and by determining the intracellular 
concentrations of the natural polyamines. Furthermore, we tested the effects of an inhibitor of 
ODC, e.g. difluoromethylornithine (DFMO), an inhibitor of polyamine catabolism 
(MDL72527) and a polyamine analog, N 1,N11-di(ethyl)norspermine (BE-3-3-3), on 
ionomycin-induced apoptosis.
Material and methods
Materials
DFMO and MDL72527 were supplied in courtesy of Marion Merrell Dow Pharmaceuticals 
(Strassbourg, France). Putrescine, ionomycin and thapsigargin were obtained from Sigma (St. 
Louis, MO, USA). Spermidine and spermine were bought from Serva (Heidelberg, Germany). 
BE-3-3-3 was synthesized according to Bergeron et al. (1988). FITC-labeled annexin-V was a 
generous gift of Dr. B. Schutte of the Department of Molecular Biology, University of 
Maastricht, Maastricht, the Netherlands. All chemicals were used without further purification.
Cell culture
The cell lines studied included the androgen-independent rat (AT-3) and human (DU-145) 
prostatic tumor sublines. Cells were passaged or grown in RPMI-1640 medium supplemented 
with 10 % heat-inactivated fetal calf serum (FCS, Integro BV; Zaandam, The Netherlands), 
glutamine and antibiotics.
Cell viability
Cells were plated in 96-well microtitre plates, incubated for 24 hours and subsequently treated 
with different doses with ionomycin or thapsigargin. Cell viability was measured in triplicate 
after 24, 48, 72 and 96 hours after the start of the treatment, Cell numbers were analyzed using 
a tetrazolium-based colorimetric assay (Boeringer-Mannheim, Germany) and by means of 
manual counting on at random selected fields in a Buckler counting chamber.
Apoptosis
DNA fragmentation. Cells were lysed for 2 hrs at 50 C in a nuclear lysis buffer containing 
50mM Tris pH 8.0, 300 mM NaCl, 5 mM EDTA, 15 mM MgCl2 and 1% NP40. DNA was 
precipitated with 2 volumes of absolute ethanol, followed by 30 min incubation at -  80 C, 
centrifugation at maximal speed for 30 min followed by electrophoretic analysis on 1.7 % 
agarose in the presence of ethidium bromide.
Enrichment of nucleosomes in the cytoplasm as measure for the extent of DNA 
fragmentation was measured according to Duke and Cohen (1986). Morphological analysis of 
DNA fragmentation was performed in unfixed cells using propidium iodide/bisbenzymide. 
The in situ nick translation (ISNT) technique as described by Wijsman et al. (1993) was 
performed to detect DNA fragmentation in fixed cell preparations attached to slides. 
Annexin-V staining. To measure phosphotidyl serine exposure, cells were labeled with 
annexin-V-FITC according to Van Engeland et al. (1997).
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Assays of polyamine metabolism
To investigate the effect of the calcium ionophores on polyamine metabolism AT-3 cells were 
cultured in T-25 flasks and treated with 10 ^M ionomycin, a dose that produced the maximal 
apoptotic rate in these cells. After 48 hours, cells were harvested and assayed for the enzyme 
activity of ODC and SSAT, and for polyamine content.
ODC activity was determined essentially according to the procedure described by Seely 
and Pegg (1983) on the basis o f quantification o f [14C]CO2 released from [14C]carboxyl- 
labeled L-ornithine. Enzyme activity of SSAT was measured following the incorporation of 
[acetyl-1-14C]-CoA in spermidine according to a method described by Matsui and Pegg 
(1980). Enzyme activities are expressed as pmol/min/mg protein.
Intracellular polyamine concentrations were determined by HPLC according to 
Kirschbaum et al. (1994) with some modifications. In short, cells were deproteinized with 
sulphosalicylic acid (60% v/v in water). After centrifugation supernatant was collected and 
neutralized with 6N NaOH. After derivatization with Fmoc-ONSu in borate buffer, the 
samples were subjected to HPLC analysis.
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F ig u re  1. Induction o f apoptosis in androgen-independent prostatic cancer cells by calcium ionophores. Effect o f iono­
mycin or thapsigargin on (A) cell viability o f AT-3 and DU-145 cells and (B) DNA fragmentation in AT-3 cells as revealed 
by ISNT and enrichment o f cytoplasmic nucleosomes (Enrichment factor = E405 control /  E405 treatment. Note the 
pronounced effect on cell viability after treatment with 10 jiM  ionomycin or 500 nM thapsigargin for 48 hours. The type o f 
cell death was attributed to apoptosis as revealed by the DNA fragmentation assays.
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RESULTS
Ionomycin-induced apoptosis of prostatic cancer cells
To investigate the effect of ionomycin on cell growth and cell viability we screened the 
number of viable cultured AT-3 and DU-145 cells after continuous exposure to different doses 
of ionomycin (0, 0.1, 1 and 10 ^M) or thapsigargin (5, 50 or 500 nM) for 5 days. Typical 
effects of the calcium ionophores on cell viability and DNA fragmentation are presented in 
Figure 1A/D. Results show that 10 of ionomycin as well as 500 nM of thapsigargin has a 
profound effect on the viability of AT-3 and DU-145 cells respectively after 48 hours. 
Examination of these cells clearly showed that the cells died by apoptosis as could be 
confirmed by ISNT and Annexin V staining. Furthermore, a substantial enrichment of 
nucleosomes in the cytoplasm in AT-3 cells could be detected after treatment with 10 of 
ionomycin. Figure 2 shows the effect of ionomycin treatment on ODC activity, SSAT activity 
and polyamine pools. In control cells, ODC reaches maximal activity after 48 hours. 
Treatment with 0,1 or 1 ^M ionomycin lengthened the duration of maximal ODC activity, 
whereas at concentrations of 10 ^M  ionomycin maximal ODC activity was augmented. Under 
these conditions putrescine levels increased whereas spermidine and spermine levels 
decreased (Figure 2B).
The effect of interference with polyamine homeostasis on cell growth and 
apoptosis of prostatic cancer cells
E ffect o f  DFMO, MDL72527and BE-3-3-3 cell growth and polyamine pools in AT-3 cells
To determine the dose-response effects of the polyamine inhibitors/analog AT-3 cells were 
cultured in presence of different concentrations of DFMO, MDL72 and BE-3-3-3 and assayed 
for cell viability. Figures 3A and 3C shows that DFMO and BE-3-3-3 have a cytostatic effect 
on AT-3 cells at concentrations of 10 mM and 100 ^M, respectively. MDL72527 had no 
effect on cell growth in concentrations up to 1 mM (Figure 3B). To investigate the effect of 
polyamine inhibitors/analog on polyamine pools, AT-3 cells were treated with 10 mM DFMO, 
1 mM MDL7275 and 100 BE-3-3-3 for 48 hours and assayed for polyamine 
concentrations. These results show that DFMO decreases putrescine and spermidine levels but 
increases spermine level (Figure 3A). MDL72527 had only a slight increasing effect on 
spermidine levels (Figure 3B). Treatment with BE-3-3-3 resulted in a profound decrease of the 
natural polyamines and intracellular accumulation of the polyamine analog (Figure 3 C).
E ffect o f  DFMO, MDL72527and BE-3-3-3 on ionomycin-induced apoptosis o f  AT-3 cells
Cells were treated with 10 mM DFMO, 100 ^M  BE-3-3-3 or 1 mM MDL72527 in 
combination with 10 ionomycin to induce apoptosis. As shown in Figure 4B and 4C, 
DFMO and BE-3-3-3 have a protective effect whereas MDL72527 had no effect on 
ionomycin-induced apoptosis. Similar results were obtained in DU-145, except that in this 
case the protective effect of BE-3-3-3 was less pronounced (results not shown).
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Discussion
Tumor growth is determined by the balance between cell proliferation and cell death rate. 
Therefore, successful treatment of tumors can be obtained either by lowering the rate of 
proliferation and/or raising the rate of cell death. In standard cytotoxic chemotherapy the rate 
of cell proliferation is reduced by eliminating actively proliferating cells. Unfortunately, the 
majority (i.e., > 90%) of prostatic cancer cells is not actively proliferating and thus resistant to 
standard cytotoxic chemotherapy (Nemoto et al. 1990; Bergers et al. 1995). The standard 
treatment of disseminated prostate cancer, i.e. androgen ablation therapy, is aimed to stimulate 
cell death in prostatic cancer cells. However, in the long term androgen ablation therapy fails 
since in each patient prostatic cancer cells are heterogeneous, including both androgen- 
dependent and androgen-independent cells (Isaacs et Coffey 1981). Androgen ablation 
induces a sustained elevation in intracellular free Ca2+, which, after reaching a critical level 
leads to apoptosis in the androgen-dependent prostatic (cancer) cells (Kyprianou et al. 1990). 
Martikainen et al. (1991) examined why apoptosis does not occur in androgen-independent 
cells upon androgen ablation. Their studies showed that androgen-independent cells can be 
brought into apoptosis by treatment with the calcium ionophore ionomycin inducing a 
sustained elevation of intracellular free calcium. Thus apart from the initial step all other 
components of the apoptotic cascade seem to be retained in the androgen-independent 
prostatic cancer cells.
Involvement o f polyamine metabolic enzymes in calcium ionophore-induced apoptosis
In the present study we investigated if changes occur in the polyamine metabolism in cultured 
androgen-independent prostatic cancer cells during apoptosis induced by calcium ionophores. 
Results show that in apoptosis induced by ionomycin ODC markedly increased (Figure 2A). 
Increased ODC expression has also been reported in various other in vitro studies on 
apoptosis (see chapter 9). Furthermore, blocking of ODC activity with DFMO inhibited 
apoptosis in almost all systems tested (see Table 2, chapter 9). In our study, DFMO treatment 
had also a protective effect on ionomycin-induced apoptosis.
Although induction of ODC and accumulation of polyamines have been observed during 
apoptotic cell death, at least in some cell systems, a direct role of polyamine synthesis has yet 
to be established. For instance, in our study on the role of ODC in TNF-induced apoptosis we 
found that ODC activity was increased by TNF. However, sensitization towards the apoptotic 
effect of TNF clearly was independent of ODC activity per se (chapter 10). Thus, ODC 
induction might be merely an attempt towards protection of stressed cells as was found in 
studies on the involvement of ODC in neuronal cell death (Bernstein and Muller, 1999 and 
references herein).
Evidence is merging that apoptosis and proliferation are connected and that the apoptotic 
and cell cycle machinery share common regulators. Cell cycle regulators such as c-myc, cyclin 
D3, p53, pRb, and E2F have also been implicated in apoptosis (King et al, 1998). ODC 
activity is normally rapidly and transiently induced by cell growth promoting stimuli and 
polyamines are essential for cell cycle transition. Cell cycle progression mediated by ODC or 
inappropriate expression of ODC in growth arrested conditions may facilitate the activation of 
apoptosis. Thus, the protective effects of DFMO and BE-3-3-3 on apoptosis, as observed in 
our present study (Figure 4B and 4D), might be based on their inhibiting effects on cell cycle 
progression. However, studies of Isaacs and co-workers (Kyprianou and Isaacs 1989;
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Martikainen et al. 1992; Bergers et al. 1993; Furuya et al. 1994; Lin et al. 1997) suggest that 
in androgen-independent prostatic cancer cells apoptosis can be induced in any phase of the 
cell cycle and does not necessarily require progression through the cell cycle.
The rate-limiting step in polyamine catabolism is the acetylation of spermidine or spermine 
catalyzed by Spd/Spm N 1-acetyl-transferase (SSAT). Interestingly, SSAT is induced by 
various toxic agents and other stress stimuli (Xiao and Casero 1995). Increased expression of 
SSAT during apoptosis has also been reported (Desiderio et al. 1995; Ha et al. 1997) 
suggesting that stimulation of polyamine catabolism is a general cellular response in cell 
death. Toxic compounds produced by the oxidation of polyamines might be the link between 
polyamine catabolism and apoptosis (Parchment 1996). However, in our present study 
inhibition of polyamine oxidase by MDL72527 did not alter the rate of apoptotic cell death 
induced by ionomycin (Figure 4C). Furthermore, induction of SSAT in AT-3 cells treated with 
10 ionomycin was observed after relatively long exposure times (Figure 2 A). Similar 
results were obtained in etoposide-induced apoptosis (Lindsay and Wallace 1999). These 
authors showed that at the time of maximal apoptosis, enzyme activities of SSAT and PAO 
were not significantly changed although an increase of polyamine efflux and a decrease of 
total polyamine levels were observed. After long exposure to etoposide, SSAT and PAO 
activities were augmented whilst polyamine efflux and the polyamine depletion further 
increased. These results suggest that polyamine catabolism is not involved in the initial stages 
of apoptosis but may have significance in the final stages of apoptosis.
Is apoptosis mediated by shifts in polyamine levels?
Eukaryotic cells have developed a potent regulatory machinery, which controls polyamine 
pools in a fast, sensitive and accurate manner. It is believed that these complex homeostatic 
mechanisms exist in order to maintain polyamine pool size and balance within narrow limits. 
Presumably, inappropriate polyamine levels can affect cell growth or, maybe more important, 
induce cell death (Coffino and Poznanski 1991). In the past several studies presented data 
indicating that accumulation of polyamines can trigger apoptosis. However, decrease of 
polyamine levels, especially of spermidine and spermine, seems to be a more common feature 
in apoptosis (see Table 1, chapter 9).
In spite of the induction of ODC activity and subsequent production of putrescine during 
ionomycin-induced apoptosis we observed a decrease in the levels of spermidine and 
spermine (Figure 2B). Such a paradoxical decrease of spermidine and spermine after ODC 
induction during apoptosis has also been reported in other in vitro studies (Manchester et al. 
1993; Desiderio et al. 1995; Grasilli et al. 1995; Lindsay and Wallace 1999; chapter 10). 
Notably, in vivo, ODC activity and polyamine levels are decreased following castration 
induced apoptosis of prostatic epithelial cells (Pegg et al. 1970, see Figure 1, chapter 6). 
Therefore, a decrease of polyamines rather than an increased polyamine biosynthesis might be 
an important event in apoptosis of prostatic (cancer) cells.
An explanation for the decrease of polyamines commonly seen in cell death pathways may 
be the extensive use of polyamines by transglutaminases during apoptosis. Several recent 
studies indicate that transglutaminase-mediated cross-linking of proteins is an important, 
irreversible event in various cell death and apoptosis pathways (for reviews see Fesus et al. 
1996; Melino and Piacentini 1998). Polyamines have been shown to serve as a physiological 
amine donor substrate for transglutaminases resulting in bis(-glutamyl) polyamine cross­
bridges between proteins and/or covalent incorporation of polyamines into proteins. (Folk et
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al. 1980). It is therefore tempting to speculate that polyamines and transglutaminase 
participate in a coordinated way in cell death. Increase of putrescine biosynthesis could 
precede the expression of transglutaminase and protein cross-linking in which polyamines are 
used as substrates.
The down-regulation of polyamine levels observed in most apoptosis models suggest a 
protective role against apoptosis by spermidine or spermine or both. Polyamines have been 
shown to protect against programmed cell death in embryonic development (Gilad et al., 
1985), in ischemia-induced neuronal cell death (Gilad and Gilad 1991) and against apoptosis 
in various in vitro models (See chapter 9). Studies with inhibitors of the spermine 
biosynthetic enzyme S-adenosylmethionine decarboxylase (SAMDC) support the idea that 
spermine has a role in the cellular resistance to apoptotic cell death (see Table 2, chapter 9). In 
line with this, the protective effect of DFMO in ionomycin-induced apoptosis might actually 
be based on the DFMO-induced increase in the levels of spermine (Figure 3A). This raise in 
spermine levels can be explained by the intracellular accumulation of dcSAM promoting the 
conversion of the remaining putrescine and spermidine into spermine. An argument against 
the assumption that spermine protects against ionomycin-induced apoptosis is the observation 
is that BE-3-3-3 depleted spermine (Figure 3C) but exhibited a protective effect against 
apoptosis (Figure 4D). It is however possible that BE-3-3-3 as a structural analog of spermine 
might still mimic the protective actions of spermine. The nature of the protective effect of 
spermine is not well understood but several mechanisms have been suggested, e.g. inhibition 
of endonucleases (Ribeiro and Carson 1993), stabilization of DNA (Brooks 1995; Basu et al.
1997) or protection DNA against oxidative stress (Khan, et al. 1992; Muscari et al. 1995; 
Dypbukt et al. 1994; Ha et al. 1998). Interestingly, polyamines have been shown to modulate 
mitochondrial calcium transport (McCormack 1989; Rottenberg and Marbach 1990; Jensen et 
al. 1990) and androgenic calcium fluxes (Koenig et al. 1989). Therefore, polyamines might be 
involved in the calcium-related steps of apoptosis.
In conclusion, polyamines are critically involved in apoptosis of androgen-independent 
prostatic cancer cells which makes them suitable targets for therapeutic intervention in 
(metastatic) prostate cancer. For this purpose, DFMO and BE-3-3-3 might not be suitable 
agents since they are protectors rather than effectors of apoptosis. However, other recently 
developed polyamine analogs were found to be effective inducers of apoptosis in androgen­
independent prostatic cancer cells (Eiseman et al. 1998; McCloskey et al. 2000) indicating 
that interference with polyamine homeostasis could provide a promising target for 
chemotherapy of prostate cancer.
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Summary
The three most commonly occurring natural polyamines are putrescine, spermidine and spermine. 
These aliphatic amines have a low molecular weight, a simple chemical structure and are highly 
charged cations at physiological conditions. Because of their basic character at physiological pH, 
in vitro, polyamines are able to bind to a variety of organic compounds, such as nucleic acids, 
proteins and phospholipids. Therefore, it has been suggested that in vivo polyamines are 
involved in the stabilization of these molecules and/or possibly facilitate their conformational 
shifts. Polyamine levels are markedly increased in cell proliferation and differentiation under 
normal (embryogenesis) as well as pathological (carcinogenesis, malignant cell growth) 
conditions. These observations prompted many studies on the usefulness of parameters of 
polyamine homeostasis as diagnostic or prognostic indicator in cancer. Furthermore, the 
involvement of polyamines in tumor cell growth has aroused considerable interest in the 
chemotherapeutic or chemopreventive potential of polyamine synthesis inhibitors and 
polyamine analogs. A general overview of the polyamines, the regulatory mechanisms that 
control polyamine homeostasis and the oncological aspects of interference with polyamine 
homeostasis are described in Chapter 1.
Despite extensive biochemical and molecular biological research the precise role of the 
polyamine system in cellular physiology remains to be clarified. Present knowledge on the 
biological roles is almost exclusively based on biochemical procedures applied to cell or tissue 
homogenates. Insight in the exact cellular and subcellular localization of polyamine metabolic 
enzymes might greatly contribute to the elucidation of the specific functions of polyamines in 
(tumor) cell growth.
This thesis comprises ten chapters that are divided in three parts:
Part I  describes our efforts to develop cytochemical methods for the (sub)cellular 
localization of ornithine decarboxylase (ODC) and polyamine oxidase (PAO), which are 
involved in the biosynthesis and catabolism of polyamines, respectively.
The second objective of this thesis, as outlined in Part I I  and Part I II , was to establish 
the use of polyamines as determinants of malignant cellular behavior and as potential targets 
for chemotherapy in prostate cancer.
Prostate cancer is the second cause of death by cancer in men and its incidence is 
increasing every year. In spite of all efforts, disseminated prostate cancer is still a disease for 
which no effective therapy exists. Polyamines are important factors in the growth and function 
of the prostate. Prostatic epithelial cells produce high concentrations of spermine, which is 
secreted into the semen.
It was investigated if cell growth (Part II) or (programmed) cell death (Part III) of prostate 
cancer cells can be manipulated by interfering with polyamine homeostasis.
186
Summary
Pa r t  I
Intracellularly, polyamine pool size and balance are strictly controlled depending on the 
physiological needs of the cell. Ornithine decarboxylase (ODC) is a key enzyme in polyamine 
biosynthesis. The enzyme exhibits rapid and diverse changes in biological activity as an early 
response to virtually all growth promoting stimuli to cells including that of hormones, drugs, 
growth factors, mitogens and tumor promoters. Rapid and dramatic regulation of ODC 
expression is possible because of its extremely short half-life, which varies between several 
minutes and one hour (the shortest half-live of any known enzyme).
Chapter 2 summarizes and compares the various methods (biochemical, enzyme 
cytochemical, immunocytochemical and hybridocytochemical) that have been described in 
literature for the in situ detection of ODC. Furthermore, the results obtained with these 
methods with respect to distribution patterns of ODC in tissues and cells in various organ 
systems are presented and interpreted. Differential localization patterns at the cellular level 
have been described, depending on the detection method used or on the type of cells or tissues 
that were studied. These patterns varied from exclusively cytoplasmic to both cytoplasmic and 
nuclear. Although it may be expected that ODC is heterogeneously expressed in different cell 
and tissue types, the discrepancy in localization patterns between the various studies can also 
be to due to variation in specificity and sensitivity of the detection methods used. For instance, 
the use of partially purified ODC as antigen can lead to production of antibodies with different 
specificities resulting in a possibly aspecific reactivity in the immunocytochemical procedure. 
Furthermore, inappropriate immunocytochemical procedures (such as fixation, embedding, 
and permeabilization) can lead to alterations, loss or masking of ODC epitope(s) or can cause 
aspecific binding of the antibodies to cellular components other than ODC.
In order to develop a reliable method for the immunocytochemical detection of ODC, we 
produced and characterized antibodies to ODC (Chapter 3). In collaboration with the research 
group of Prof. Dr. G.I. Tesser (Department of Organic Chemistry, Catholic University 
Nijmegen) we raised monoclonal antibodies to a synthetic hexadecapeptide (P16) 
corresponding to a computer-calculated epitope (ODC-345-360) of ODC. To examine whether 
the anti-P16 antibodies recognized the complete (native) ODC protein we purified ODC from 
mouse kidneys in collaboration with Dr. M. Sauerbeck en Prof. Dr. P. Bohley (Physiologisch­
Chemisches Institut, Universität Tübingen). These studies showed that the antibodies also 
recognized native ODC. However, the antibodies failed to recognize ODC that was labeled with 
the irreversible inhibitor difluoromethylornithine (DFMO) indicating that the selected epitope 
was associated with the active site of ODC.
With the antibody MP16-2 we systematically developed and optimized an immunocyto- 
chemical method for the in situ detection of ODC (Chapter 4). For this, we studied the effects 
of cell and tissue preparation (fixation procedures, permeabilization, incubation conditions, 
etc.) on the preservation and/or accessibility of the ODC protein. Localization studies of ODC 
in different cell lines showed that strongest staining for ODC was found in the nucleoplasm of 
mitotic cells whereas confluent cells showed moderate perinuclear staining. Immunocyto- 
chemical studies of various rat tissues showed high immunoreactivity of ODC in the 
cytoplasm of cells of adrenal medulla, kidney and prostate of testosterone-treated rats, and in 
small intestine and pancreas of neonatal rats.
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Specific degradation of spermine and spermidine occurs in a metabolic pathway in which the 
polyamines are acetylated first before they are oxidized into spermidine and putrescine, 
respectively. In this so-called retroconversion pathway the oxidation reactions are catalyzed by 
the enzyme polyamine oxidase (PAO). Information on the localization of the polyamine 
catabolic enzyme PAO is very limited. In addition, contradictions exist between biochemical 
data and cytochemical data with respect to the substrate specificity and exact subcellular 
localization of this enzyme. This discrepancy may be explained by the fixation procedures that 
are used in the cytochemical studies. Chemical fixation can affect the in vivo localization and 
properties of enzymes leading to inaccurate cytochemical observations.
In collaboration with Dr. R.J.M. van den Munckhof, Dr. W.M. Frederiks, and Prof. Dr. C.J.F. 
van Noorden of the Department of Cell Biology and Histology (Academic Medical Center, 
University of Amsterdam) a cytochemical method was developed to localize PAO activity in 
unfixed tissues.
This method was used for the localization of PAO activity in various rat tissues, as described 
in Chapter 5. These studies clearly showed that PAO is localized exclusively in peroxisomes. 
The enzyme was highly specific for acetylated spermidine and acetylated spermine, which is in 
agreement with biochemical data on the substrate specificity of the enzyme. In addition, a strong 
heterogeneity in polyamine oxidase activity was observed between different tissues, between 
different cells in one tissue, and between different peroxisomes in one cell.
Part I I
In The Netherlands and many other countries, prostate cancer is one of the most frequent type 
of malignancies in males. Present methods for the diagnosis and prognosis of prostate cancer 
are insufficient causing inadequate treatment of patients. To be able to predict the clinical 
course of this type of cancer it is of great importance to gain insight in processes that control 
malignant behavior of prostatic cancer cells.
As reviewed in Chapter 6 polyamines are of crucial importance in the biological behavior 
of both normal and malignant prostatic epithelial cells.
In Chapter 7  we explored if polyamines, especially Spm, might be valuable markers for the 
discrimination of normal and benign versus malignant prostatic tissue. Biochemical analysis of 
various human prostatic tissues showed that spermine concentrations were substantially lower in 
prostatic carcinoma compared to normal or benign prostatic tissue.
In collaboration with the Departments of Urology (G.O.N. Oosterhof) and Radiology (Dr. M. 
van der Graaf, Prof. Dr. A. Heerschap) of the University Medical Centre Nijmegen we explored 
if magnetic resonance spectroscopy (MRS) could be used for the non-invasive determination of 
spermine in the prostate. Studies on prostatic biopsy samples showed that spermine can be 
detected and identified with MRS. Therefore, this method may provide a valuable new tool in 
the early diagnosis and in predicting the biological behavior of prostatic cancer.
Disseminated prostate cancer is still a disease for which no effective therapy is presently 
available. Hormonal therapy, the standard treatment for metastatic prostate cancer, fails in 
long term due to the presence or formation of hormone-independent prostatic cancer cells.
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Therefore, chemotherapeutic agents that can eliminate hormone-independent prostatic cancer 
cells are urgently needed.
Polyamine analogs may be good candidates for the job. These chemically modified 
polyamines interfere with homeostasis and function of the natural polyamines. Both in vitro 
and in vivo studies showed that polyamine analogs can have cytostatic or cytotoxic effects on 
tumor cells (see also Chapter 6).
Chapter 8 describes the antitumor effect of the polyamine analog N1,N11-di(ethyl)norspermine 
(DENSpm) on human hormone-independent prostatic cancer cells. The in vitro studies 
showed that treatment with DENSpm evoked intracellular accumulation of the analog and 
various regulatory responses. DENSpm had sustained inhibitory effects on the in vitro growth 
of human prostate carcinoma cells in a dose and time-dependent manner. The cellular 
sensitivity to growth inhibition correlated with the degree in which ODC was downregulated 
and the catabolic enzyme spermidine/spermine N 1-acetyl-transferase (SSAT) was induced by 
DENSpm. SSAT is involved in the production of acetylated polyamines which, subsequently, 
can be excreted or further metabolized. An in vivo study in athymic nude mice showed that 
DENSpm was also able to inhibit tumor growth of xenografts of a human prostatic cancer cell 
line. These studies show that polyamine analogs like DENSpm may provide a valuable tool in 
the chemotherapy of prostate cancer.
Pa r t  I I I
Cell death plays a crucial role in the development and survival of an organism. Programmed cell 
death or apoptosis, is an active process (activation of specific genes, protein synthesis) in contrast 
to necrosis (accidental or pathological cell death resulting from extreme environmental 
conditions). Apoptosis involves a cascade of biochemical events (e.g. production of proteolytic 
enzymes, DNA fragmentation) and morphological changes (e.g. condensation of nucleus and 
cytoplasm, fragmentation into small membrane bound "apoptotic bodies"). Many diseases, 
including cancer, are related to dysfunctions in the process of apoptosis. Identification of the 
molecular mechanisms involved in apoptosis can give rise to new therapeutic approaches to 
induce cell death in cancer cells. Recent studies indicate that polyamines as well as products of 
polyamine metabolism are intimately involved in the process of cell death.
Chapter 9  gives an overview of the recent studies on the involvement of polyamines in 
apoptosis. Induction of ODC and production of putrescine seem to be early events in neuronal 
necrosis and apoptosis. However, it has yet to be unraveled if polyamine production has real 
physiological significance in cell death or is merely a secondary response or an attempt 
towards cell survival. Decrease of polyamine levels, especially of spermidine and spermine, 
seems to be a more common feature in apoptosis. Furthermore, spermine has been shown to 
have protective effects against apoptosis.
A relationship between polyamine catabolism and apoptosis has been reported in research on 
cell death in embryonic systems. Apoptosis in embryonic cells was due to oxidation products 
associated with polyamine catabolism. Most likely one of the "killing" substance is hydrogen 
peroxide. This substance is produced during the oxidation of acetylated polyamines.
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Together, these studies clearly show that polyamines are critically involved in apoptosis. 
Furthermore, the effects of interference with polyamine homeostasis using polyamine enzyme 
inhibitors or polyamine analogs on the process of apoptotic cell death strengthens the idea that 
polyamines are important factors in the control of apoptotic cell death. However, the working 
mechanisms of polyamines in apoptosis are still inconclusive. Several mechanisms by which 
polyamines mediate cell death have been suggested, such as the stimulation of calcium fluxes, 
the formation of oxygen radicals, the modulation of transglutaminase activity, the regulation 
of cation channels, the protection against oxidative stress, and their ability to modulate DNA 
structure.
From the studies reviewed, it can be concluded that polyamines are not only essential for cell 
growth and viability but also are intimately involved in cell injury and cell death. Interference 
with polyamine homeostasis can induce cell growth arrest, or in conjunction with other factors 
result in the execution of cell death. These observations support the general idea that cell cycle 
events and apoptosis are closely connected.
In Chapter 10  it was investigated if polyamine metabolism was involved in apoptosis induced 
by tumor necrosis factor (TNF). TNF, mainly produced by activated macrophages, is a cytokine 
with a broad spectrum of biological activities including induction of apoptosis.
To test the involvement of polyamine metabolism in cytokine-induced apoptosis, we treated 
T-cells with TNF and monitored the changes in ODC activity and polyamine concentrations. We 
observed an increase in ODC activity and a little increase in putrescine concentrations. However, 
in time all three polyamines decreased. Interestingly, manipulation of polyamine homeostasis 
resulting in further reduction of intracellular spermine levels clearly sensitized the cells towards 
apoptosis. Moreover, an increase in intracellular spermine concentrations (with DFMO or 
externally added spermine) always resulted in reduced cell death. Therefore, our data showed 
that a decrease in intracellular spermine rather than enhanced ODC activity per se, is correlated 
with apoptosis. The same observations were made in other cells of human and rodent origin 
indicating that the protective effect of spermine against apoptosis was a general phenomenon.
For its growth and function, the prostate is dependent on hormones, i.e. androgens. Withdrawal 
of androgens induces apoptosis of androgen-dependent prostatic epithelial cells. The standard 
therapy for the treatment of metastatic prostate cancer, i.e. androgen ablation, is based on this 
cell death-inducing effect of androgen withdrawal. Androgen ablation fails in long term due to 
the presence of androgen-independent cells. Androgen ablation does not induce apoptosis in 
androgen-independent cells. However, in vitro, androgen-independent can be triggered by 
calcium ionophores to undergo apoptosis, i.e. the pathway needed for apoptosis is retained. 
Therefore, a strong need is requested to search for a type of non-hormonal therapy enabling 
the induction of apoptosis in androgen-independent prostatic cancer cells in vivo.
In Chapter 11 it was studied if polyamine metabolism was changed during calcium 
ionophore-induced apoptosis in androgen-independent prostatic cancer cells. For this, studies 
were performed on the androgen-independent AT-3 rat prostatic tumor subline. In calcium 
ionophore-induced apoptosis ODC activity was augmented. Putrescine levels increased but 
paradoxically spermidine and spermine levels decreased. Studies using polyamine-metabolic 
inhibitors showed that the ODC inhibitor DFMO and the spermine-analog DENSpm inhibited 
cell growth but also protected against calcium ionophore-induced programmed cell death.
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From the studies, described in this thesis, it can be concluded that polyamines play a 
fundamentally important role in cell kinetic behavior (cell growth, cell differentiation, cell 
death). It is becoming more and more evident that the polyamine system takes part of well- 
regulated control machinery, which at any time takes final decisions in the choice between 
growth, survival or death of a cell. Therefore, the polyamine system provides an attractive target 
to study, to predict and to manipulate the cell kinetic behavior of tumor cells.
In addition, this study provided new tools and/or techniques for the in situ monitoring of 
polyamine metabolism. These novel techniques are currently implemented in projects, 
sponsored by the Dutch Cancer Society, which further explore the use of polyamine 
metabolism as determinant of malignant cellular behavior and as potential target for cancer 
therapy in prostate cancer.
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SAMENVATTING
Met de term polyaminen wordt in het algemeen verwezen naar de drie in de natuur meest 
voorkomende alifatische aminen nl. putrescine, spermidine en spermine. Deze laagmoleculaire 
celcomponenten bezitten bij neutrale pH (fysiologische pH) een sterk basisch karakter waardoor 
zij gemakkelijk verbindingen aangaan met diverse soorten organische verbindingen (DNA, 
RNA, eiwitten, fosfolipiden, e.d.). Deze bindingsneiging vormt de basis voor de uiteenlopende 
functies die aan polyaminen worden toegeschreven (o.a. stabilisatie van nucleïnezuren en 
membraanstructuren, modulatie van de aanmaak van DNA, RNA en eiwitten). Opvallend is de 
sterke toename van de hoeveelheid polyaminen bij celdifferentiatie en celgroei, zowel onder 
normale (embryonale processen) als pathologische (carcinogenese, maligne celgroei) 
omstandigheden. In diverse studies is/wordt nagegaan of bij maligne celgroei de hoeveelheid 
polyaminen in tumorweefsel gebruikt kan worden als diagnostische en/of prognostische 
parameter. Daarnaast bestaat er een grote belangstelling voor de toepasbaarheid van poly­
aminesynthese remmers en polyamine analogen als chemopreventief of chemotherapeutisch 
middel.
Een algemene beschrijving van polyaminen, de mechanismen waarmee de huishouding 
(homeostase) van polyaminen in de cel wordt gereguleerd, en de manipulatie hiervan voor 
oncologische doeleinden, worden weergegeven in Hoofdstuk 1.
Ondanks intensief onderzoek zijn de exacte functies van polyaminen op cellulair en moleculair 
niveau nog niet geheel duidelijk. Ten dele wordt dit veroorzaakt door een gebrekkige kennis 
omtrent de cellulaire lokalisatie van het polyamine systeem: vrijwel alle hedendaagse inzichten 
zijn gebaseerd op biochemische bepalingen in weefsel-/celhomogenaten of daaruit geïsoleerde 
fracties. Informatie over de intracellulaire distributie van de enzymen die betrokken zijn bij de 
aanmaak (biosynthese) of de afbraak (katabolisme) van polyaminen zou kunnen leiden tot een 
beter inzicht in de mechanismen waarmee polyamine hun functies vervullen in (tumor)celgroei.
Het proefschrift omvat een tiental hoofdstukken, die in drie delen zijn gegroepeerd:
In Deel I  wordt het onderzoek beschreven naar de ontwikkeling van cytochemische 
methoden voor de (sub)cellulaire lokalisatie van het ornithine decarboxylase (ODC) en het 
polyamine oxidase (PAO), enzymen die betrokken zijn bij de biosynthese, respectievelijk het 
katabolisme van polyaminen.
In Deel I I  en Deel I I I  van het proefschrift wordt gepoogd meer inzicht te krijgen in de 
mogelijke betekenis van het polyaminemetabolisme bij de diagnose, prognose of behandeling 
van prostaatkanker. Prostaatkanker is de tweede doodsoorzaak door kanker bij mannen en 
kent een toenemende incidentie. Ondanks veel onderzoek hebben de huidige mogelijkheden 
voor behandeling slechts een beperkt succes. Het polyaminemetabolisme speelt een 
belangrijke rol bij de groei en functie van de prostaat. Spermine wordt in hoge concentraties 
aangemaakt door de prostaatkliercellen en uitgescheiden in het zaadvocht.
Onderzocht werd of via het polyaminemetabolisme de celgroei (Deel II) dan wel de (gepro­
grammeerde) celdood (Deel III) van prostaatkankercellen gemanipuleerd kan worden.
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Samenvatting
D eel I
De cellulaire concentratie van polyaminen worden streng gereguleerd afhankelijk van de 
fysiologische condities waarin de cel verkeert. Het enzym ODC, betrokken bij de biosynthese 
van polyaminen, kan zeer snel worden aangemaakt maar wordt ook weer snel afgebroken 
(zeer korte halfwaardetijd). ODC kan worden geïnduceerd door uiteenlopende stimuli, met 
name stimuli die de celgroei bevorderen.
Hoofdstuk 2 geeft een overzicht van de verschillende (biochemische, enzymcytochemische, 
immunocytochemische en hybridocytochemische) methoden die in de literatuur beschreven 
zijn voor de lokalisatie van ODC in cellen en weefsels. Daarnaast worden de resultaten van 
deze studies geïnterpreteerd in relatie tot de mogelijke functies van ODC/polyaminen bij de 
verschillende cel- en weefseltypen. Samengevat luidt de conclusie van deze literatuurstudie 
dat er verschillende distributiepatronen van ODC zijn waargenomen, afhankelijk van de 
toegepaste methode of het bestudeerde onderzoeksmateriaal. Deze variatie in ODC distributie 
kan een weerspiegeling zijn van de meerdere functies die ODC mogelijk vervult in verschil­
lende weefsel-/celtypen. Een andere verklaring voor de (vaak tegenstrijdige) waarnemingen 
zou kunnen zijn dat de gebruikte methode niet sensitief of specifiek genoeg is voor een 
betrouwbare studie naar de lokalisatie van ODC. Zo kan bijvoorbeeld het gebruik van 
onzuivere ODC-fracties als antigen leiden tot productie van antilichamen met variabele 
specificiteit. Het gebruik van deze antilichamen in een immunocytochemische methode kan 
aanleiding geven tot het optreden van aspecifieke reacties. Daarnaast kan een inadequate 
weefselbewerking tot gevolg hebben dat of het ODC-epitoop onherkenbaar veranderd of 
gemaskeerd wordt, of dat antilichamen aspecifiek aan andere celcomponenten binden.
Teneinde een betrouwbare immunocytochemische methode te ontwikkelen voor de 
lokalisatie van ODC in cellen en weefsels, werden in samenwerking met de afdeling 
Organische Chemie van de K.U. Nijmegen (Prof. Dr. G.I. Tesser) monoklonale antilichamen 
tegen ODC ontwikkeld (Hoofdstuk 3). Uitgaande van de primaire structuur van het ODC werd 
een epitoop geselecteerd. Vervolgens werd een peptide, bestaande uit 16 aminozuren, die 
overeenkomen met aminozuren 345-360 van de ODC-gensequentie, gesynthetiseerd en gebruikt 
als immunogeen voor de productie van antilichamen. Twee hybridoma cellijnen (MP16-2, 
MP16-3) die specifieke antilichamen produceerden tegen het ODC-peptide werden geïsoleerd en 
gekarakteriseerd. Om na te gaan of deze antilichamen ook aan het complete (natieve) ODC-eiwit 
binden, werd ODC gezuiverd uit muizennieren (in samenwerking met Dr. M. Sauerbeck en 
Prof. Dr. P. Bohley van het Physiologisch-Chemisches Institut, Universität Tübingen). Uit deze 
studies bleek dat de monoklonale antilichamen gericht tegen het synthetische peptide ook 
specifiek het natieve enzym herkenden. Daarentegen bleken de antilichamen niet te reageren met 
ODC dat behandeld was met difluoromethylornithine (DFMO), een irreversible remmer van het 
enzym. Deze resultaten wijzen erop dat het geselecteerde epitoop deel uit maakt van het actieve 
centrum van het enzym.
Het antilichaam MP16-2 werd vervolgens gebruikt voor de ontwikkeling van 
immunocytochemische methoden voor de cellulaire lokalisatie van ODC waarbij de invloed 
van diverse stappen van de weefselbewerking (fixatie, permeabilisatie, incubatietijden e.d.) op 
de immunocytochemische reacties werd onderzocht (Hoofdstuk 4). Uit studies met gekweekte 
kankercellen bleek dat delende cellen een sterke aankleuring van het ODC vertoonden. Een 
hoge ODC-immunoreactiviteit werd ook gevonden in specifieke cellen binnen het darm- en 
pancreasweefsel van pasgeboren ratten en in de epitheliale cellen van de nier, bijnier, prostaat 
van ratten die met testosteron waren behandeld.
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De polyaminen spermine en spermidine kunnen via hun geacetyleerde intermediairen 
geoxideerd worden tot respectievelijk spermidine en putrescine. De oxidatie reacties van deze 
zogenaamde retroconversie van polyaminen wordt gekatalyseerd door het enzym PAO. 
Cytochemische informatie over PAO is schaars en niet in overeenstemming met de 
biochemische resultaten wat betreft de specificiteit van het enzym voor geacetyleerde 
polyaminen. Een reden hiervoor kunnen zijn dat deze resultaten werden verkregen met 
gefixeerd materiaal. Fixatie kan de lokalisatie en eigenschappen van enzymen in vivo 
beïnvloeden en leiden tot onbetrouwbare resultaten.
In samenwerking met de afdeling Celbiologie en Histologie, Academisch Medisch Centrum, 
Universiteit van Amsterdam (Dr. R.J.M. van den Munckhof, Dr. W.M. Frederiks, Prof. Dr. 
C.J.F. van Noorden) is een cytochemische methode voor de lokalisatie van PAO toegepast op 
ongefixeerd weefsel. Hoofdstuk 5  beschrijft de lokalisatie van PAO activiteit in diverse 
rattenweefsels met behulp van deze methode Deze studies wezen duidelijk uit dat PAO 
gelokaliseerd is in de peroxisomen en dat het enzym een zeer sterke voorkeur heeft voor de 
geacytyleerde polyaminen wat in overeenstemming is met biochemische studies. Verder bleek 
dat PAO activiteit zeer heterogeen verdeeld was over de verschillende weefsels, tussen 
verschillende cellen in één weefsel en tussen verschillende peroxisomen in één cel.
D eel I I
Prostaatkanker is bij mannen, in Nederland en vele andere landen, een van de meest 
voorkomende kwaadaardige gezwellen. De huidige methoden voor diagnostiek, stadiëring en 
het vaststellen van de prognose zijn onvoldoende en leiden zowel tot onder- als over- 
behandeling. Teneinde het beloop van deze vorm van kanker beter te kunnen voorspellen is 
het van groot belang het biologisch gedrag van prostaatkanker te doorgronden.
Uit de literatuur (Hoofdstuk 6) blijkt dat polyaminen een belangrijke rol spelen bij het 
biologisch gedrag van zowel normale als kwaadaardige prostaatkliercellen.
In Hoofdstuk 7  wordt onderzocht of via metingen van polyamine concentraties prostaat- 
kankerweefsel kan worden onderscheiden van normaal of goedaardig weefsel (prostaat- 
vergroting). Uit biochemische analyses van verschillende soorten prostaatweefsel blijkt dat in 
prostaatkankerweefsel de spermine concentratie veel lager is dan in normaal of goedaardig 
weefsel.
In samenwerking met de afdelingen Urologie (G.O.N. Oosterhof) en Radiodiagnostiek (Dr. 
M. van der Graaf, Prof. Dr. A. Heerschap) van het Universitair Medisch Centrum St Radboud 
werd onderzocht of met magnetische resonantie spectroscopie (MRS) non-invasief (zonder 
chirurgische ingreep of punctie) gegevens kunnen worden verkregen over de verspreiding van 
spermine over de prostaat.
Uit metingen aan de buitenzijde van weefselbiopten bleek dat spermine met MRS zichtbaar 
gemaakt kan worden. Deze methode opent mogelijk nieuwe perspectieven voor het vroegtijdig 
opsporen van prostaatkanker en een betere voorspelling van de mate van agressiviteit van 
prostaatkanker.
Adequate behandelingsmethoden voor prostaatkanker met uitzaaiingen (gemetastaseerd 
prostaatcarcinoom) zijn (nog) niet beschikbaar. Hormonale therapie, de standaardbehandeling 
bij prostaatkanker, blijkt slechts tijdelijk effect te hebben bij patiënten met gemetastaseerd 
prostaatcarcinoom. Dat aanvankelijk wel, doch later geen effect wordt gezien kan worden 
verklaard door het uitgroeien van al aanwezige of nieuw gevormde hormoon-ongevoelige
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prostaatkankercellen. Het is daarom belangrijk te zoeken naar chemotherapeutica die effectief 
deze hormoon-onafhankelijke kankercellen kunnen elimineren.
Een mogelijke rol is hierbij weggelegd voor polyamine analogen. Deze chemisch- 
gemodificeerde polyaminen interfereren met de homeostase en de functie van de natuurlijke 
polyaminen. Uit zowel in vitro studies (onderzoek met gekweekte kankercellen) als in vivo 
studies (onderzoek met gezwellen die geïmplanteerd zijn in een muis) blijkt dat na 
behandeling met polyamine analogen de kankercellen in hun groei worden geremd of zelfs 
afsterven (zie ook Hoofdstuk 6).
Hoofdstuk 8 beschrijft het onderzoek naar de biologische effecten van de polyamine analoog 
N 1,N11-di(ethyl)norspermine (DENSpm) op hormoon-onafhankelijke prostaatkankercellen. In 
gekweekte prostaatkankercellen werd aangetoond dat DENSpm in deze cellen goed wordt 
opgenomen, en, na opname, de aanmaak en afbraak van polyaminen sterk beïnvloedt. Ook 
werd vastgesteld dat, afhankelijk van de dosis en inwerkingsduur, prostaatkankercellen in hun 
groei worden geremd. Soortgelijke bevindingen bleken te gelden voor prostaatkankercellen 
die deel uitmaken van een gezwel (geïmplanteerd in een naakte muis), een situatie die veel 
complexer is dan in celkweken kan worden nagebootst. De groei-remmende werking van 
DENSpm correleerde met de mate waarin ODC werd geremd en het enzym spermidine/­
spermine N 1 acetyltransferase (SSAT) werd geïnduceerd. SSAT is betrokken bj de produktie 
van geacetyleerde polyaminen die vervolgens door de cel kunnen worden uitgescheiden of 
geoxideerd kunnen worden. Deze resultaten tonen aan dat polyamine analogen zoals 
DENSpm, die aangrijpen op de polyaminehomeostase in hormoon-onafhankelijke prostaat- 
kankercellen, van therapeutische waarde kunnen zijn bij de behandeling van prostaatkanker.
Deel  i i i
Celdood speelt een cruciale rol bij de ontwikkeling en het voortbestaan van een organisme. 
Geprogrammeerde celdood of apoptose kenmerkt zich in tegenstelling tot necrose (celdood die 
veroorzaakt wordt door ernstige, acute schade aan cellen) doordat celdood door de cel zelf op 
een actieve manier (genactivatie, eiwitsynthese) stapsgewijs wordt bewerkstelligd. Deze celdood 
gaat veelal gepaard met een cascade van biochemische (bijvoorbeeld productie van proteo­
lytische enzymen genaamd caspases, fragmentatie van het DNA) en morfologische veranderin­
gen (cel fragmenteert in "apoptotic bodies"). Afwijkingen in het proces van apoptose zijn 
gerelateerd aan een grote verscheidenheid van ziekten waaronder kanker. Identificatie van de 
moleculaire mechanismen die betrokken zijn de inductie van of bescherming tegen apoptose kan 
leiden tot nieuwe therapeutische ingangen teneinde celdood in bijvoorbeeld kankercellen 
farmacologisch te induceren. Recente publicaties wijzen erop dat zowel polyaminen als 
metabolieten afkomstig van het polyaminemetabolisme betrokken zijn bij celdood.
Hoofdstuk 9 geeft een overzicht van recente studies naar de rol van polyaminen in apoptose. 
In verschillende studies blijkt apoptose gepaard te gaan met een snelle toename van ODC- 
activiteit en productie van putrescine. Het is echter niet duidelijk of er een direct causaal 
verband bestaat tussen deze toename van ODC-activiteit en de inductie van apoptose. In de 
meeste studies neemt de concentratie van polyaminen af tijdens apoptose en blijken 
polyaminen, vooral spermine, beschermende effecten te hebben op het proces van apoptose. Een 
relatie tussen polyaminekatabolisme en apoptose is gevonden in onderzoek naar de celdood van 
embryonale cellen. Deze geprogrammeerde celdood werd veroorzaakt door oxidatieproducten
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geassocieerd met polyaminekatabolisme, vermoedelijk waterstofperoxide. Deze toxische stof 
wordt geproduceerd tijdens de oxidatie van geacetyleerde polyaminen.
Het is duidelijk dat polyaminen op de een of andere manier betrokken zijn bij apoptose, 
temeer omdat dit proces gemanipuleerd kan worden door stoffen die interfereren met de 
polyaminehomeostase. De exacte rol van polyaminen bij celdood is nog onbekend. Wel zijn 
verschillende mogelijke werkingsmechanismen geopperd, onder andere de stabilisatie van DNA, 
bescherming tegen zuurstofradicalen, modulatie van ionkanalen, etc.)
Concluderend kan men stellen dat polyaminen niet alleen essentieel zijn voor celgroei maar 
ook nauw betrokken zijn bij de overleving van de cel. Een verstoring in het polyamine- 
metabolisme kan aanleiding geven tot groei-inhibitie maar in samenhang met andere factoren 
ook leiden tot de inductie van apoptose. Deze data ondersteunen de algemene opvatting dat 
processen van celproliferatie en celdood sterk met elkaar geassocieerd zijn.
In Hoofdstuk 10  werd onderzocht of er een relatie bestaat tussen het polyaminemetabolisme en 
de inductie van apoptose door tumor necrosis factor (TNF). TNF is een cytokine die 
hoofdzakelijk wordt geproduceerd door macrofagen en vele biologische activiteiten bezit 
waaronder de inductie van apoptose.
Om inzicht te verkrijgen in de rol van polyaminen in apoptose werden T-cellen behandeld 
met TNF en onderzocht op veranderingen in polyamine concentraties en de activiteit van het 
enzym ODC. Uit deze studies bleek dat na TNF behandeling een snelle inductie van ODC 
plaatsvond gevolgd door een lichte toename van putrescine concentraties. Echter, in de tijd 
namen de concentraties van alle drie de polyaminen weer af. Toevoeging van spermine 
voorafgaande aan de TNF-behandeling had een vertragend effect werking op het apoptose 
proces wat duidt op een beschermende werking van spermine. Deze veronderstelling werd 
ondersteund door studies waarbij TNF gebruikt werd in combinatie met stoffen die interfereren 
met de polyaminehomeostase. De farmacologische behandelingen die gepaard gaan met een 
daling in de cellulaire spermine concentraties bleken een sensitiverende werking te hebben op de 
inductie van apoptose. Deze bevindingen bleken ook te gelden voor andere humane en murine 
cellijnen wat erop duidt dat de bescherming van spermine tegen apoptose een universeel 
gegeven is.
De prostaat is voor zijn groei en functie afhankelijk van androgenen. Een tekort leidt tot de 
inductie van apoptose in de prostaatkliercellen. Dit gegeven vormt het uitgangspunt van de 
hormonale therapie bij prostaatkanker waarbij men door een androgeen-blokkade 
prostaatkankercellen probeert te laten afsterven. Echter, deze therapie is zelden genezend omdat 
in een prostaattumor androgeen-onafhankelijke prostaatkankercellen aanwezig zijn die geen 
apoptose ondergaan na androgeen-blokkade. Verondersteld wordt dat dit het gevolg is van een 
defect in een van de initiële stappen van apoptose, namelijk de toename van het intracellulair 
calcium. In vitro studies hebben namelijk aangetoond dat androgeen-onafhankelijke 
prostaatkankercellen wel apoptose ondergaan na behandeling met calcium-ionoforen. Afgezien 
van deze initiële stap lijken de andere componenten in het proces van apoptose dus nog intact.
In Hoofdstuk 11 werd onderzocht of het polyaminemetabolisme verandert in androgeen- 
onafhankelijke prostaatkankercellen tijdens de inductie van apoptose door calcium-ionoforen. 
Na de behandeling met calcium-ionoforen bleek er een snelle inductie van ODC en putrescine 
plaats te vinden, echter de concentraties van spermidine en spermine namen af. De ODC- 
remmer DFMO en de polyamine analoog DENSpm hadden een beschermend effect op het 
apoptose proces.
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Samenvatting
Uit de studies die in dit proefschrift zijn weergegeven kan geconcludeerd worden dat 
polyaminen een belangrijke rol spelen bij celkinetische processen (celgroei, celdifferentiatie, 
celdood). Polyaminen maken deel uit van een complex regelsysteem dat voortdurend 
beslissingen neemt over het lot van de cel: óf het zich deelt, óf zich differentieert óf zich van 
het leven ontneemt. Het polyaminemetabolisme vormt dan ook een geschikt doelwit om 
enerzijds het biologisch gedrag van tumorcellen te karakteriseren en te voorspellen, anderzijds 
de tumorcelkinetiek te manipuleren.
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